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Abstract 
ST-elevation myocardial infarction (STEMI) management has evolved dramatically, with 
improved pharmacological treatment, rapid achievement of reperfusion with percutaneous 
coronary intervention (PCI) and advanced secondary prevention programmes, resulting in 
a decline in morbidity and mortality. However, it is well recognised that myocardial 
perfusion remains compromised in up to 50% of STEMI patients, despite rapid and 
successful mechanical revascularisation of the epicardial artery. This occurrence is called 
the “no-reflow” phenomenon and as a result, a substantial proportion of acute STEMI 
patients develop chronic cardiac failure, owing to poor microvascular function and 
myocardial perfusion. Although pathological and clinical observations initially seemed to 
support the theory that no-reflow was a consequence of microvascular obstruction 
(predominantly from distal embolisation of athero-thrombotic debris), irreversible 
microvascular injury and subsequent intramyocardial haemorrhage (IMH) are now also 
thought to play important factors in this process. 
T2*-CMR is the reference diagnostic method for imaging myocardial haemorrhage in-vivo, 
however technical issues have limited T2* imaging in clinical practice. The largest cohort 
studies of myocardial haemorrhage in STEMI patients to date, have not used T2* CMR, 
but instead used qualitative T2-weighted imaging methods to detect haemorrhage, which 
are hampered by image artefact. Because of the different CMR techniques, uncertainties 
have arisen surrounding the pathophysiology and clinical significance of myocardial 
haemorrhage, and its relationships with microvascular obstruction (MVO). In some 
studies, myocardial haemorrhage is associated with adverse remodelling and adverse 
clinical outcome, however other studies have shown that myocardial haemorrhage does not 
have prognostic significance beyond MVO.   
Recent developments in CMR imaging techniques have enabled clinically feasible, rapid 
parametric mapping, which allows direct determination of myocardial magnetic relaxation 
times (T1, T2 and T2*). These quantitative, novel mapping methods, address many of the 
inherent limitations associated with dark blood T2-weighted techniques, for a more 
objective assessment of the infarct core. 
The principal aim of this thesis is to define the clinical significance of myocardial 
haemorrhage using quantitative CMR mapping techniques and to determine whether 
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detection of haemorrhage might improve risk stratification in STEMI survivors. In 
addition, I aim to characterise the evolution and inter-relationships between IMH and 
MVO in STEMI survivors to inform and implement targeted therapeutic interventions. 
Methods 
(1) Natural history study: We performed a single centre cohort study in 324 reperfused 
STEMI patients treated predominantly by emergency percutaneous coronary intervention 
(PCI) (The BHF MR-MI study; Clinicaltrials.gov NCT02072850). The index of 
microcirculatory resistance (IMR), a prognostically validated invasive microcirculatory 
biomarker, was measured acutely in the culprit coronary artery at the end of PCI using 
guidewire based-thermodilution. Infarct zone IMH and MVO were delineated as 
hypointense zones on T2* mapping CMR (T2* value <20 ms) and contrast-enhanced-
CMR at 1.5 Tesla, respectively, 2 days and 6 months post-MI. T1- and T2-mapping  
techniques were also used to assess the infarct core and evaluate IMH. 
(2) Time-course study: 30 patients underwent serial CMR at 4 time-points: < 1 day (4 to 
12 hours), 3 days, 10 days and 6-7 months post-reperfusion. Adverse remodelling was 
defined as an increase in left ventricular end-diastolic volume (LVEDV) ≥ 20% at 6 
months. Adverse cardiovascular events were pre-specified and defined according to 
internationally accepted criteria. All-cause death or heart failure were independently 
assessed during follow-up blind to other data.  
(3) Randomised proof-of-concept trial: We hypothesised that brief deferral of stenting 
after initial reperfusion, associated with the benefits of normal coronary flow and anti-
thrombotic therapies, would reduce microvascular injury and increase myocardial salvage. 
We implemented a randomised proof-of-concept clinical trial of deferred PCI vs. 
immediate stenting (NCT01717573) (Carrick et al., 2014). 
In summary, the main findings of this thesis are: 
 Myocardial haemorrhage (defined by T2* CMR) is an independent predictor of 
adverse remodelling and all cause death or heart failure in the longer-term post 
STEMI. 
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 Myocardial hemorrhage occurs in primary and secondary phases within the first 10 
days post-MI and is a secondary phenomenon to the initial occurrence of 
microvascular obstruction. 
 Myocardial haemorrhage peaked at day 3 post-MI in reperfused STEMI patients, 
and the temporal changes in oedema may be a secondary process.  
 A hypointense infarct core on T2-mapping always occurred in the presence of 
microvascular obstruction and commonly in the absence of myocardial 
haemorrhage within 12 hours and 3 days post-MI, indicating that the presence of 
T2-core is more closely associated with microvascular obstruction than myocardial 
haemorrhage. 
 Infarct core pathology revealed by T2 (ms) was independently associated with all-
cause death or heart failure hospitalisation during longer term follow-up. 
 Native T1 values (ms) within the infarct core were independently associated with 
adverse remodelling and adverse clinical outcome and had similar prognostic value 
when compared to microvascular obstruction. 
 IMR measured in the culprit coronary artery after reperfusion is more strongly 
associated with myocardial haemorrhage than microvascular obstruction in STEMI 
survivors 2 days later.  
 The proof-of-concept pilot deferred stenting trial showed that compared with 
standard of care with immediate stenting, brief deferral of stenting after initial 
reperfusion; reduced angiographic no-reflow, tended to reduce IMH and MVO, and 
increased myocardial salvage. 
The findings of this PhD are novel and have important clinical implications. Firstly, we 
found that myocardial haemorrhage occurs commonly and is a biomarker for prognostication 
in STEMI survivors. Secondly, IMR adds early prognostic information at the time of 
emergency reperfusion and has potential to stratify patients at risk of IMH for more 
intensive therapy. Thirdly, our results confirm that infarct pathologies are evolving 
dynamically and potentially, may be amenable to targeted therapeutic interventions. 
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Finally, IMR has the potential to stratify STEMI patients acutely and deferred PCI is a 
simple intervention that could be practice changing, if the planned Phase 3 trial DEFER-
STEMI confirms the hypothesis. 
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1 Chapter 1: Introduction
1.1 Background 
Acute ST-segment elevation myocardial infarction (STEMI) is a leading global cause of 
premature morbidity and mortality (Steg et al., 2012). STEMI management has evolved 
dramatically, now encompassing dedicated STEMI networks, potent antithrombotic drugs, 
rapid achievement of reperfusion, and advanced secondary prevention programmes, which 
has resulted in a decline in morbidity and mortality in STEMI patients (Widimsky et al., 
2010, McManus et al., 2011, Jernberg et al., 2011, Fox et al., 2007). Despite this, mortality 
remains substantial with approximately 12% of patients dead within 6 months (Fox et al., 
2006), but with higher mortality rates in high-risk patients (Fox et al., 2010), which 
justifies continued research to improve therapeutic strategies and outcome.  
Early restoration of myocardial perfusion is the most important goal of treating patients 
with acute STEMI and has been shown to be effective at reducing mortality (Steg et al., 
2012). However, it is well recognised that myocardial tissue perfusion remains 
compromised in up to 50% of STEMI patients, despite rapid restoration of epicardial 
patency (Hombach et al., 2005, Wu et al., 1998b, Carrick and Berry, 2013). This 
phenomenon, referred to as “no-reflow”, is associated with larger post-infarction 
myocardial necrosis, which is a major determinant of morbidity and mortality in STEMI 
survivors.  
Although pathological and clinical observations initially seemed to support the notion that 
“no-reflow” was the result of microvascular obstruction (MVO), assumed to be due to 
distal embolisation of epicardial thrombotic and atheromatous debris; irreversible 
microvascular injury and subsequent intramyocardial haemorrhage (IMH) are now also 
thought to be important factors in this process. Understanding the role of intramyocardial 
haemorrhage in the no-reflow phenomenon and myocardial injury, as well as its evolution 
and relationships with MVO, is crucial to the development of novel reperfusion therapeutic 
strategies to treat acute MI. 
There is conflicting evidence in the literature about the clinical significance of IMH, partly 
because of non-standardised methods to detect IMH in vivo, with most studies to date not 
using haemorrhage sensitive sequences. Also, in acute MI patients, the inter-relationships 
  
30 
 
between myocardial haemorrhage and other infarct pathologies, such as MVO, and their 
temporal evolution are uncertain.  
In this chapter, I shall provide background to the pathophysiology of ischaemic-reperfusion 
haemorrhage and its relationship with other infarct characteristics such as MVO, before 
providing details on the techniques for detection of IMH. Finally, I shall review the current 
evidence regarding the clinical significance of IMH. 
 
1.2 Pathophysiology of myocardial haemorrhage in acute reperfused 
myocardial infarction 
1.2.1 Reperfusion injury 
Early restoration of myocardial perfusion, with either thrombolytic therapy or primary 
percutaneous intervention (PCI), is the main therapeutic objective in patients with ST-
elevation myocardial infarction (STEMI) (Steg et al., 2012, Windecker et al., 2014). Whilst 
prompt reperfusion increases myocardial salvage and improves clinical outcome (Steg et 
al., 2012), the restoration of flow to ischaemic myocardium can induce injury, 
paradoxically reducing the beneficial effects of myocardial reperfusion (Yellon and 
Hausenloy, 2007). This phenomenon, termed “myocardial reperfusion injury” leads to four 
main types of cardiac dysfunction: (1) myocardial stunning, which is reversible post-
ischaemic contractile dysfunction; (2) lethal reperfusion injury as an independent mediator 
of cardiomyocyte death; (3) microvascular obstruction (MVO) (also referred to as “no-
reflow”) and intramyocardial haemorrhage (IMH) and (4) reperfusion arrhythmias 
(Frohlich et al., 2013, Yellon and Hausenloy, 2007). 
The concept of myocardial reperfusion injury as an independent mediator of 
cardiomyocyte death, distinct from ischaemic injury is contentious. The evidence for the 
existence of myocardial reperfusion injury as a distinct entity, has been indirect and relied 
upon the demonstration that an intervention used at the beginning of myocardial 
reperfusion can reduce infarct size (Yellon and Hausenloy, 2007). The postulated major 
components of myocardial reperfusion injury include: oxidative stress, intracellular 
calcium overload, rapid restoration of physiological pH within the cell and inflammation 
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(neutrophil infiltration). These factors mediate cardiomyocyte death by opening the 
mitochondrial permeability transition pore and inducing cardiomyocyte hypercontracture 
(Frohlich et al., 2013, Hausenloy and Yellon, 2003) (figure 1-1).  
1.2.2 Pathophysiology of microvascular obstruction 
Success of coronary reperfusion in STEMI is often limited by failed tissue perfusion, as 
might be indicated by persistent ST-elevation on the electrocardiogram. Patients with the 
no-reflow phenomenon have a poor clinical prognosis (Ito et al., 1996, Wu et al., 1998b, 
Eitel et al., 2014, van Kranenburg et al., 2014). The focus of primary PCI has extended 
from merely achieving epicardial artery patency towards preserving the integrity of the 
coronary microcirculation. 
The pathophysiology of IMH is inextricably associated with MVO (Driesen et al., 2012, 
Fishbein et al., 1980, Kumar et al., 2011, O'Regan et al., 2010, Robbers et al., 2013, van 
den Bos et al., 2006). The no-reflow phenomenon was originally described in 1974 by 
Kloner et al. (Kloner et al., 1974). No-reflow or MVO is characterised by small vessel 
changes that prevent adequate tissue perfusion despite a revascularised and patent 
epicardial coronary artery (Basso and Thiene, 2006, Kloner et al., 1974). MVO is thought 
to be due to both luminal obstruction (i.e. neutrophil plugging, platelets, athero-thrombotic 
embolisation and endothelial swelling) and external compression (oedema, haemorrhage) 
(Kloner et al., 1980, Manciet et al., 1994). The release of inflammatory, thrombogenic and 
vasoconstrictor substances have also been implicated in the aetiology (Kleinbongard et al., 
2011). 
These complex pathophysiological mechanisms of MVO can lead to it being classified as 
“structural” or “functional” (Galiuto, 2004). Functional MVO may have potentially 
reversible components (e.g. microembolisation inducing microvascular spasm (Wilson et 
al., 1989) and extrinsic oedema) and structural MVO reflects irreversible damage to the 
microvascular bed with endothelial disruption. 
1.2.3 Pathological basis of IMH and its anatomical distribution 
Reperfusion is a prerequisite for macroscopic haemorrhage and it does not occur in the 
presence of a persistent coronary occlusion (Garcia-Dorado et al., 1990, Pislaru et al., 
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1997). The extent of IMH after acute MI is highly correlated with infarct size and the 
duration of ischaemia, but interestingly has been found to be independent of thrombolytic 
therapy (Kloner and Alker, 1984, Basso and Thiene, 2006, Garcia-Dorado et al., 1990). 
The occurrence of IMH after severe microvascular injury can be explained by loss of 
endothelial integrity. Reperfusion of myocardium after a prolonged period of ischaemia 
leads to oncosis (cell death) of the vascular endothelium and thus to a breakdown of the 
microvascular barrier resulting in capillary fragility and extravasation of erythrocytes into 
the reperfused myocardium i.e. haemorrhage (Garcia-Dorado et al., 1990, Higginson et al., 
1982) (figure 1-1). Due to the wavefront of myocardial necrosis (Reimer et al., 1977), the 
endocardium is the most vulnerable area for ischaemic damage. In animal models it is 
observed that IMH is confined to the region of most severe microvascular injury, in the 
infarct core and that it lags behind the no-reflow process (Fishbein et al., 1980, Higginson 
et al., 1982, Payne et al., 2011a, Robbers et al., 2013, Kumar et al., 2011). In contrast to the 
infarct core, no haemorrhage is seen in the border zone of the infarct (McNamara et al., 
1981, Reimer et al., 1977, Robbers et al., 2013), an area which is potentially salvageable. 
Other recent clinical studies using T2* CMR to define haemorrhage, also observed that 
haemorrhage only occurred within regions of MVO, whereas MVO could occur without 
the presence of haemorrhage (Kali et al., 2013b, Kumar et al., 2011, Zia et al., 2012, Kidambi 
et al., 2013, O'Regan et al., 2010), supporting the hypothesis that MVO precedes haemorrhage. 
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Figure 1-1 A schematic diagram of the pathophysiology of intramyocardial haemorrhage 
 
A schematic figure of the mechanisms which underlie and predict the development of 
intramyocardial haemorrhage following coronary artery occlusion (MPTP, mitochondrial 
permeability transition pore; Hb, Haemoglobin; oxyHb, oxyhaemoglobin; deoxyHb, 
deoxyhaemoglobin). 
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Initial pathological and clinical observations seemed to support the hypothesis that distal 
embolisation of epicardial thrombotic and atheromatous material was the main mechanism 
for precipitating MVO and no-reflow. This notion led to the general assumption that the 
contrast-devoid core of gadolinium-enhanced CMR images represented MVO. This 
terminology reflects the original hypothesis of microvascular blockage as the underlying 
cause of no-reflow. However, in 2013, new evidence emerged from a comprehensive CMR 
translational study using a porcine STEMI model (Robbers et al., 2013) that indicated that 
the areas of the MVO and IMH largely overlap, and together indicate myocardial tissue 
with vascular damage and extravasation of erythrocytes, rather than microvascular 
occlusion. The assumption of obstruction was found to be true for the border zone of the 
infarcted myocardium (corresponding to the hyperenhanced region on late gadolinium 
enhancement), where intact microvessels were identified that contained microthrombi. 
Whereas the contrast-devoid core of the infarcted tissue was shown to represent IMH 
secondary to microvascular destruction, rather than obstruction. Figure 1-2 shows contrast-
enhanced CMR images from reperfused STEMI patients (day 2 post-PCI), one with and 
one without MVO. Highlighted is the contrast-devoid infarct core (“microvascular 
destruction”) and the hyperenhanced border zone in the patient with MVO. 
Figure 1-2 Late gadolinium enhancement images from acute reperfused STEMI patients, 2 
days post-PCI  
(A) late gadolinium enhancement (LGE) image showing extensive hyperenhancement of 
the inferior wall, representing near transmural infarction, with no evidence of MVO. (B) 
LGE image again showing transmural hyperenhancement with a central contrast-devoid 
core (red star), representing the area known as “microvascular obstruction”. The 
hyperenhanced border of the infarct is denoted by the green circle. 
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1.2.4 Summary 
IMH reflects severe reperfusion injury in acute myocardial infarction involving the 
structural and functional integrity of the microcirculation. Aggressive antithrombotic 
regimens dominate pharmacological adjunctive strategies in PPCI, due to consideration of 
distal embolisation of thrombus fragments as the main determinant of MVO or no-reflow. 
Presumably, excessive antiplatelet therapy could be involved in the development/ 
aggravation of IMH. In support of this theory, use of glycoprotein IIb/IIIa inhibitors in 
addition to bivalirudin in a porcine model, showed significant increase in the frequency of 
IMH compared to bivalirudin alone (Buszman et al., 2012). In contrast, the administration 
of low-dose intracoronary streptokinase immediately following PPCI, was shown to 
improve microvascular function, limit infarct size and preserve LV function (Sezer et al., 
2009, Sezer et al., 2007). 
It remains unclear, whether haemorrhage represents an unintended consequence of 
evidence-based anticoagulant and antiplatelet therapies, or more likely is a manifestation of 
more severe MI. Based on pathological studies (Fishbein et al., 1980, Garcia-Dorado et al., 
1990, Robbers et al., 2013) microvascular obstruction is a precursor to the development of 
intramyocardial haemorrhage, which is confined to the most severe area of microvascular 
injury in the infarct core. However, the inter-relationships between haemorrhage and other 
infarct pathologies, including MVO, and their temporal evolution in the early reperfusion 
period remain uncertain. 
1.3 Detection of myocardial haemorrhage 
1.3.1 Introduction 
Alternative methods to CMR that can be used to assess microvascular injury and the risk of 
intramyocardial haemorrhage following coronary reperfusion include: persistent ST-
segment elevation on the ECG (Nijveldt et al., 2008), angiographic measures (such as 
myocardial blush grade and corrected TIMI frame count) (Marra et al., 2010, Vicente et 
al., 2009), myocardial contrast echo (Wu et al., 1998a), PET, SPECT (Schofer et al., 1985), 
and recently multidetector cardiac CT (Gerber et al., 2006). However, these techniques 
assess myocardial perfusion rather than haemorrhage and CMR is considered to be the 
gold-standard method of assessment, which is able to specifically detect IMH and has been 
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validated histologically (Ghugre et al., 2011, Kumar et al., 2011, Payne et al., 2011a, 
Robbers et al., 2013). Haemorrhage can be detected with T1, T2 and T2* sequences and 
have been validated with histopathological findings. The vast majority of studies to date, 
both clinical and experimental, have used T2 or T2* sequences rather than T1 sequence to 
detect haemorrhage (Eitel et al., 2011, Ganame et al., 2009, Kali et al., 2013b, Kandler et 
al., 2014, Kidambi et al., 2013, Mather et al., 2011b, O'Regan et al., 2010). However, the 
standardised imaging method or protocol for assessment of IMH is still debated, as is the 
timing of image acquisition post-reperfusion. 
1.3.2 MRI and the detection of haemorrhage   
MRI characterises ischaemic injury based on water content and fundamental nuclear 
magnetic properties of tissue: longitudinal (T1) and transverse (T2) relaxation times. 
Ischaemia causes oedema in the area-at-risk, which increases T2/ T1 relaxation times and 
this is depicted by increased signal intensity (i.e. hyperenhancement) on CMR (Berry et al., 
2010, Payne et al., 2011b, Aletras et al., 2006, Garcia-Dorado et al., 1993). The appearance 
of haemorrhage on MRI is based upon the paramagnetic effects of haemoglobin 
degradation products (Bradley, 1993). These breakdown products produce different signal 
intensities on CMR and therefore imaging of intramyocardial haemorrhage will depend on 
the time post-reperfusion and the particular sequence used. IMH may initially consist of 
oxyhaemoglobin which lacks paramagnetic properties. Subsequently, in the hours and days 
after reperfusion, oxyhaemoglobin is denatured to deoxyhaemoglobin, which exerts 
paramagnetic effects, in turn depleting T2/ T2* signal. Deoxyhaemoglobin is later 
converted into methaemoglobin which is strongly paramagnetic with respect to both T1- 
and T2-magnetisation. After about two weeks methaemoglobin is further converted into 
haemosiderin which is contained within macrophages and results in low T2/ T2* values 
(Wu, 2012). Therefore, in the early reperfusion period, myocardial haemorrhage can be 
visualised on CMR as a hypointense region (T2/ T2* sequences), within the infarct core, 
surrounded by high signal intensity from oedema (figure 1-3).   
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Figure 1-3 Appearances of IMH on T2 and T2* sequences 
CMR images from 3 acute reperfused STEMI patients, acquired day 2 post-MI. (A) 
Transmural lateral infarction, with MVO present (orange arrow) on contrast-enhanced 
image. There is a hypointense core shown on both the T2 and T2* map, with a surrounding 
area of elevated signal form oedema; this area corresponds to the contrast-devoid core on 
the late gadolinium enhancement (LGE) image. (B) Subendocardial infero-septal infarct, 
with no evidence of MVO. The elevated T2 signal from oedema can be appreciated (middle 
left). (C) Similar to (A), images reveal a haemorrhagic antero-septal infarction. The 
hypointense core on T2 and T2* maps is due to the paramagnetic effects of 
intramyocardial haemorrhage. 
   
1.3.3 T2 weighted MRI  
Technical differences exist between several proposed cardiac MRI techniques in detecting 
IMH. Most studies to date have used dark-blood inversion recovery T2-weighted MRI 
methods either solely (Amabile et al., 2012, Beek et al., 2010, Bekkers et al., 2010a, Eitel 
et al., 2011, Ganame et al., 2009, Husser et al., 2013), or in combination with T2* imaging 
(Ghugre et al., 2011, Kali et al., 2013b, Kandler et al., 2014, Kidambi et al., 2013, Kumar 
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et al., 2011, Mather et al., 2011b, O'Regan et al., 2010). Dark blood T2-weighted MRI is 
known to be hampered by poor image quality, partly due to the low contrast-to-noise ratio 
between normal and abnormal myocardium (Kellman et al., 2007, Wince and Kim, 2010). 
This method is also prone to artefact from motion and from blood stasis at the left 
ventricular wall, causing subendocardial bright rim artefacts. A further limitation is the 
qualitative nature of this technique, which gives rise to diagnostic uncertainty.  
Bright-blood T2-weighted MRI techniques are potential alternatives to dark blood T2-
weighted MRI that may offer a more robust image quality (Aletras et al., 2008, Kellman et 
al., 2007). A pre-clinical validation study in swine (n=15) found bright-blood T2-weighted 
MRI to have a high diagnostic accuracy for IMH with  positive and negative predictive 
values for pathological evidence of haemorrhage of 94% and 96% respectively (Payne et 
al., 2011a) 
A hypointense core within the hyperintense infarct zone revealed by T2-weighted CMR is 
a common observation that in some (Basso et al., 2007, Payne et al., 2011a), but not all 
(Cannan et al., 2010, Jackowski et al., 2006), studies corresponds with histology evidence 
of myocardial haemorrhage. Therefore it has been proposed that a T2 hypointense core 
may simply represent the presence of MVO without IMH. This may be due to reduction in 
perfusion to the infarct core secondary to obstructed capillary flow, resulting in reduced 
oedema and thus lower T2-signal (Wu, 2012, Verhaert et al., 2011). Consequently, it does 
not seem possible to differentiate if a T2 hypointense core represents MVO, IMH or both, 
by using exclusively T2-weighted sequences. 
1.3.4 T2* imaging 
T2*-weighted CMR is the reference diagnostic method for myocardial haemorrhage in 
vivo (Basso et al., 2007, Kali et al., 2013b, Kumar et al., 2011), however technical issues 
have limited T2* imaging in clinical practice.  Despite the sensitivity of T2* imaging for 
iron (Carpenter et al., 2011), it is also sensitive to off-resonance artefacts arising from bulk 
magnetic susceptibility differences at the heart-lung interface, particularly affecting the 
infero-lateral LV wall. Because T2* loss from off-resonance artefacts and IMH arise from 
opposite sides of the myocardial wall (i.e. epicardial wall for off-resonance artefacts and 
endocardial wall for IMH), it is possible to carefully discriminate between haemorrhage 
and off-resonance artefacts. 
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T2* imaging is more specific in detecting myocardial haemorrhage in comparison to T2-
weighted imaging because the paramagnetic effects of haemoglobin products are stronger 
on T2* than T2, causing greater signal depletion within the infarct core (Kali et al., 2013b, 
Kumar et al., 2011). Since T2 imaging is known to be highly sensitive to oedema, which 
commonly accompanies acute reperfusion haemorrhage, the appearance of haemorrhage 
may be masked or reduced on T2 images, whereas T2* is relatively insensitive to oedema 
(Lotan et al., 1992). The role of T2* weighted sequences for detecting IMH has been 
extensively validated by histology, one such study using a canine model (Kumar et al., 
2011), showed a strong correlation between haemorrhage sizes assessed in vivo with T2* 
and assessed ex vivo by triphenyltetrazoliumchloride (TTC). Kali et al. (Kali et al., 2013b) 
more recently compared T2 versus T2* imaging for the detection of IMH in both humans 
and canines. They observed that T2* was more suitable for the detection and 
characterisation of reperfusion haemorrhage. Furthermore, a clinical study by Kandler et 
al. (Kandler et al., 2014) in 151 STEMI patients, demonstrated that hypointense core on 
T2* were also present on T2 imaging but not vice versa, suggesting that T2* sequences 
were more accurate for IMH detection than T2.  
 
1.3.5 Quantitative T2 mapping  
Recent developments in CMR imaging techniques are enabling clinically-feasible rapid 
parametric mapping of myocardial magnetic relaxation properties (T1, T2, and T2* 
relaxation times). There is a growing body of evidence for the clinical utility of 
quantitative assessment of relaxation times. To generate a parametric map of relaxation 
times, multiple images of the same region of the myocardium are acquired with different 
sensitivity to the parameter of interest, and the signal intensities of these images are fit to a 
model that describes the underlying physiology or relaxation parameters. The parametric 
map is an image of the fitted perfusion parameters or relaxation times. These mapping 
techniques hold great promise for quantitative assessment of infarct characteristics, but to 
date there has been few studies, with small patient numbers in this field. 
Quantitative T2 mapping, which allows direct determination of T2 relaxation times, 
overcomes many of the inherent limitations associated with dark blood T2-weighted CMR 
and may allow for a more objective assessment of the infarct core (Giri et al., 2009, 
Verhaert et al., 2011, Ghugre et al., 2011, Zia et al., 2012, Ugander et al., 2012, 
Nassenstein et al., 2014, Park et al., 2013). Verhaert et al. (Verhaert et al., 2011)  
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compared quantitative T2 mapping to dark-blood T2 STIR, in a cohort of 27 acute MI 
patients. They showed that T2 mapping was more accurate and robust than T2 STIR in 
detecting myocardial oedema.  However, to date there has been no experimental animal 
studies or clinical trials using this novel methodology to detect and quantify IMH.  
1.3.6 T1 weighted sequences 
In a swine model, Pedersen et al. (Pedersen et al., 2012) investigated whether IMH could 
be detected by exploiting the T1-shortening effect of methaemoglobin. They demonstrated 
for the first time, a higher diagnostic sensitivity and specificity of T1-weighted inversion 
recovery sequences (T1WIR), compared to T2 short tau inversion recovery sequences (T2-
STIR) and to T2* weighted sequences, for the detection of reperfusion IMH. This was 
validated with pathology and T1WIR sequences depicted IMH as an area of hyperintense 
signal, instead of the usual hypointense signal appreciated with T2 and T2* CMR.  
One small study by Dall’Armellina et al. (Dall'Armellina et al., 2012), including 32 
STEMI patients, used T1 mapping to assess myocardial injury 24 hours post-MI. They 
found that MVO resulted in a hypointense core on T1 maps and showed that the T1 values 
in the injury zone were associated with functional recovery at 6 months. However, 
segments with MVO/ T1 core were excluded from this analysis and therefore no 
conclusions could be drawn regarding intramyocardial haemorrhage. 
1.3.7 Clinical significance of myocardial haemorrhage in STEMI 
The clinical significance of IMH is still unclear because of non-standardised methods to 
detect IMH in vivo. The largest cohort studies of myocardial haemorrhage in STEMI 
patients to date have not used T2* imaging (Amabile et al., 2012, Ganame et al., 2009, 
Husser et al., 2013, Robbers et al., 2013, Bekkers et al., 2010a, Beek et al., 2010), although 
some smaller studies have used T2* CMR (Kandler et al., 2014, Mather et al., 2011b, 
O'Regan et al., 2010, Kidambi et al., 2013) (table 1-1). Because of these different CMR 
techniques, uncertainties have arisen around the pathophysiology and clinical significance 
of myocardial haemorrhage, and its relationships with microvascular obstruction. 
Ganame et al. showed, in a multivariate analysis, that intramyocardial haemorrhage 
detected on T2-weighted images is an independent predictor of adverse LV remodelling at 
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4 months, regardless of infarct size (Ganame et al., 2009). The largest prospective study to 
date was conducted by Eitel et al. and included 346 STEMI survivors (Eitel et al., 2011). 
They demonstrated that the presence of haemorrhage, defined as a hypointense core on T2-
weighted imaging, occurred in 35% of patients and was associated with larger infarcts, 
greater extent of MVO, less myocardial salvage and reduced LV ejection fraction. They 
were the first to demonstrate the prognostic significance of a T2 hypointense core, since it 
was a strong predictor of adverse outcome at 6 months. In a similar sized cohort (n=304), 
Husser et al. (Husser et al., 2013) also showed that a T2-weighted hypointense core after 
STEMI predicted MACE and adverse remodelling. However, due to the strong 
interrelation with MVO, the addition of T2 imaging did not improve the predictive value of 
contrast-enhanced CMR. 
On the contrary, two smaller studies demonstrated that T2 hypointense core was not an 
independent predictor of adverse LV remodelling, nor had prognostic significance beyond 
that of MVO (Beek et al., 2010, Bekkers et al., 2010a). Of note, the studies in table 1-1 that 
showed an association between IMH and adverse remodelling were those in which baseline 
LV ejection fraction was significantly reduced and therefore patients were more likely to 
remodel adversely over time. 
Using a combination of T2-weighted and T2* imaging, Mather et al. (Mather et al., 2011b) 
described an association between IMH and prolonged QRS duration on signal-averaged 
ECG, a marker of arrhythmic risk. IMH was also observed to be associated with adverse 
remodelling. 
In summary, previous studies examining the significance of myocardial haemorrhage post-
STEMI have been limited by their qualitative techniques, not including haemorrhage 
sensitive sequences, together with small sample sizes (table 1-1). I propose a multi-
parametric MRI protocol, including parametric mapping techniques, T2* imaging and late 
enhancement imaging for a comprehensive, quantitative assessment of severe reperfusion 
injury. The key question remains: whether or not myocardial haemorrhage has independent 
predictive value for adverse LV remodelling and health outcomes in the longer term, and 
this question can only be answered through a reasonably large cohort study.   
 
  
42 
 
Table 1-1 Clinical studies on the prognostic significance of CMR defined IMH 
Study  MRI method 
for IMH 
detection 
Imaging 
time post-
reperfusion 
Incidence 
IMH (%) 
Findings 
Ganame et al. 
(Ganame et al., 
2009) (n = 98) 
T2-weighted 1 week and 
4 months 
24 IMH is an independent 
predictor of adverse LV 
remodelling at 4 months 
Bekkers et al. 
(Bekkers et al., 
2010a) (n = 
90) 
T2-weighted 5 days and 
103 days 
43 Only infarct size was an 
independent predictor of LV 
remodelling 
Beek et al. 
(Beek et al., 
2010) (n = 45) 
T2-weighted 2-9 days 
and 4 
months 
49 IMH was not an independent 
predictor of functional changes 
at follow-up, and had no 
prognostic value beyond MVO 
O’ Regan  et 
al. (O'Regan et 
al., 2010) (n = 
50)  
T2* 3 days 58 IMH was closely associated 
with the development of MVO 
and was associated with infarct 
transmurality 
Mather et al. 
(Mather et al., 
2011b) (n = 
48) 
T2* and T2-
weighted 
2 days and 
3 months 
25 IMH is an independent 
predictor of adverse 
remodelling and associated 
with prolonged fQRS duration; 
a marker of arrhythmic risk 
 
Eitel et al. 
(Eitel et al., 
T2-weighted 3 days 35 Presence of IMH is a strong 
predictor of MACE at 6 month 
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2011) (n = 
346) 
follow up 
Amiable et al. 
(Amabile et 
al., 2012) (n = 
114) 
T2-weighted 4-8 days 10 IMH associated with larger 
infarct sizes and worse clinical 
outcome 
Husser et al. 
(Husser et al., 
2013) (n = 
304) 
T2-weighted 1 week and 
6 months 
34 IMH is a predictor of MACE 
and correlates strongly with 
MVO; the addition of T2-
imaging does not improve 
predictive value beyond LGE 
CMR 
Zia et al. (Zia 
et al., 2012) (n 
= 62) 
T2* and T2-
weighted 
2 days, 3 
weeks and 6 
months 
32 Presence of IMH resulted in a 
trend towards LV remodelling 
at 6 months 
Kali et al. 
(Kali et al., 
2013b, Kali et 
al., 2013a) (n = 
15) 
T2* and T2-
weighted 
3 days and 
6-months 
73 Patients with IMH are at risk of 
developing chronic iron 
deposits within the infarct 
zone, which can be a source of 
prolonged inflammatory 
burden  
Kidmabi et al. 
(Kidambi et 
al., 2013) (n = 
39) 
T2* and T2-
weighted 
Day 2, 7, 30 
and 90 
36 MVO and IMH are greater 
independent predictors of 
infarct zone contractile 
recovery than infarct volume or 
transmural extent 
Kandler et al. 
(Kandler et al., 
2014) (n = 
151) 
T2* and T2-
weighted 
3 days 50 IMH was associated with 
impaired LV function and 
larger infarct size 
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1.4 Coronary pressure wire to assess microvascular dysfunction at the 
time of emergency PCI 
1.4.1 Role of Microcirculation   
Myocardial blood flow comprises the epicardial circulation, smaller branches of the 
coronary tree collectively referred to as the microcirculation as well as the contribution 
from collateral flow. An important determinant of myocardial blood flow involves the 
modulation of vascular tone within the microcirculation with the epicardial circulation 
fulfilling a conduit vessel function only (Camici and Crea, 2007).  Therefore specifically 
focusing on the microcirculation rather than solely the epicardial circulation may provide a 
further path for prognostic improvements in patients with IHD, particularly in the acute 
setting. 
1.4.2 Coronary microvascular resistance   
Resistance equals pressure gradient divided by flow. In the case of the coronary 
circulation, the mean aortic to distal coronary back pressure gradient divided by total sinus 
blood flow over time yields total coronary resistance (mmhg/ml/min). Under normal 
conditions the epicardial arteries which run over the surface of the heart do not create any 
significant resistance to blood flow. Even at high flow rates only a negligible pressure 
difference exists between the central aorta and the most distal part of the angiographically 
smooth epicardial artery (Marcus et al., 1990). 
Under normal physiological conditions, resistance is principally determined by vasomotor 
regulation of the arterioles with a diameter of less than 400 μm and flow is kept constant 
over a wide level of perfusion pressures by auto-regulation (Chilian, 1997, Marcus et al., 
1990). Therefore, under baseline conditions the knowledge of coronary resistance reflects 
basal metabolism, but when auto-regulation is exhausted, as in under pharmacological 
hyperaemia, minimal resistance can be calculated.    
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1.4.3 Thermodilution 
Thermodilution is a method based on the indicator dilution principle (Stewart, 1897, Meier 
and Zierler, 1954), which states that by injecting a certain amount of indicator into the 
bloodstream and measuring the concentration of indicator over time distal to the injection 
site, volumetric flow can be quantified. It is based on the following basic relationship: 
Flow = volume/mean transit time. Coronary blood flow and volume can be quantified by 
thermodilution. For this purpose, a coronary guidewire is used with a shaft that acts as a 
proximal thermistor and a combined pressure/temperature microsensor mounted close to 
the tip (De Bruyne et al., 2001, Pijls et al., 2002, Fearon et al., 2003b). 
There are some technical limitations and practical issues however to be considered when 
quantifying coronary blood flow and volume using this method. First, stable positioning of 
the catheter is required, which might be challenging as the catheter should be kept in the 
same place during baseline and hyperaemic measurements (De Bruyne et al., 2001). Also it 
is recommended to maintain a distance of at least 6 cm between the guiding catheter and 
the temperature sensor at the tip in order to allow adequate mixing of blood and saline (De 
Bruyne et al., 2001). Disappearing of saline into side branches might lead to 
overestimation of blood flow. Injection of saline mainly during systole or diastole can be 
misleading, so measurements should be performed in triplicate to correct for this error 
which can occur especially in patients with bradycardia (De Bruyne et al., 2001). Also the 
volume of injected saline itself should be sufficiently low as to not influence coronary 
blood flow. 
1.4.4  Thermodilution derived coronary flow reserve 
Human coronary artery blood flow can increase three to fourfold in response to ischaemia 
(Vassalli and Hess, 1998). This property has been formalised as a concept known as the 
coronary flow reserve (CFR). CFR is defined as the ratio of hyperaemic flow to baseline 
flow. In determining CFR, pharmacological agents such as adenosine and papaverine are 
used to induce maximal hyperaemia (Vassalli and Hess, 1998). CFR was originally 
developed to assess the severity of epicardial coronary disease and used as a marker of PCI 
adequacy. However, the use of CFR in this manner has been shown to be somewhat 
limited as CFR not only assesses the epicardial compartment but also reflects 
microvascular function (Knaapen et al., 2009).    
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Under resting conditions, coronary blood flow is dependent on determinants of myocardial 
oxygen demand, namely heart rate, contractility and ventricular load. However when 
myocardial oxygen demand is constant and within the realms of autoregulation, coronary 
blood-flow is independent of perfusion pressure.  During maximal hyperaemia when 
resistance vessels are maximally dilated, blood flow is no longer autoregulated and varies 
linearly with perfusion pressure. Thus, as CFR is the ratio of peak hyperaemic-to-resting 
flow it is affected by determinants of resting coronary blood flow a fact that can affect the 
reproducibility of the ratio (Ng et al., 2006).  It is also influenced significantly by 
epicardial vessel disease and is therefore an invalid method of quantifying microvascular 
disease in the majority of patients presenting to cardiology practices. 
The validity of the thermodilution principle to demonstrate CFR on a commercially 
available guide-wire (PressureWire 3, Radi Medical Systems) was first validated in an 
experimental dog model by De Bruyne et al in 2001 (De Bruyne et al., 2001). In this in-
vitro model, absolute flow was compared with the inverse mean transit time (1/Tmn) of a 
thermodilution curve obtained after a bolus of 3ml saline at room temperature. A very 
close correlation (r>0.95) was found between absolute flow and 1/Tmn. In the canine 
model a significant correlation was found between CFR, calculated from the ratio of 
hyperaemic to resting flow velocities using a Doppler flow wire, and the CFR derived from 
the ratio of resting to hyperaemic Tmn (r=0.76;p = <0.001)   
Therefore thermodilution derived CRF is calculated as follows (De Bruyne et al., 2001). 
Coronary flow reserve  
(CFR) is defined as the ratio of peak hyperaemic to resting flow (F) (Gould et al., 1974).   
  1.  CFR = F at hyperaemia / F at rest   
Flow is the ratio of the volume (V) divided by Tmn. Thus, CFR can be expressed as 
follows.   
  2.  CFR = (V/Tmn) at hyperaemia / (V/Tmn) at rest   
Assuming the epicardial volume (V) remains unchanged, CFR can be calculated as 
follows.   
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  3.  CFR = Tmn at rest / at hyperaemia   
However, CFR has two well-recognised limitations when used to assess coronary 
microvascular resistance: (1) its inability to distinguish between relative epicardial and 
microvascular contribution to total resistance (Kern, 2000) and (2) its dependence upon 
haemodynamic factors (ie, blood pressure, heart rate, etc) (Ng et al., 2006), affecting its 
reproducibility negatively. To circumvent these limitations, a novel index of microvascular 
resistance (IMR) was proposed by Fearon et al. (Fearon et al., 2003a). 
1.4.5 Index of Microvascular Resistance  
The index of microvascular resistance (IMR) is a well-validated method of measuring 
microvascular resistance and function. Like thermodilution derived CFR, it utilises the 
temperature pressure sensitive guidewire to simultaneously measure transit time and distal 
coronary pressure during maximal hyperaemia. IMR is the product of these two 
parameters.    
    IMR = Pd x Tmn   
A fundamental assumption in the theory is that Tmn is inversely proportional to 
hyperaemic blood flow. Because   
F = V/ Tmn   
Where flow (F) equals the ratio of epicardial vascular volume (V) and mean transit time 
(Tmn). Because true microvascular resistance (TMR) equals distal perfusion pressure 
divided by flow:   
TMR = Pd/F   
And because the vascular volume (V) may be assumed to remain constant at maximal 
hyperaemia by combining equations 1 and 2, can be derived that TMR is proportional to 
the product of distal coronary pressure and Tmn:   
TMR = Pd.Tmn   
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Using an open chest swine model, Fearon et al compared true microvascular resistance 
(TMR) defined at the distal LAD pressure divided by absolute coronary flow derived from 
the use of an ultrasonic flow probe, with IMR (Fearon et al., 2003a) with and without 
microvascular dysfunction. Microvascular dysfunction was artificially generated using 
microspheres injected into the coronary arteries. The investigators found a reasonable 
correlation between IMR and TMR (r = 0.54 p<0.0001. The investigators also found that 
IMR increased with worsening microvascular function independent of epicardial stenosis.  
Work performed by Arnoudse et al confirmed the utility of IMR in assessing 
microvascular resistance. Using an in-vitro model the group demonstrated an excellent 
correlation between TMR and IMR (r2 0.94) and suggested that the tool is independent of 
epicardial stenosis (Aarnoudse et al., 2004b).   
In the presence of severe stenoses, some investigators have shown that neglecting the 
increasing contribution of collateral flow may lead to an overestimation of microvascular 
resistance (Aarnoudse et al., 2004a, Fearon et al., 2004).  Thus in the presence of epicardial 
stenosis the IMR equation is modified as follows:    
IMR = PaTmn(Pd-Pw/Pa-Pw)    
where Pa is the hyperemic aortic pressure, Pd the hyperemic distal pressure beyond a 
stenosis and Pw the coronary wedge pressure defined as the mean distal coronary pressure 
in the target vessel during balloon occlusion (Aarnoudse et al., 2004a). 
IMR has been compared with CFR in patients without significant epicardial stenosis. In a 
small study, Ng and colleagues compared CFR and IMR in the same patients under 
different haemodynamic conditions (Ng et al., 2006).  The group examined the effects of 
increasing heart rate with the use of temporary pacing, afterload reduction with the use of 
sodium nitroprusside and increasing contractility with the use of dobutamine.  Compared 
with CFR, IMR demonstrated superior reproducibility and significantly less influence of 
the underlying haemodynamic environment (Ng et al., 2006). Accordingly IMR appears to 
be a specific measure of microvascular integrity independent of epicardial stenosis and is 
thus perhaps more applicable to the general catheter laboratory population of patients with 
IHD. 
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1.4.6 IMR in STEMI 
In a few clinical studies with patients with acute myocardial infarction, IMR measured 
directly after primary PCI was linked to myocardial damage after MI (Fearon et al., 2008, 
Lim et al., 2009, McGeoch et al., 2010). IMR predicted infarct size, as shown by 
biomarkers including peak CK (Fearon et al., 2008, Lim et al., 2009) and troponin I 
(McGeoch et al., 2010), as well as severity of myocardial infarction, as shown by infarct 
volume (McGeoch et al., 2010) and LV function (Fearon et al., 2008, Lim et al., 2009, 
McGeoch et al., 2010). Moreover, McGeoch et al. (McGeoch et al., 2010) showed that 
patients who displayed MVO, as measured by contrast-enhanced CMR, had higher IMR 
after PCI than patients in whom MVO did not occur. 
A recent study by Payne et al. (Payne et al., 2012) confirmed the ability of IMR to predict 
infarct size, LV function and MVO determined by contrast-enhanced CMR at 3-month 
follow-up in a larger group of patients with acute STEMI. IMR predicted myocardial 
salvage was linked to the presence of MVO as well as the extent of MVO as assessed by 
CMR. 
In a landmark recent study, 253 acute STEMI patients with IMR >40 had a higher rate of 
the primary endpoint of death or rehospitalisation for heart failure at one year than patients 
with an IMR ≤40 (17.1% versus 6.6%; p=0.027) (Fearon et al., 2013). This marker has the 
potential to identify those patients who may require closer follow-up and more aggressive 
medical management to avoid poorer outcome. 
The potential advantages of IMR are that it is readily available in the catheterisation lab, 
specific for the microvasculature, quantitative and reproducible, in addition to being a 
predictor of outcomes in STEMI. Therefore, the direct quantitative measure of 
microvascular function during primary PCI, in combination with MRI, may potentially 
enhance our understanding of severe ischaemic-reperfusion injury and provide a more 
comprehensive assessment for the characterisation of myocardial haemorrhage.
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1.5 Aims of thesis 
The hypothesis that this thesis will test is whether the detection of intramyocardial 
haemorrhage by CMR has prognostic value in STEMI survivors. This thesis will also 
examine the evolution and inter-relationships between myocardial haemorrhage and 
microvascular obstruction, to inform and implement novel therapeutic interventions. 
Furthermore, it will evaluate the prognostic significance of infarct core tissue 
characteristics using parametric mapping techniques in survivors of acute STEMI. A full 
outline of the aims of this thesis are stated below: 
 To detect myocardial haemorrhage using T2* mapping in a large relatively 
unselected STEMI population and re-evaluate its clinical associates and prognostic 
significance. 
 To study the time-course of myocardial haemorrhage evolution with serial CMR 
after reperfusion and assess the temporal relationships between myocardial 
haemorrhage versus microvascular obstruction. 
 To assess the clinical associates and prognostic significance of a T2 hypointense 
core, revealed by T2 mapping and determine the relationship with myocardial 
haemorrhage revealed by T2* CMR. 
 To assess the evolution of myocardial haemorrhage and oedema using quantitative 
T2 and T2* methods at serial time-points post-MI. 
 To assess the clinical associates and prognostic significance of native T1 measured 
within the hypointense infarct core, using T1 mapping and determine the 
relationship with myocardial haemorrhage revealed by T2* CMR. 
 To assess whether IMR measured at the end of primary percutaneous coronary 
intervention (PPCI) might discriminate STEMI patients at risk of subsequent 
intramyocardial haemorrhage. 
 To assess whether during primary PCI, brief deferral of stenting after initial 
coronary reperfusion, might reduce the occurrence of angiographic no-reflow, 
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microvascular obstruction and myocardial haemorrhage, compared to usual care 
with immediate stenting. 
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2 Chapter 2: Methods
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2.1 Preamble 
In this section I will describe the CMR and statistical methods used that were common to 
studies in this thesis. Detailed study specific methods are described within the relevant 
chapters. 
2.2 Setting and recruitment 
This prospective CMR cohort study was conducted at the Golden Jubilee National 
Hospital, Clydebank between 11 May 2011 and 22 November 2012. This hospital is a 
regional referral centre for primary and rescue percutaneous coronary intervention (PCI). 
The hospital provides clinical services for a population of 2.2 million. A screening log was 
recorded, including patients who did not participate in the cohort study. Near consecutive 
patients were screened and consented predominantly by myself or by the consultant 
cardiologist on-call who was performing the PCI if I was not in the hospital. All consultant 
interventional cardiologists in our institution (KGO, CB, AD, SH, MP, MM, MML, CO, 
SW, HE, AR, RN) enrolled patients into the study and recruitment took place round the 
clock. A breakdown of study recruitment by day of week, to the nearest hour and 
proportion undertaken out of hours is shown in figures 2-1, 2-2 and 2-3. The study was 
publically registered (ClinicalTrials.gov identifier is NCT02072850). 
Figure 2-1 Study recruitment broken down by day of the week 
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Figure 2-2 Study recruitment broken down to the nearest hour 
 
Figure 2-3 Proportion of study recruitment undertaken outside "normal working hours" 
 
2.3 Study populations 
2.3.1 STEMI patients  
Three hundred and seventy two STEMI patients provided written informed consent. The 
eligibility criteria included an indication for primary PCI or thrombolysis for acute STEMI 
due to a history of symptoms consistent with acute myocardial ischemia and with 
supporting changes on the electrocardiogram (ECG) (i.e. ST-segment elevation or new left 
bundle-branch block) (O'Gara et al., 2013). Exclusion criteria represented standard contra-
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indications to contrast CMR, including a pacemaker and an estimated glomerular filtration 
rate < 30 ml/min/1.73 m2.  
2.3.2 Serial imaging sub-study 
Thirty STEMI patients underwent serial CMR in order to characterise the evolution of 
myocardial haemorrhage by T2 and T2* quantification, and evaluate the temporal 
relationship with microvascular obstruction. Each patient was imaged at 4 time points, with 
the identical imaging protocol that was used in the main STEMI cohort: 4 to 12 hours, 3 
days, 10 days and 6-7 months post-reperfusion. 
2.3.3 Deferred stenting sub-study 
One hundred and one STEMI patients were enrolled in a prospective randomised 
controlled parallel group trial of deferred PCI versus immediate stenting during primary 
PCI, to assess whether deferred stenting might reduce no-reflow and salvage myocardium 
in primary PCI. This trial was a proof-of-concept trial nested in the main prospective 
cohort study. This will be described in detail in Chapter 9. 
2.3.4 Healthy volunteers 
CMR was also performed in 50 healthy volunteers of similar age and gender in order to 
obtain local reference values for myocardial T1, T2 and T2*. Patients and healthy 
volunteers underwent the same imaging protocol except that healthy volunteers <45 years 
did not receive gadolinium contrast. Thirteen healthy volunteers were aged <45 years and 
therefore did not receive contrast. 
2.4 Coronary angiogram acquisition and analyses 
Coronary angiograms were acquired during usual care with cardiac catheter laboratory X-
ray (Innova) and IT equipment (Centricity) made by GE Healthcare. The coronary 
anatomy and disease characteristics of study participants were described based on the 
clinical reports of the attending cardiologist.  
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2.4.1 TIMI coronary flow grade 
Coronary blood flow can be described based on the visual assessment of coronary blood 
flow revealed by contrast injection into the coronary arteries (TIMI-Study-Group, 1985) 
(table 2-1).  
Table 2-1 TIMI coronary flow grade definition. 
TIMI Coronary Flow Grade  
0 No flow 
1 Minimal flow past obstruction 
2 Slow (but complete) filling and slow clearance 
3 Normal flow and clearance 
 
2.5 Percutaneous coronary intervention 
During ambulance transfer to the hospital, the patients received 300 mg of aspirin, 600 mg 
of clopidogrel and 5000 IU of unfractionated heparin (O'Gara et al., 2013, Steg et al., 
2012). The initial primary PCI procedure was performed using radial artery access. A 
conventional approach to primary PCI was adopted in line with usual care in our hospital 
(O'Gara et al., 2013, Steg et al., 2012). Conventional bare metal and drug eluting stents 
were used in line with guideline recommendations and clinical judgement. The standard 
transcatheter approach for reperfusion involves minimal intervention with aspiration 
thrombectomy only or minimal balloon angioplasty (e.g. a compliant balloon sized 
according to the reference vessel diameter and inflated at 4-6 atmospheres 1-2 times). 
During PCI, glycoprotein IIbIIIa inhibitor therapy was initiated with high dose tirofiban 
(25 g/kg/bolus) followed by an intravenous infusion of 0.15 g/kg/min for 12 hours, 
according to clinical judgement and indications for bail-out therapy (O'Gara et al., 2013, 
Steg et al., 2012). No reflow was treated according to contemporary standards of care with 
intra-coronary nitrate (i.e. 200 g) and adenosine (i.e. 30 – 60 g) (O'Gara et al., 2013, 
Steg et al., 2012), as clinically appropriate. In patients with multivessel coronary disease, 
multivessel PCI was not recommended, in line with clinical guidelines (O'Gara et al., 2013, 
Steg et al., 2012). The subsequent management of these patients was symptom-guided. 
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2.6 Invasive coronary physiology protocol 
In this study, a commercially available 0.014 inch floppy pressure guide wire 
(PressureWire-6, St Jude Medical) was used with the appropriate software and interface 
(Radi-Analyzer, RADI Medical Systems). This wire has a micro-sensor at a location 3 cm 
from the floppy tip, which enables simultaneous recording of coronary pressure (referred 
to as Pd i.e. distal coronary pressure) measurement as well as temperature measurement at 
the location of that sensor, with an accuracy of 0.02°C. The shaft of this wire, acting as 
additional electric resistance, can be used as a second thermistor, providing the input signal 
at the coronary ostium of any fluid injection with a temperature is different from blood. All 
signals can be displayed and recorded on the commercially available analyser for future 
off-line analysis. 
2.6.1 Pressure wire preparation 
In the majority of cases the coronary pressure/temperature sensitive guidewire was used as 
the primary guide-wire. The guide-wire was calibrated outside the body, equalised within 
the guide catheter, with the pressure sensor positioned at the ostium of the guide catheter, 
and then advanced into the distal segment of the culprit artery. Meticulous attention was 
taken to ensure appropriate catheter engagement and only guide catheters without side 
holes were used in the study. Study numbers were entered into the analyser unit so that de-
identified recording and storage of coronary physiological data could be made. 
2.6.2 Hyperaemic agent used during pressure wire studies 
In this study we used intravenous adenosine administered through an anti-cubital vein at a 
dose of 140/micrograms/kg/min via a volume controlled infusion pump. The patient was 
then assessed for a symptomatic and physiological response to adenosine. When this 
occurred the physiological measurements were taken. This route of adenosine 
administration was chosen to allow a hyperaemic “steady state” to occur allowing time to 
take the appropriate measurements. Prior to administration of the intravenous infusion we 
administered a bolus of intracoronary glyceryl tri-nitrate into the coronary artery to 
minimise the potential effects of arterial spasm on the readings. 
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Central venous infusion of adenosine through the femoral vein has been the gold standard 
method of hyperaemia induction (Pijls et al., 1996). However, it requires an additional 
procedure for femoral vein access and is less convenient to use during transradial coronary 
catheterisation procedures, which is the preferred method of arterial access, particularly in 
the emergency setting.  
In a study by Seo et al, involving 71 patients, no difference was found in the hyperaemic 
efficiency of intravenous administration of adenosine via the forearm compared to the 
femoral vein (Seo et al., 2012). There was no difference between the hyperaemic mean 
transit time and index of microcirculatory resistance between the two routes of adenosine 
infusion suggesting minimal resistance and thus maximal hyperaemic response was 
achieved with both forms of intravenous access. Consistent with these findings, De Bruyne 
et al showed that the hyperaemic efficacy of adenosine was similar between central and 
peripheral venous infusions, and increasing the dose to >140 µg/kg/min did not improve 
the vasodilatory action of adenosine (De Bruyne et al., 2003).   
2.6.3 Thermodilution curves 
Thermodilution curves were generated following stenting in the infarct related artery. We 
used guide catheters without side holes to allow accurate delivery of a saline bolus into the 
coronary ostium. Care was also taken to flush the catheter with saline thereby removing 
contrast that could potentially interfere with the measurements. Thermodilution curves in 
the culprit coronary artery were obtained by short manual injections of 3 ml of room 
temperature saline. The average of the 3 values was taken as the mean baseline transit time 
(TmnBase), shown previously to be inversely proportional to coronary blood flow (De 
Bruyne et al., 2001). Care was taken to obtain consistent and reproducible curves with 
superimposed envelopes as shown in figure 2-4.  We were also careful not to advance or 
pull back the wire during these measurements. Following the attainment of hyperemia the 
injection protocol was repeated to derive the hyperemic transit time (TmnHyp). 
Simultaneous measurement of mean aortic and distal coronary pressure under resting and 
hyperaemic conditions was also undertaken (PaBase, PdBase, PaHyp PdHyp respectively).    
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2.6.4 Measurement of coronary wedge pressure (Pw) 
This was measured by balloon inflation within the area of the stented segment. When the 
delivery balloon was inflated, occluding antegrade flow, mean pressure distal to the 
stenosis was recorded as the coronary wedge pressure (Pw) in millimetres of mercury 
(mmHg).  
2.6.5 Coronary Flow Reserve   
Coronary Flow Reserve was also measured during physiological assessment and was 
defined as: CFR = TmnBase / TmnHyp.   
CFR interrogates both the epicardial and microvascular compartments providing a 
comprehensive assessment. 
2.6.6 Measurement of the index of microcirculatory resistance (IMR)     
IMR is calculated as the product of simultaneously measured distal coronary pressure (Pd) 
and thermodilution-derived mean transit time (Tmn) of a bolus of Saline injected at room 
temperature into the coronary artery during maximal hyperaemia induced by continuous 
intravenous infusion of adenosine (140mcg/kg/min) (figure 2-4). The inverse of Tmn has 
been shown to correlate with absolute coronary blood flow. In the absence of any stenosis 
in the epicardial artery IMR is equal to Pd x Tmn at maximal hyperaemia. When an 
epicardial stenosis is present accurate determination of IMR requires knowledge of 
coronary wedge pressure and can be represented by the following equation:       
   IMR=Pa.Tmn [(Pd-Pw)/(Pa-Pw)]   
where Pa represents the aortic pressure measured by the guiding catheter and Pw is the 
coronary wedge pressure measured by the pressure wire during balloon occlusion as 
described previously. 
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Figure 2-4 Typical output from RADI analyser with thermodilution curves at rest and 
hyperaemia, with simultaneous Pa and Pd recording 
T
hermodilution curves under resting conditions (blue lines) and during hyperaemia induced 
by intravenous adenosine infusion (yellow lines). 
 
2.7 Consent and ethics 
The study was approved by the West of Scotland Research Ethics Committee, reference 
10-S0703-28 (appendix 1) and informed consent was obtained from each patient. Given 
the time constraints involved recruiting patients in the acute setting, verbal consent was 
obtained once the patient was stabilised following emergency PCI, prior to conducting 
pressure wire studies. Once the patient was transferred to the coronary care unit and before 
CMR, patients were given a detailed patient information sheet (appendix 2). After a period 
for consideration and discussion, patients were asked to sign the consent form (appendix 
3).  
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2.8 CMR acquisition 
CMR was performed on a Siemens MAGNETOM Avanto (Erlangen, Germany) 1.5-Tesla 
scanner with a 12-element phased array cardiac surface coil (Kramer et al., 2013, Moon et 
al., 2013). All patients underwent a standard protocol (including the healthy volunteer and 
serial imaging sub-study patients) and had ECG monitoring during the CMR exam. The 
imaging protocol included cine CMR with steady-state free precession (SSFP), T2*-
mapping, T2-mapping (Giri et al., 2009, Verhaert et al., 2011), native T1 mapping 
(Messroghli et al., 2007a, Messroghli et al., 2004) and delayed-enhancement phase-
sensitive inversion-recovery pulse sequences (Kellman et al., 2002). The scan acquisitions 
were spatially co-registered and also included different slice orientations to enhance 
diagnostic confidence. The standard CMR protocol is outlined in figure 2-5. 
Figure 2-5 Standard CMR protocol 
 
I shall now proceed to describe each sequence in more detail. 
2.8.1 Steady-state free precession (SSFP) – “Cine” imaging 
SSFP cine imaging (using multi-slice single-shot breath-hold true fast imaging – trueFISP) 
was used for functional assessment and a short-axis cine stack of the LV from base to apex 
was acquired, consisting of 7 mm thick slices, with a 3-mm interslice gap. Cine images 
were also obtained in the 3-chamber, horizontal long-axis and vertical long-axis planes 
(figure 2-6). Typical sequence parameters were TE 1.2 ms, TR 3.3 ms, flip angle 70º, field 
of view 340x27 0mm, matrix size 256x180 . 
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Figure 2-6 Cine imaging - assessment of LV function and volumes 
 
(A) Vertical long axis (VLA) cine, (B) horizontal long axis (HLA) cine, and (C) short axis 
cine stack. Using the diastolic frame from both the HLA and VLA cines, parallel cines are 
acquired until the whole ventricle has been covered, at 1cm intervals (e.g. a slice thickness 
of 7mm with a 3mm interslice gap). This forms the basis for LV volumetric, mass and 
quantitative functional analysis.  
 
2.8.2 T2* mapping 
T2*-maps were obtained using an investigational prototype T2* map sequence (multi-echo 
GRE) acquired in 3 short-axis slices (basal, mid and apical). Typical imaging parameters 
were: bandwidth ~814 (x8) Hz/pixel; flip angle 18°; matrix 256x115; spatial resolution 2.6 
x 1.6 x 10 mm; slice thickness 8 mm. Eight echoes were acquired with TE ranging from 
1.9 to 15.7 ms.  
2.8.3 T2 mapping 
T2 maps were acquired in contiguous short axis slices covering the whole ventricle, using 
an investigational prototype T2-prepared (T2P) TrueFisp sequence (Giri et al., 2009, 
Verhaert et al., 2011). T2 maps were generated from 3 images, acquired during a single 
breath hold, at different echo times (0 ms, 24 ms, 55 ms) represented by the T2P. A motion 
correction algorithm was applied, that minimised the misregistration between individual 
T2P images (Xue et al., 2008). Finally, the three acquired images were automatically 
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processed to fit the T2 decay curve at each pixel to generate a T2 map. Typical imaging 
parameters were: bandwidth ~947 Hz/pixel; flip angle 70°; T2 preparations: 0 ms, 24 ms, 
and 55 ms respectively; matrix 160 x 105 pixels; spatial resolution 2.6 x 2.1 x 8.0 mm; 
slice thickness 8 mm.  
2.8.4 T1 mapping 
Native T1 maps were acquired in 3 short-axial slices (basal, mid and apical), using an 
optimised modified look-locker inversion-recovery (MOLLI) investigational prototype 
sequence (Messroghli et al., 2007a, Messroghli et al., 2004) before contrast administration. 
MOLLI merges images from three consecutive inversion-recovery experiments into one 
data set. After the inversion pulse, the recovery of longitudinal magnetization is 
repetitively sampled. Three experiments are combined within one protocol (3 (3) 3 (3) 5) 
(Messroghli et al., 2007a), with slightly shifted inversion times (TI), thereby enabling a 
pixel-based T1 quantification in the myocardium, during one breath-hold. Between 
experiments, there are a number of heart cycles without any data acquisition to allow for 
full recovery of magnetization. The following typical parameters were common to all 
acquired studies: band width ~1090 Hz/pixel; flip angle 35°; echo time (TE) 1.1 ms; T1 of 
first experiment 100 ms; TI increment 80 ms; matrix 192 x 124 pixels; spatial resolution 
2.1 x 1.1 x 8.0 mm; slice thickness 8 mm; scan time 17 heartbeats. 
2.8.5 Early and late gadolinium enhancement 
Early gadolinium enhancement (EGE) imaging was acquired 1, 3, 5 and 7 minutes post-
contrast injection using a TrueFISP readout and fixed inversion time (TI) of 440 ms. Late 
gadolinium enhancement images covering the entire LV were acquired 10-15 minutes after 
IV injection of 0.15 mmol/kg of gadoterate meglumine (Gd2+-DOTA, Dotarem, Guebert 
S.A., Villepinte, France) using segmented phase-sensitive inversion recovery (PSIR) turbo 
fast low-angle shot sequence (Kellman et al., 2002). Typical imaging parameters were: 
matrix = 192 x 256, flip angle = 25, TE = 3.36 ms, bandwidth = 130 Hz/pixel, echo 
spacing = 8.7ms and trigger pulse = 2. The voxel size was 1.8 x 1.3 x 8 mm3. A Look-
Locker scout scan was undertaken to determine the inversion times associated with optimal 
nulling of the myocardial signal. The inversion times were in the range 240 to 350 ms. 
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2.9 Healthy volunteers 
The purpose of including healthy volunteers was to collect normative reference data for 
myocardial native T1, T2 and T2* in individuals without prior cardiovascular disease or 
therapy and who were reasonably representative of the population of individuals from 
whom the STEMI patients were drawn. Second, the reference native T1, T2 and T2* 
values were required to be measured on the same CMR scanner and with the same protocol 
that was used for the STEMI patients including during the same time-period. 
Healthy volunteers were invited to participate by placing adverts in public buildings (e.g. 
hospital, University) and through personal contacts of the researchers. Matching and 
selection of the healthy volunteers was done by the researchers in order to reflect the age 
and gender distribution of the STEMI patients. The healthy volunteers were resident in the 
same catchment area as the STEMI population. Fifty age- and gender-matched healthy 
volunteers who had a normal ECG and no prior history of cardiovascular disease or 
therapy underwent CMR during the same time period. The absence of late gadolinium 
enhancement (myocardial fibrosis or scar) was determined qualitatively by visual 
assessment, and the absence of late gadolinium enhancement was a requirement for 
inclusion of the volunteer in this analysis. 
The rationale for including healthy volunteers in this study is as follows: firstly, native T1, 
T2 and T2* values may vary between CMR scanners and so a local reference range is 
recommended in CMR guidelines (Kramer et al., 2013, Moon et al., 2013). Secondly, 
native T1, T2 and T2* values may vary spatially in the heart. Myocardial native T1, T2 
and T2* values were regionally segmented in regions-of-interest and summarised 
according to the AHA model (Cerqueira et al., 2002). 
Two of the healthy volunteers had abnormal CMR scans with evidence of hyper-
enhancement on contrast imaging and were therefore excluded from analyses. One 
volunteer had evidence of recent myocardial infarction, with a clinical history consistent 
with crescendo angina and was referred for coronary angiography and subsequent PCI. The 
other volunteer had CMR findings consistent with dilated cardiomyopathy and was 
referred to the appropriate cardiology services for assessment. 
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2.10 CMR image analyses 
The images were analysed on a Siemens work-station by observers with at least 2 years 
CMR experience. D.C. did the majority of analysis, N.A. and I.M. assisted with infarct 
analysis, S.R. assisted with healthy volunteer sub-group analysis. LV dimensions, volumes 
and ejection fraction were quantified using computer assisted planimetry (syngo MR®, 
Siemens Healthcare, Erlangen, Germany). All scan acquisitions were spatially co-
registered. The late gadolinium enhancement images were analysed for infarct size and 
microvascular obstruction by observers (N.A., I.M.) who were blinded to all of the other 
data. In healthy volunteers, the absence of LGE was determined qualitatively by visual 
assessment.  
2.10.1 Assessment of LV mass and function 
Post-processing was performed using commercially-available Argus software (Siemens, 
Erlangen). The number of slices required to cover the LV in end-diastole and end-systole 
varied from scan to scan dependent on the long axis diameter of the LV. End-systole was 
chosen as the point where the total LV blood pool was smallest and end-diastole as the 
point where it was largest. The most basal LV slice at both end-systole and end-diastole 
was defined as that in which the blood pool was surrounded by 50% or more of ventricular 
myocardium. Once selected, the endocardial and epicardial borders were manually 
outlined. Papillary muscles were included as part of the myocardial blood pool. Following 
tracing of the myocardial borders for each slice, an automated calculation was carried out 
by the Argus software to obtain left ventricular mass, end-systolic volume, end-diastolic 
volume and left ventricular ejection fraction using a sum of discs method (figure 2-7).  
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Figure 2-7 Manual planimetry for LV volume and mass analysis 
 
Endocardial (red boarder) and epicardial (green boarder) boarders are traced at end-
systole and end-diastole. LV volumes are calculated by contouring the endocardial 
boarders, then summing the endocardial surface area measured from each slice, multiplied 
by the inter-slice distance. 
 
2.10.2 T1, T2 and T2* - standardised measurements in myocardial regions of interest 
LV contours were delineated with computer assisted planimetry on the raw T2* image and 
the last corresponding T2 raw image, with echo time of 55 ms (Wassmuth et al., 2013). 
Contours were then copied onto the colour-encoded spatially co-registered maps and 
corrected when necessary by consulting the SSFP cine images. Apical segments were not 
included because of partial volume effects. Particular care was taken to delineate regions of 
interest with adequate margins of separation from tissue interfaces prone to partial volume 
averaging such as between myocardium and blood. T1 maps were analysed in a similar 
fashion to the T2 and T2* maps, with delineation of the LV contours on the raw images 
and then copying these onto the colour-encoded maps, in keeping with contemporary 
guidelines (Moon et al., 2013). Each T1/ T2/ T2* map image was assessed for the presence 
of artefacts relating to susceptibility effects or cardio-respiratory motion. Each map was 
evaluated against the original images. When artefacts occurred, the affected segments were 
not included in the analysis.  
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T1/ T2/ T2* values were segmented spatially and regions of interest were defined as (1) 
remote myocardium, (2) injured myocardium and (3) infarct core. The regions-of-interest 
were planimetered to include the entire area of interest with distinct margins of separation 
from tissue interfaces to exclude partial volume averaging (figure 2-8). The remote 
myocardial region-of-interest was defined as myocardium 180º from the affected zone with 
no visible evidence of infarction, oedema or wall motion abnormalities (assessed by 
inspecting corresponding contrast enhanced T1-weighted, T2-weighted and cine images, 
respectively). The infarct zone region-of-interest was defined as myocardium with pixel 
values (T2) >2 SD from remote myocardium on T2-weighted CMR (Giri et al., 2009, 
Verhaert et al., 2011). The infarct core was defined as an area in the centre of the infarct 
territory having a mean T1/ T2/ T2* value of at least 2 standard deviations (SDs) below the 
T1/ T2/ T2* value of the periphery of the area-at-risk. The assessment of T1/ T2/ T2* 
maps and adjudication (present/absent) of a hypointense core was performed independently 
by D.C.  
Healthy volunteers 
In healthy volunteers, the mid-ventricular T1-, T2- and T2*- colour-encoded maps were 
segmented into 6 equal segments, using the anterior right ventricular-left ventricular 
insertion point as the reference point (Cerqueira et al., 2002). T1, T2 and T2* were 
measured in each of these segments, and regions of interest were planimetered distinct and 
separate from blood-pool and tissue interfaces. These segmental values were also averaged 
to provide one value per subject. Results are presented as average values for segments and 
slices.   
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Figure 2-8 Quantitative parametric mapping analysis with defined regions-of-interest 
 
MRI images from an acute reperfused antero-septal STEMI patient, acquired on day 2 
post-MI. The regions-of-interest (ROI) were planimetered to include the entire area of 
interest with distinct margins of separation from tissue interfaces, to directly measure T1, 
T2 and T2* relaxation times. 
2.10.3 Myocardial haemorrhage 
On the T2* maps, a region of reduced signal intensity within the infarcted area, with a T2* 
value of <20 ms (Ghugre et al., 2011, Kandler et al., 2014, O'Regan et al., 2010, Anderson 
et al., 2001), was considered to confirm the presence of myocardial haemorrhage. 
2.10.4 Infarct definition and size 
The presence of acute infarction was established based on abnormalities in cine wall 
motion, rest first-pass myocardial perfusion, and delayed-enhancement imaging in two 
imaging planes. In addition, supporting changes on the electrocardiogram and coronary 
angiogram were also required. Acute infarction was considered present only if late 
gadolinium enhancement was confirmed on both the axial and long axis acquisitions. The 
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myocardial mass of late gadolinium (grams) was quantified using computer assisted 
planimetry and the territory of infarction was delineated using a signal intensity threshold 
of >5 standard deviations above a remote reference region and expressed as a percentage of 
total LV mass (Kramer et al., 2013, Flett et al., 2011) (figure 2-9). Infarct regions with 
evidence of microvascular obstruction were included within the infarct area and the extent 
of microvascular obstruction LV ventricular mass was also measured.  
Figure 2-9 Quantification of infarct size on late gadolinium enhancement imaging  
 
(A) Subendocardial infarct with no MVO - manual planimetry of the region of 
hyperenhancement (red) with contrast thresholding set to signal intensity 5SD above 
remote myocardium. This was repeated in every short-axis left ventricular slice and the 
infarct size was expressed as a percentage of total LV mass ((area of LGE/total myocardial 
area) x 100). (B) Transmural infarct with MVO (orange) – area of MVO was included 
within infarct area and the extent of MVO was also measured. 
 
2.10.5 Microvascular obstruction 
Microvascular obstruction was defined as a dark zone on EGE imaging 1, 3, 5 and 7 
minutes post-contrast injection that remained present within an area of LGE at 15 minutes 
(figure 2-9). Identification of microvascular obstruction was performed independently by 
I.M. and N.A. 
2.10.6 Area-at-risk 
Area-at-risk was defined as LV myocardium with pixel values (T2) >2 standard deviations 
from remote myocardium (Eitel et al., 2010, Dall'Armellina et al., 2011, Ugander et al., 
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2012, Berry et al., 2010, Payne et al., 2011b, Payne et al., 2012). In order to assess the 
area-at-risk the epicardial and endocardial contours on the last corresponding T2-weighted 
raw image with an echo time of 55 ms were planimetered (Giri et al., 2009, Wassmuth et 
al., 2013). Contours were then copied to the computed T2 map and corrected when 
necessary by consulting the SSFP cine images.  
2.10.7 Myocardial salvage 
Myocardial salvage was calculated by subtraction of percent infarct size from percent area-
at-risk (Eitel et al., 2010, Berry et al., 2010, Payne et al., 2011b, Payne et al., 2012) (figure 
2-10). The myocardial salvage index was calculated by dividing the myocardial salvage 
area by the initial area-at-risk. 
Figure 2-10 Myocardial salvage analysis 
 
2.10.8 Adverse remodelling 
A number of definitions of remodelling have been used in different studies, including 
increase in LV end-diastolic and end-systolic volumes (White et al., 1987). In this thesis 
we defined adverse remodelling as an increase in LV end-diastolic volume ≥ 20% at 6 
months from baseline, in keeping with recent studies in the same field (van Kranenburg et 
al., 2014, Hombach et al., 2005). 
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2.10.9 Reference ranges 
Reference ranges used in the laboratory were 105 – 215 g for LV mass in men, 70 – 170 g 
for LV mass in women, 77 – 195 ml for LV end-diastolic volume in men, 52 – 141 ml for 
LV end-diastolic volume in women, 19 – 72 ml for LV end-systolic volume in men and 13 
– 51 ml for LV end-systolic volume in women. 
2.10.10  Assessment of artefacts 
I was present for all of the scans to assess for artefacts pertaining to the different imaging 
sequences and if necessary instructed repeat acquisition. I created a quality control chart to 
inform, the radiographers acquiring scans and physicians performing analyses, of the type 
of artefacts to expect. 
Figure 2-11 Image quality assessment 
Artefact Description Example 
Motion M Ghosting in the phase-
encoding direction due to 
patient 
movement/breathing – 
relevant to all images 
 
Gating G Blurred cardiac border – 
relevant to all images 
 
Susceptibility S Distortion due to the 
presence of metallic 
objects within the field of 
view – relevant to all 
images 
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Artefact Description Example 
Wrap W Superimposition of 
anatomy due to incorrect 
field of view – relevant to 
all images, but only if the 
segment of interest is 
affected 
 
SSFP off-
resonance  
SSFP Banding artefact passing 
through the myocardium – 
relevant to cine, T1 and 
T2 maps 
 
Flow  F Blurring/distortion due to 
blood flow – relevant to 
cine, T1 and T2 maps 
 
LGE Contrast LC Sub-optimal contrast 
between normal 
myocardium, infarcted 
myocardium and blood 
pool, due to sub-optimal 
timing of image 
acquisition, inappropriate 
choice of TI or pathology – 
relevant to LGE 
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Artefact Description Example 
Chemical shift CS Bright or black line at fat-
tissue interface.   
 
In patients with MI, 
subencodcardial chemical 
shift artefacts can be 
observed in SSFP images 
(cine, T1 & T2 maps) due 
to the presence of 
lipomatous metaplasia 
 
 
Partial volume PV Reduced definition due to 
large voxel size 
 
  
2.11 Electrocardiogram 
A 12 lead electrocardiogram (ECG) was obtained before coronary reperfusion and 60 
minutes afterwards with Mac-Lab technology (GE Healthcare) in the catheter laboratory 
and a MAC 5500 HD recorder (GE Healthcare) in the Coronary Care Unit. The ECGs were 
acquired by trained cardiology staff. The ECGs were de-identified and transferred to the 
local ECG management system. The ECGs were then analysed by the University of 
Glasgow ECG Core Laboratory which is certified to ISO 9001: 2008 standards as a UKAS 
Accredited Organization.  
 
The extent of ST-segment resolution on the ECG assessed 60 minutes after reperfusion 
compared to the baseline ECG before reperfusion (O'Gara et al., 2013) was expressed as 
complete (70%), incomplete (30% to < 70%) or none (30%). 
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2.12 Biochemical and haematological laboratory analyses 
2.12.1 Biochemical assessment of infarct size 
Troponin T was measured (Elecsys Troponin T, Roche) as a biochemical measure of 
infarct size. The high sensitive assay reaches a level of detection of 5 pg/ml and achieves 
less than 10% variation at 14 pg/ml corresponding to the 99th percentile of a reference 
population. A blood sample was routinely obtained 12 – 24 hours after hospital admission. 
2.12.2 Biochemical markers of inflammation and adverse remodelling 
Serial systemic blood sample were obtained immediately after reperfusion in the cardiac 
catheterisation laboratory, and subsequently between 0600 - 0700 hours each day during 
the initial in-patient stay in the Coronary Care Unit. C-reactive protein (CRP) was 
measured in an NHS hospital biochemistry laboratory using a particle enhanced 
immunoturbimetric assay method (Cobras C501, Roche),) and the manufacturers 
calibrators and quality control material, as a biochemical measure of inflammation. The 
high sensitive assay CRP measuring range is 0.1-250 mg/L. The expected CRP values in a 
healthy adult are < 5 mg/L, and the reference range in our hospital is 0 - 10 mg/L. A blood 
sample was routinely obtained in the cardiac catheter laboratory immediately following 
revascularization and then again at 0700 hrs on the first and second days after admission to 
hospital.  
NT-proBNP, a biochemical measure of LV wall stress, was measured in a research 
laboratory using an electrochemiluminescence method (e411, Roche) and the 
manufacturers calibrators and quality control material. The limit of detection is 5 pg/ml. 
Long-term coefficient of variations of low and high controls are typically <5%, and were 
all within the manufacturers range. 
 
2.12.3 Haematological measures of inflammation 
Leucocyte count and leucocyte sub-populations were measured as a hematological measure 
of inflammation using sheath flow technology incorporating semi-conductor laser beam, 
forward and side scattered light  (Sysmex XT200i and XT1800i for white blood cell and 
differential white blood cell counts, respectively). The linearity ranges for white blood 
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cells was 0.00-440.0 x10(9) /L. The following are the normal ranges for full blood count 
parameters: 
Figure 2-12 Normal ranges for full blood count parameters. 
 MALE FEMALE 
WBC x  10^9/L 4.0 - 11.0 4.0 - 11.0 
RBC x 10^12/L 4.50 - 6.50 3.80 - 5.80 
Hgb g/L 130 - 180 115 - 165 
HCT L/L 0.400 - 0.540 0.370 - 0.470 
MCV fL 78 - 99 78 - 99 
MCH Pg 27.0 - 32.0 27.0 - 32.0 
MCHC g/L 310 - 360 310 - 360 
PLATELETS x 10^9/L 150 - 400 150 - 400 
NEUTROPHILS x 10^9/L 2.5 - 7.5 2.5 - 7.5 
LYMPHOCYTES x 10^9/L 1.5 - 4.0 1.5 - 4.0 
MONOCYTES x 10^9/L 0.2 - 0.8 0.2 - 0.8 
EOSINOPHILS  x 10^9/L 0.0 - 0.4 0.0 - 0.4 
BASOPHILS x 10^9/L 0.01 - 0.10 0.01 - 0.10 
 
A blood sample was routinely obtained in the cardiac catheter laboratory, immediately 
following revascularization and then again at 0700 on the first and second days after 
admission to hospital. 
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2.13 Pre-specified health outcomes 
A comprehensive definition of adverse events and their adjudication is detailed in the 
Clinical Event Charter (appendix 4). We pre-specified adverse health outcomes that are 
pathophysiologically linked with STEMI. We defined adverse events as: 
 
1) Major Adverse Cardiovascular Events (MACE) is the composite of 'cardiovascular 
death, non-fatal MI, unplanned hospitalization for transient ischemic attack or stroke.' 
2) 'Major Adverse Cardiac Events' are defined as 'cardiac death, or unplanned 
hospitalization for myocardial infarction or heart failure’. 
The serious adverse events (SAEs) were independently assessed by an accredited 
cardiologist (A.M.) who was not a member of the research team. This cardiologist 
followed an agreed charter (appendix 4) and he was blinded to all of the other clinical data. 
The SAEs were defined according to standard guidelines (appendix 4) and categorised as 
having occurred either during the index admission or post-discharge. All study participants 
were followed up by patient contacts through telephone calls, clinic visits and review of 
the electronic medical records for a minimum of 18 months after discharge. 
2.14 Statistical methods 
2.14.1 Sample size calculation for the whole cohort  
The sample size of 300 was predetermined based on the incidence of infarct pathology 
(e.g. myocardial haemorrhage or microvascular obstruction) affecting at least one third of 
the cohort. With an estimated haemorrhage incidence of 33% at 48 h post-STEMI, 100 
subjects would have evidence of myocardial haemorrhage and 200 subjects would not. The 
study would have 90% power at a 5% level of significance using a two sided two sample t-
test to detect a between-group difference in mean LV end-systolic volume index of 4.65 
ml/m2 equivalent to three eighths of a common standard deviation (or an effect size of 
0.375). We predicted a between-group difference in mean LVESVI of 4.65 ml/m2 
equivalent to three eighths of a common standard deviation (or an effect size of 0.375). 
This number of patients will be sufficiently large to determine whether the occurrence of 
haemorrhage might predict the occurrence of adverse remodelling represented by an 
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LVESVI > 15% ULN which occurs in about 40% of all STEMI patients We also estimated 
that at least 30 MACE events would occur based on a conservative estimate of the event 
rate (10-12%) at 18 months.   The sample size calculation was performed using nQuery 
version 7.0. 
2.14.2 Statistical analysis 
Categorical variables are expressed as number and percentage of patients. Most continuous 
variables followed a normal distribution and are therefore presented as means together with 
standard deviation. Those variables that did not follow a normal distribution are presented 
as medians with interquartile range.  Differences in continuous variables between groups 
were assessed by the Student’s t-test or analysis of variance (ANOVA) for continuous data 
with normal distribution, otherwise the nonparametric Wilcoxon rank sum test or Kruskal-
Wallis test. Differences in categorical variables between groups were assessed using a Chi-
square test or Fisher’s test, as appropriate.  Correlation analyses were Pearson or Spearman 
tests, as indicated. Random effects models were used to compute inter-rater reliability 
measures (intra-class correlation coefficient (ICC)) for the reliability of CMR parameters 
measured independently by 2 observers in 20 randomly selected patients from the whole 
cohort. Outcome analysis was performed using Receiver operating curve (ROC), Cox 
logistic regression and time-to event curves constructed using the Kaplan-Meier method. 
All p-values were 2-sided, and a p-value > 0.05 indicated the absence of a statistically 
significant effect. Statistical analyses was performed on MINITAB 17.1.0 software or SAS 
version 9.3.  
2.15 Funding of the study 
This research was supported by the British Heart Foundation Grant (Project Grant 
PG/11/2/28474), the National Health Service, and the Chief Scientist Office. Professor 
Berry was supported by a Senior Fellowship from the Scottish Funding Council
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3 Chapter 3: Patient characteristics, index admission 
data, angiographic and CMR results
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3.1 Patient screening and recruitment 
A total of 372 STEMI patients provided written informed consent, between 11th May 2011 
and 22nd November 2012, to undergo CMR 2 days and 6 months post-MI. Of these 372 
patients referred for emergency reperfusion therapy, 324 (87%) underwent CMR at 1.5 
Tesla, 2.2±1.9 days post-revascularisation. The reasons for not undergoing CMR are 
shown in figure 3-1. 289 (89%) of the 324 patients with a baseline CMR, had pressure wire 
studies performed at the time of primary PCI (35 patients enrolled into the deferred 
stenting sub-study did not have pressure wire studies carried out due to operator 
discretion). 30 of the 324 STEMI patients were enrolled into a serial imaging sub-study 
(figure 3-1); all of these patients attended for all of the CMR scans at the 4 time-points 
(described in chapter 2). In addition, 101 of the 324 patients were enrolled into the deferred 
stenting sub-study (described in chapters 2 and chapter 9; a randomised controlled proof-
of-concept trial nested into the larger prospective cohort study (figure 3-1).    
Overall 300 (93%) patients had repeat CMR 6 months post-MI (figure 3-1). All patients 
(n=324) with CMR had vital status assessed at least 18 months after enrolment (figure 3-
1). 
3.2 Patient characteristics 
The characteristics of the patients are shown in table 3-1. Of the 324 patients with a 
baseline CMR scan, 237 (73%) were male and mean (standard deviation (SD)) age was 59 
(11). Within the cohort, cardiovascular risk factors included current smoking at the time of 
admission in 196 (61%) patients, hypertension in 105 (32%) patients and diabetes mellitus 
(defined as a history of diet-controlled or treated diabetes) in 34 (11%) patients. 
3.2.1 Presenting characteristics at index admission and haemodynamic instability 
The mean time from symptom onset to reperfusion was 253 (212) minutes. 21 (7%) 
patients had successfully cardioverted ventricular fibrillation from time of initial 
presentation or during emergency PCI. The majority of patients were Killip heart failure 
class I or II at presentation, but 23 (7%) patients were Killip heart failure class III or IV. 34 
(11%) patients had a systolic blood pressure recorded at < 90 mmHg at some point during 
primary PCI procedure or on the coronary care unit (CCU) in the early reperfusion period. 
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4 (1%) patients required haemodynamic support with an intra-aortic balloon pump 
following reperfusion and 3 (1%) patients required intravenous inotropes whilst on CCU. 
3.2.2 Mode of reperfusion 
The reperfusion strategy in the study population (n=324), was primary PCI in 302 (93%) 
patients and 22 (7%) patients received thrombolysis whilst en route to our tertiary referral 
centre. Of the 22 patients that received thrombolysis, 14 (4%) failed to reperfuse and 
underwent emergency rescue PCI. 8 (3%) patients had successful thrombolysis and went to 
the cath lab within 24 hours of presentation.
Figure 3-1 Study flow diagram 
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Table 3-1 Baseline clinical and angiographic characteristics of patients with acute STEMI and a CMR at baseline. 
Characteristics*   All STEMI patients 
n=324 
Clinical    
Age, years   59 (11) 
Male sex, n (%)   237 (73) 
BMI, (kg/m2)   29 (5) 
History    
Hypertension, n (%)   105 (32) 
Current smoking, n (%)   196 (61) 
Hypercholesterolemia, n (%)   94 (29) 
Diabetes mellitus‡, n (%)   34 (11) 
Previous angina, n (%)   40 (12) 
Previous myocardial infarction, n (%)   25 (8) 
Previous PCI, n (%)   18 (6) 
Presenting characteristics    
Heart rate, bpm   78 (17) 
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Systolic blood pressure, mmHg   132 (25) 
Diastolic blood pressure, mmHg   79 (14) 
Time from symptom onset to reperfusion, min   253 (212) 
Ventricular fibrillation†, n (%)   21 (7) 
Heart failure, Killip class at presentation, n (%)  I 233 (72) 
  II 68 (21) 
  III 17 (5) 
  IV 6 (2) 
Medications at discharge    
Betablockers, n (%)   308 (95) 
Statins, n (%)   324 (100) 
ACE-inhibitors, n (%)   320 (99) 
Aspirin, n (%)   324 (100) 
Clopidogrel, n (%)   324 (100) 
ECG    
ST segment elevation resolution post PCI, n (%)    
    Complete, 70 %   148 (46) 
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    Partial, 30% to < 70%   127 (39) 
    None, 30%   48 (15) 
Coronary angiography    
Reperfusion strategy, n (%)    
    Primary PCI   302 (93) 
    Rescue PCI (failed thrombolysis)   14 (4) 
    Successful thrombolysis   8 (3) 
Number of diseased arteries¥, n (%)  1 174 (54) 
  2 105 (32) 
  3 45 (14) 
Culprit artery, n (%)   Left anterior descending 121 (37) 
  Left circumflex 59 (18) 
  Right coronary 144 (44) 
TIMI coronary flow grade pre-PCI, n (%)  0/1 236 (73) 
  2 58 (18) 
  3 30 (9) 
TIMI coronary flow grade post-PCI, n (%)  0/1 4 (1) 
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  2 15 (5) 
  3 305 (94) 
Footnote: TIMI = Thrombolysis in Myocardial Infarction grade, PCI = percutaneous coronary intervention. Killip classification of heart failure after 
acute myocardial infarction: class I - no heart failure, class II - pulmonary rales or crepitations, a third heart sound, and elevated jugular venous pressure, 
class III - acute pulmonary oedema, class IV - cardiogenic shock. * Data are given as n (%) or mean (SD). ‡ Diabetes mellitus was defined as a history of 
diet-controlled or treated diabetes. † Successfully electrically cardioverted ventricular fibrillation at presentation or during emergency PCI procedure. ¥ 
Multivessel coronary artery disease was defined according to the number of stenoses of at least 50% of the reference vessel diameter, by visual 
assessment and whether or not there was left main stem involvement. Missing data: Heart rate, n=3; Time from symptom onset to reperfusion, n=17; ST-
segment resolution, n=1.
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3.2.3 Angiographic data 
236 (73%) patients had an occluded culprit artery (TIMI coronary flow grades 0/1) at 
initial angiography (table 3-1). Following primary PCI, 305 (94%) patients had TIMI grade 
3 flow in the culprit artery at the end of the procedure. The culprit artery was the left 
anterior descending artery (LAD) in 121 (37%) cases, right coronary artery (RCA) in 144 
(44%) cases and the left circumflex artery (LCX) in 59 (18%) cases. Of note, 297 (92%) 
patients received intravenous glycoprotein IIbIIIa inhibitor therapy, initiated at bolus dose 
in the catheterisation lab, followed by continuous infusion for 12 hours. 
3.3 Pressure wire assessment following emergency reperfusion 
The methodology of these measurements is described in chapter 2. 289 (89%) of the 324 
patients with baseline CMR had pressure wire studies at the end of the PCI procedure. 
There were no procedural related complications/ adverse events, whilst conducting 
invasive assessment of coronary physiology. A summary of the pressure wire data is 
shown in table 3-2. Index of microvascular resistance (IMR) was available in all 289 
patients. Coronary flow reserve (CFR) data was missing in 6 patients because the operator 
only acquired hyperaemic thermodilution measurements and did not acquire during resting 
conditions. Fractional flow reserve (FFR) was missing in 46 patients because the operator 
never opened the arterial pressure transducer port on the manifold and therefore the 
hyperaemic aortic pressure was not recorded. 
Table 3-2 Summary of invasive coronary physiology assessment, measured immediately 
following PCI. 
Invasive coronary physiological 
parameter* 
All STEMI patients with pressure wire 
assessment after PCI (n=289) 
FFR (units) 0.92 (0.87, 0.97) 
CFR (units) 1.6 (1.1, 2.1) 
IMR (units) 24 (14, 44) 
  
86 
 
Footnote: IMR = Index of microvascular resistance; CFR = coronary flow reserve; FFR = 
fractional flow reserve. *Data are given as median (IQR). Missing data: FFR, n=46; CFR, 
n=6. 
3.4 CMR data 
3.4.1 Completeness of data acquisition 
The MRI protocol is described in the methods section. Of the 324 patients that had baseline 
CMR, all patients had cine MRI, T2 mapping and late gadolinium enhancement imaging 
acquired. All patients had evaluable T2 maps. LV function / volume analysis was not 
possible in 3 patients due to artefact on cine images, related to arrhythmia. Delayed 
enhancement imaging was of insufficient quality for analysis in 2 cases, due to severe 
cardio-respiratory motion artefact. The investigational prototype MOLLI T1 mapping was 
only made available to us after 24 patients had already been recruited and was not acquired 
in a further 8 patients, due to them poorly tolerating the scan. T1 maps from 4 patients 
were non-evaluable due to motion artefact and therefore we had evaluable T1 maps in 288 
patients at baseline. The investigational prototype T2* mapping technique was also only 
made available at a later date, after 26 patients had been recruited and was not acquired in 
a further 12 patients due to them poorly tolerating the scan. T2* maps were insufficient 
quality for analysis in 41 patients due to severe motion artefact and therefore we had 
evaluable T2* maps in 245 patients at day 2 CMR. 
300 (93%) patients attended for 6 month follow-up CMR. The reasons for not attending for 
follow-up CMR were refusal in 21 cases and death in 3 cases. LV function / volume 
analysis was not possible in 5 cases, due to artefact on cine images, related to arrhythmia. 
Delayed enhancement imaging was insufficient quality for analysis in 2 patients and was 
not acquired in a further 2 patients because they exited the CMR scanner early due to 
poorly tolerating the scan. 
3.5 CMR findings at baseline and follow-up in STEMI patients 
The results of baseline and follow-up CMR findings for the main STEMI cohort (n=324) 
are shown in table 3-3. Overall, the mean (SD) acute infarct size was 18.0 (13.5) %; 51% 
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of patients had evidence of late microvascular obstruction and 41% of patients had 
evidence of myocardial haemorrhage. 
Table 3-3 CMR findings in STEMI patients at day 2 and 6 month follow-up. 
CMR parameters CMR day 2 post-MI 
(n=324) 
CMR 6 month post-
MI (n=300) 
LV ejection fraction, % (SD)  55.0 (9.6) 61.9 (9.4) 
LV end-diastolic volume, ml (SD)   
    Men 161.3 (33.3) 168.6 (42.0) 
    Women 125.0 (25.4) 127.3 (28.6) 
LV end-systolic volume, ml (SD)   
    Men 75.3 (26.6) 68.0 (34.2) 
    Women 55.1 (18.0) 46.3 (17.5) 
LV mass, g (SD)   
    Men 144.54 (32.7) 127.5 (26.5) 
    Women 99.1 (23.3) 92.0 (19.6) 
Oedema and infarct characteristics   
Area at risk, % LV mass (SD) 31.9 (11.9) - 
Infarct size, % LV mass (SD) 18.0 (13.5) 12.8 (10.1) 
Myocardial salvage, % of LV mass (SD) 13.9 (8.8) - 
Myocardial salvage index, % of LV mass (SD) 49 (30) - 
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Early microvascular obstruction present, n (%) 186 (57)  
Late microvascular obstruction present, n (%) 164 (51) - 
Late microvascular obstruction, % LV mass (SD) 2.9 (5.0) - 
Myocardial native T2* values‡   
Myocardial haemorrhage, n (%) 101 (41) - 
T2* remote myocardium (all subjects), ms (SD) 31.5 (2.4) - 
    Men, ms 31.5 (2.1) - 
    Women, ms 31.5 (3.1) - 
T2* infarct zone (all subjects), ms (SD) 31.8 (7.7) - 
    Subjects with core, ms 25.3 (5.2)  
    Subjects without core, ms 36.3 (5.7)  
T2* hypointense infarct core, ms (SD) 14.1 (3.7) - 
Myocardial native T2 values   
T2 remote myocardium (all subjects), ms (SD) 49.7 (2.1) - 
    Men, ms 49.6 (2.0) - 
    Women, ms 50.1 (2.1) - 
T2 infarct zone (all subjects), ms (SD) 62.9 (5.1) - 
    Subjects with core, ms 62.8 (5.4)  
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    Subjects without core, ms 63.1 (4.7)  
T2 hypointense core present, n (%) 197 (61) - 
T2 hypointense infarct core, ms (SD) 53.9 (4.8) - 
Myocardial native T1 values¥   
T1 remote myocardium (all subjects), ms (SD) 961 (25) - 
    Men, ms 959 (25) - 
    Women, ms 968 (25) - 
T1 infarct zone (all subjects), ms (SD) 1097 (52) - 
    Subjects with core, ms 1093.1 (51.9)  
    Subjects without core, ms 1102.6 (51.1)  
T1 hypointense core present, n (%) 160 (56) - 
T1 hypointense infarct core, ms (SD) 997 (57) - 
Footnote: * Data are given as n (%) or mean (SD). Abbreviations: LV = left ventricle 
T2 maps were acquired with full LV coverage. In one patient, area at risk could not be 
measured due to SSFP off-resonance artefact, otherwise all T2 maps were suitable for 
analysis. ¥ T1 maps were acquired with 3 short-axis slices (n=288 with evaluable T1 maps 
at baseline). ‡ T2* maps were acquired with 3 short-axis slices (n=245 with evaluable T2* 
maps at baseline). Myocardial haemorrhage was defined as T2* infarct core <20 ms. 
 
3.5.1 T2*, T2 and T2* values in STEMI patients 
T2*, T2 and T1 values measured in the: remote zone, injury zone and infarct hypointense 
core were independent of the culprit artery territory (tables 3-4, 3-5 and 3-6). 
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Table 3-4 Differences in T2 values measured in the infarct hypointense core, remote- and 
injury zones by culprit artery territory. 
Myocardial region of interest Culprit artery T2 value, ms (SD) P-value 
Remote zone 
LAD 
LCX 
RCA 
49.8 (2.1) 
50.1 (2.3) 
49.6 (1.9) 
0.240 
Injury zone 
LAD 
LCX 
RCA 
62. 7 (5.1) 
62.3 (6.0) 
63.3 (4.8) 
0.407 
Infarct core 
LAD 
LCX 
RCA 
53.3 (4.9) 
53.6 (5.4) 
54.6 (4.5) 
0.238 
Footnote: P-values from one way ANOVA. LAD = left anterior descending artery; LCX = 
left circumflex artery; RCA = right coronary artery. 
Table 3-5 Differences in T2* values measured in the infarct hypointense core, remote- and 
injury zones by culprit artery territory. 
Myocardial region of interest Culprit artery T2* value, ms (SD) P-value 
Remote zone 
LAD 
LCX 
RCA 
31.8 (2.2) 
31.4 (2.1) 
31.3 (2.6) 
0.340 
Injury zone 
LAD 
LCX 
RCA 
31.5 (7.8) 
31.4 (8.0) 
32.0 (7.5) 
0.882 
Infarct core 
LAD 
LCX 
RCA 
14.3 (3.7) 
14.4 (3.6) 
13.9 (3.8) 
0.854 
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Footnote: P-values from one way ANOVA. LAD = left anterior descending artery; LCX = 
left circumflex artery; RCA = right coronary artery. 
Table 3-6 Differences in T1 values measured in the infarct hypointense core, remote- and 
injury zones by culprit artery territory. 
Myocardial region of interest Culprit artery T1 value, ms (SD) P-value 
Remote zone 
LAD 
LCX 
RCA 
963.90 (23.66) 
965.60 (26.92) 
957.49 (25.09) 
0.059 
Injury zone 
LAD 
LCX 
RCA 
1088.73 (48.38) 
1105.09 (57.72) 
1101.44 (51.26) 
0.084 
Infarct core 
LAD 
LCX 
RCA 
991.8 (64.5) 
995.6 (62.6) 
1002.1 (47.9) 
0.592 
Footnote: P-values from one way ANOVA. LAD = left anterior descending artery; LCX = 
left circumflex artery; RCA = right coronary artery. 
 
3.5.2 Intra- and inter-observer agreement of T1, T2 and T2* measurements 
Native T1 in regions-of-interest in remote zones, injured zones and infarct core in a 
subgroup of 20 randomly chosen patients were independently measured by two observers. 
The intra-class correlation coefficient for reliability of remote T1, infarct zone T1 and 
infarct core T1 were 0.92 (95% confidence interval (CI): 0.80, 0.97), 0.93 (0.84, 0.97) and 
0.92 (0.71, 0.97); all p<0.001, respectively. Bland-Altman plots showed no evidence of 
bias (figures 3-2 to 3-4).  
T2 values in regions-of-interest in remote zones, injured zones and infarct core, in a 
subgroup of 20 randomly chosen patients were also independently measured by two 
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observers. The intra-class correlation coefficients for reliability of remote T2, infarct zone 
T2 and infarct core T2 were 0.93 (95% confidence interval (CI): 0.82, 0.97), 0.89 (0.74, 
0.95) and 0.86 (0.68, 0.94); all p<0.001, respectively. Bland-Altman plots showed no 
evidence of bias (figures 3-5 to 3-7). 
In addition, T2* values in regions-of-interest in remote zones, injured zones and infarct 
core, in a subgroup of 20 randomly chosen patients were also independently measured by 
two observers. The intra-class correlation coefficients for reliability of remote T2*, infarct 
zone T2* and infarct core T2* were 0.69 (95% confidence interval (CI): 0.37, 0.87), 0.75 
(0.47, 0.89) and 0.90 (0.77, 0.96); all p<0.001, respectively. Bland-Altman plots showed 
no evidence of bias (figures 3-8 to 3-10).    
Figure 3-2 Bland-Altman plot for inter-observer agreement of myocardial remote zone T1 
values 
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Figure 3-3 Bland-Altman plot for inter-observer agreement of myocardial injury zone T1 
values 
  
Figure 3-4 Bland-Altman plot for inter-observer agreement of myocardial infarct core T1 
values 
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Figure 3-5 Bland-Altman plot for inter-observer agreement of myocardial remote zone T2 
values 
 
Figure 3-6 Bland-Altman plot for inter-observer agreement of myocardial injury zone T2 
values 
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Figure 3-7 Bland-Altman plot for inter-observer agreement of infarct core T2 values 
 
Figure 3-8 Bland-Altman plot for inter-observer agreement of myocardial remote zone T2* 
values 
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Figure 3-9 Bland-Altman plot for inter-observer agreement of myocardial injury zone T2* 
values 
 
Figure 3-10 Bland-Altman plot for inter-observer agreement of infarct core T2* values 
 
  
97 
 
3.6 Healthy volunteer CMR results 
Fifty healthy volunteers from the same geographical region (52% male, mean (SD) age 54 
(13) years) without a history of cardiovascular disease or therapy and who had a normal 
electrocardiogram were enrolled during the same time period as the STEMI patients. The 
volunteers were scanned using the same 1.5 Tesla MRI scanner (Siemens AVANTO) as 
the STEMI patients, and the approach to image analysis was the same as for STEMI 
patients also, including regional segmentation of the left ventricle according to the 
American Heart Association model (Cerqueira et al., 2002) . A summary of the CMR 
findings for healthy volunteers are shown in table 3-7. 
Table 3-7 CMR findings in 50 age- and sex-matched healthy volunteers. 
CMR parameters Healthy volunteers (n=50) 
LV ejection fraction, %  67.2 (4.5) 
LV end-diastolic volume, ml (SD)  
    Men 167.8 (31.6) 
    Women 134.1 (23.0) 
LV end-systolic volume, ml (SD)  
    Men 56.8 (14.9) 
    Women 43.6 (12.3) 
LV mass, g (SD)  
    Men 124.5 (22.7) 
    Women 92.0 (20.4) 
T2 of myocardium (all subjects), ms (SD) 49.5 (2.5) 
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    Men, ms 48.5 (2.1) 
    Women, ms 50.5 (2.5) 
T1 of myocardium (all subjects), ms (SD) 958 (24) 
    Men, ms 948 (20) 
    Women, ms 968 (25) 
T2* of myocardium (all subjects), ms (SD) 31.0 (2.1) 
    Men, ms 30.8 (2.1) 
    Women, ms 31.3 (2.1) 
 
3.6.1 T1, T2 and T2* values in healthy volunteers compared to STEMI patients 
At the mid-ventricular level, mean remote zone native T1 was similar in STEMI patients 
(961 (25) ms) and healthy volunteers (958 (24); p=0.314). Remote zone native T1 was 
higher in male STEMI patients than in male volunteers (959 (25) vs. 948 (20) ms, 
respectively; p=0.024), but similar in female STEMI patients (968 (25) ms) and volunteers 
(968 (23) ms). In healthy subjects, mid-ventricular T1 values were lower in males than in 
females (948 (20) ms vs. 968 (23) ms; p=0.003). In both men and women, the infero-lateral 
segment had the highest T1 compared to the antero-septal segment (960 (28) ms vs. 939 
(26) ms and 978 (32) ms vs. 961 (34) ms, respectively; p<0.001 and p=0.011). 
The coefficients of variation (CoV) for native T1 in the mid-ventricular level with regions-
of-interest within myocardial regions were: anterior segment CoV = 2.35; antero-lateral 
segment CoV = 2.98; antero-septal segment CoV = 3.35; inferior segment CoV = 2.49; 
infero-lateral segment CoV = 3.22; infero-septal segment CoV = 2.90. 
In healthy subjects, mid-ventricular T2 values were lower in males than females (48.5 (2.1) 
ms vs. 50.6 (2.5) ms; p=0.003). Overall, the inferior segment had the highest T2 value 
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compared to the anterior segment (50.0 (2.8) ms vs. 49.1 (3.0), respectively; p=0.031). At 
the mid-ventricular level, mean remote zone native T2 was similar in STEMI patients (49.7 
(2.1) ms) and healthy volunteers (49.5 (2.5) ms; p=0.511).  
The coefficients of variation CoV for native T2 in the mid-ventricular level with regions-
of-interest within myocardial regions were: anterior segment CoV = 6.00; antero-lateral 
segment CoV = 6.49; antero-septal segment CoV = 6.25; inferior segment CoV = 5.50; 
infero-lateral segment CoV = 4.58; infero-septal segment CoV = 5.36.  
T2* values were similar in healthy volunteers, irrespective of gender or location of 
measurement. At the mid-ventricular level, mean remote zone T2* values were similar in 
STEMI patients (31.5 (2.4) ms) and healthy volunteers (31.0 (2.1) ms; p=0.162). 
3.7 Discussion – patient characteristics, admission data, CMR findings 
and angiographic results 
3.7.1 Patient characteristics 
The mean age of patients in this study was 59 years, with the majority being male (73%), 
anterior infarction in 37% of cases and 73% of patients with TIMI ≤ 1 flow at initial 
angiography, which is in keeping with contemporary studies in this field (Bekkers et al., 
2010a, Eitel et al., 2011, Ganame et al., 2009, Husser et al., 2013, Kandler et al., 2014). 
Eitel et al. (Eitel et al., 2011), using T2-weighted methods to detect haemorrhage, included 
346 acute STEMI patients median age 64 years, 70% male, 46% anterior location 
infarction and 71% with an occluded artery (TIMI flow ≤1) at initial angiography, which is 
similar to the population in this study. Also, Husser et al. (n=304), again using qualitative 
T2-weighted methods, had a similar study population to this study, with mean age of 60 
years, 80% male, 55% anterior infarction and mean time of symptom onset to reperfusion 
of 269 (190) minutes (symptom onset to reperfusion in this study 253 (119) minutes). The 
largest study to date to include T2* imaging for the detection of IMH (n=151), again had a 
similar study population to this study, with mean age 61 years, 75% male, 61% with an 
occluded artery pre-PCI, 42% anterior infarction and mean time of symptom onset to 
reperfusion of 263 (196) minutes. 
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Our study population is inhomogeneous, and includes patients treated with PCI, 
thrombolysis and both (rescue PCI). Our study is one of the few in the CMR STEMI 
literature to include information on patients who have received thrombolysis. On sub-
group analysis there was no interaction between thrombolysis and CMR findings and 
therefore we decided to include these patients. 
My study population represents a well-treated cohort, given the high rates of secondary 
preventive medications on discharge and patients with TIMI grade 3 flow post-PCI (table 
3-1), and is in keeping with contemporary studies in the field. 
3.7.2 Pressure wire data in comparison with previous studies 
There have been many recent publications looking at IMR in acute STEMI patients, 
although there are variations in the timing of pressure wire assessment post-PCI and some 
studies limited IMR measurement to anterior infarcts. The median IMR in this study was 
24, comparable to previous published studies of similar patient groups (summarised in 
table 3-8). Our study was at the lower end of IMR values and this may be due to the 
relatively lower proportion of anterior infarcts included (37% of patients), compared with 
for example: 49% of cases in the study by McGeoch et al. (McGeoch et al., 2010) and 55% 
of cases in the study by Fearon et al. (Fearon et al., 2013). 
Table 3-8 Median IMR values in acute STEMI studies with similar patient groups to this 
study. 
Authors Year Sample 
size 
MI culprit 
territory 
Timing Median IMR 
Fearon et al. (Fearon 
et al., 2008) 
2007 29 All At PCI 32 
Ito et al. (Ito et al., 
2010) 
2009 40 All At PCI 26 
Lim et al. (Lim et 
al., 2009) 
2009 40 Anterior only At PCI 33 
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Sezer et al. (Sezer et 
al., 2010) 
2010 35 All At 48 hours 29 
McGeoch et al. 
(McGeoch et al., 
2010) 
2010 57 All At PCI 35 
Payne et al. (Payne 
et al., 2012) 
2012 108 All At PCI 26 
Fearon et al. (Fearon 
et al., 2013) 
2013 253 All At PCI 31 
Cuculi et al. (Cuculi 
et al., 2014) 
2014 82 All At PCI (mean) 42 
 
3.7.3 CMR findings in comparison with previous studies 
There is considerable variability in the reported incidence of IMH and MVO in acute 
reperfused STEMI patients and much of this is likely related to the heterogeneity in 
methods used to detect IMH/ MVO and the lack of standardisation with regard to when 
temporally these infarct characteristics are measured. The incidence if IMH/ MVO in our 
study (41% and 54% respectively, in cohort with evaluable T2* map at baseline) are in 
keeping with contemporary studies, in similar groups of patients (table 3-9).  
Table 3-9 Incidence of IMH and MVO in acute reperfused STEMI patients, in contemporary 
studies. 
Authors Year Sample 
size 
Methodology 
to detect IMH 
Methodology 
to detect MVO 
Incidence 
IMH (%) 
Incidence 
MVO (%) 
Ganame et al. 
(Ganame et al., 
2009) 
2009 98 T2-weighted Early GE 24 64 
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Bekkers et al. 
(Bekkers et al., 
2010a) 
2010 90 T2-weighted LGE 43 54 
Beek et al. (Beek et 
al., 2010) 
2010 45 T2-weighted LGE 49 60 
O’Regan et al. 
(O'Regan et al., 
2010) 
2010 50 T2* LGE 58 58 
Mather et al. 
(Mather et al., 
2011b) 
2011 48 T2* and T2-
weighted 
Early GE 25 63 
Eitel et al. (Eitel et 
al., 2011) 
2012 346 T2-weighted LGE 35 66 
Amiable et al. 
(Amabile et al., 
2012) 
2012 114 T2-weighted LGE 10 55 
Husser et al. 
(Husser et al., 
2013) 
2012 304 T2-weighted LGE 34 36 
Zia et al. (Zia et 
al., 2012) 
2012 62 T2-weighted 
and T2* 
LGE 32 62 
Kali et al. (Kali et 
al., 2013b) 
2013 14 T2-weighted 
and T2* 
LGE 50 50 
Kidambi et al. 
(Kidambi et al., 
2013) 
2013 39 T2-weighted 
and T2* 
LGE 36 56 
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Robbers et al. 
(Robbers et al., 
2013) 
2013 26 T2-weighted LGE 55 59 
Kandler et al. 
(Kandler et al., 
2014) 
2014 151 T2-weighted 
and T2* 
LGE 50 66 
Footnote: LGE = late gadolinium enhancement; Early GE = early gadolinium 
enhancement 
There are very few clinical studies, with only small patient numbers, that have used novel 
T1 mapping (Dall'Armellina et al., 2012, Messroghli et al., 2004) or T2 mapping (Giri et 
al., 2009, Nassenstein et al., 2014, Park et al., 2013, Verhaert et al., 2011) methods, in 
acute reperfused STEMI patients. These studies have generally concentrated on area-at-
risk measurement and excluded the hypointense infarct core on parametric maps 
(corresponding to the area of MVO) from analysis. In contrast, we have focussed on the 
hypointense infarct core on mapping sequences, in an effort to better evaluate IMH and its 
relationship with MVO. Our mean T2* value (14.1 ms) within the infarct core of 
haemorrhagic infarcts is consistent with previous findings (Kali et al., 2013b, O'Regan et 
al., 2010). 
The native T1 values of healthy subjects in the current study (men = 949±20 ms, women = 
968±23 ms) were similar to T1 values reported by Piechnik et al. (men = 947±20 ms and 
women = 974±25 ms) (Piechnik et al., 2010), although lower than the study by Liu et al. 
(men = 962±37 and women = 984±47 ms) (Liu et al., 2013); however the cohort studied by 
Liu et al. (Liu et al., 2013) had several cardiovascular risk factors and hypertension and 
diabetes were prevalent. T2* values of remote myocardium in STEMI patients and values 
in healthy volunteers in this current study, were consistent with previous studies (Kali et 
al., 2013b, O'Regan et al., 2010). As were our T2 values (Nassenstein et al., 2014, Verhaert 
et al., 2011, Wassmuth et al., 2013). 
It can therefore be seen that although natural variations will apply, the CMR analysis data 
for my study cohort is in keeping with contemporary work in this area. 
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3.8 Conclusion 
The raw data on which this thesis is based, patient population, invasive coronary 
physiology data and CMR findings are consistent with contemporary work in these fields.
  
105 
 
 
4 Chapter 4: Myocardial haemorrhage after acute 
reperfused ST-elevation myocardial infarction: 
temporal evolution, relation to microvascular 
obstruction and prognostic significance
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4.1 Preamble 
As discussed in chapter 1, T2* CMR is the gold standard technique to detect myocardial 
haemorrhage, although most studies in acute STEMI patients have not used T2* imaging to 
detect haemorrhage, but instead used black-blood T2-weighted methods, which are known 
to be hampered by artefacts and less specific for haemorrhage. In this chapter, I will use 
T2* imaging to define myocardial haemorrhage and therefore report the results of the 
patients with an evaluable T2*map at baseline. 
4.2 Introduction 
The success of emergency coronary reperfusion therapy in ST-elevation myocardial 
infarction (STEMI) is commonly limited by failed tissue perfusion (Yellon and Hausenloy, 
2007). This disconnect is mainly due to two pathologies: microvascular obstruction 
(Kloner et al., 1974, Jaffe et al., 2008) and intramyocardial haemorrhage (Higginson et al., 
1982). Based on morphological (Kloner et al., 1974) and functional studies (Wilson et al., 
1989), microvascular obstruction may have structural and functional components (Galiuto, 
2004), which may reflect irreversible (i.e. endothelial disruption) and reversible (e.g. 
microvascular spasm, extrinsic oedema) components. Myocardial haemorrhage manifests 
because of aggregation and extravasation of erythrocytes (Higginson et al., 1982, Fishbein 
et al., 1980, Payne et al., 2011a, Robbers et al., 2013). The time-course of these 
pathologies and when diagnostic imaging might be most appropriate is yet to be defined.  
T2*-weighted CMR is the reference diagnostic method for myocardial haemorrhage in 
vivo (Basso et al., 2007, Kali et al., 2013b, Kumar et al., 2011), however technical issues 
have limited T2* imaging in clinical practice. The largest cohort studies of myocardial 
haemorrhage in STEMI patients to date have not used T2* imaging (Amabile et al., 2012, 
Ganame et al., 2009, Husser et al., 2013, Robbers et al., 2013, Bekkers et al., 2010a, Beek 
et al., 2010), although some smaller studies have used T2* CMR (Kandler et al., 2014, 
Mather et al., 2011b, O'Regan et al., 2010, Zia et al., 2012). Because of these different 
CMR techniques, uncertainties have arisen around the pathophysiology and clinical 
significance of myocardial haemorrhage, and its relationships with microvascular 
obstruction. In some studies, myocardial haemorrhage is associated with adverse 
remodelling (Beek et al., 2010, Ganame et al., 2009, Husser et al., 2013, Kandler et al., 
2014, O'Regan et al., 2010), persistent LV systolic dysfunction (Kidambi et al., 2013), late 
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arrhythmic risk (Mather et al., 2011b) and adverse clinical outcome (Amabile et al., 2012, 
Eitel et al., 2011), however, other studies have shown that myocardial haemorrhage does 
not have prognostic significance beyond microvascular obstruction (Beek et al., 2010, 
Bekkers et al., 2010a, Husser et al., 2013).  
In this study we aimed to: (1) detect myocardial haemorrhage using T2* mapping in a 
large relatively unselected STEMI population and re-evaluate its clinical associates and 
prognostic significance, (2) study the time-course of myocardial haemorrhage evolution 
with serial CMR early after reperfusion, and (3) assess the temporal relationships between 
myocardial haemorrhage versus microvascular obstruction.  
To this end, we used quantitative T2* mapping which potentially offers increased accuracy 
for the detection of myocardial haemorrhage than T2-weighted methods because T2* 
relaxation times are measured directly (Ghugre et al., 2011, Zia et al., 2012, Kali et al., 
2013b, O'Regan et al., 2010). 
4.3 Methods 
4.3.1 Study population and STEMI management 
Recruitment for the main cohort study was between 11th May 2011 and 22nd November 
2012. However, the investigational prototype T2* map sequence was only made available 
to us on 17th July 2011, after 24 patients had already been recruited. Therefore the cohort 
of patients that had T2* imaging acquired were recruited between 17th July 2011 and 22 
November 2012. Three hundred and forty three STEMI patients provided written informed 
consent. The eligibility criteria included an indication for primary percutaneous coronary 
intervention (PCI) or thrombolysis for acute STEMI as described in chapter 2. 
4.3.2 CMR acquisition 
Al patients underwent the CMR protocol described in detail in chapter 2. In brief this 
included cine CMR with steady-state free precession (SSFP), T2*-mapping acquired in 3 
short-axis slices, T2-mapping in contiguous short-axis slices covering the whole ventricle 
(Giri et al., 2009, Verhaert et al., 2011), and delayed-enhancement phase-sensitive 
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inversion-recovery pulse sequences (Kellman et al., 2002). I will report on the T1 mapping 
sequences in chapter 7. 
Serial imaging sub-study 
Thirty STEMI patients underwent serial CMR in order to characterise the evolution of 
myocardial haemorrhage by T2 and T2* quantification, and evaluate the temporal 
relationship with microvascular obstruction. Each patient was imaged at 4 time points, with 
the identical imaging protocol as above: 4 to 12 hours, 3 days, 10 days and 6-7 months 
post-reperfusion. 
Healthy volunteers 
CMR was also performed in 50 healthy volunteers of similar age and gender in order to 
obtain local reference values for myocardial T2 and T2*.  
4.4 CMR analyses 
The CMR analyses are described in chapter 2. In the serial imaging sub-study, standardised 
measurements of T2 and T2* in myocardial regions of interest (remote myocardium, 
injured myocardium and infarct core) were performed. In the main STEMI cohort, 
myocardial haemorrhage was reported in a binary fashion, defined as a region of reduced 
signal intensity within the infarcted area on T2* maps, with a T2* value of <20 ms 
(Ghugre et al., 2011, Kandler et al., 2014, O'Regan et al., 2010, Anderson et al., 2001). 
4.5 Statistical analyses  
As described in chapter 2, categorical variables are expressed as number and percentage of 
patients. Most continuous variables followed a normal distribution and are therefore 
presented as means together with standard deviation. Those variables that did not follow a 
normal distribution are presented as medians with interquartile range.  Differences between 
groups were assessed using one-way ANOVA, Kruskal-Wallis test or Fisher’s where 
appropriate. Univariable and multivariable logistic regression analyses were performed to 
identify predictors of myocardial haemorrhage. Binary logistic regression models were 
used to identify predictors of adverse remodelling at 6-month follow-up.  In stepwise linear 
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regressions, the Akaike information criterion (AIC) was used a measure of the relative 
quality of the models for this dataset, and the model with the minimum AIC value was 
reported.  
Receiver operating curve (ROC), Kaplan-Meier and Cox proportional hazards methods 
were used to identify potential clinical predictors of all-cause death/heart failure events and 
MACE, including patient characteristics, CMR findings and myocardial haemorrhage. A p-
value > 0.05 indicates the absence of a statistically significant effect. 
4.6 Results 
Of 343 STEMI patients referred for emergency PCI, 300 underwent serial CMR at 1.5 
Tesla 2.1±1.8 days and 6 months after hospital admission (Figure 4-1). 286 STEMI 
patients had T2* maps acquired. 245 (86%) patients had evaluable T2* data (figure 4-1) 
and all of these patients had evaluable T2 maps. CMR follow-up at 6 months was achieved 
in 228 (93%) of the patients with T2* mapping performed and all (n=245) patients had 
health outcomes assessed at minimum of 18 months after enrolment. 
4.6.1 Myocardial haemorrhage time-course study 
30 STEMI patients underwent serial CMR on 4 occasions. The first CMR examination was 
performed at a mean of 8.6±3.1 hours following emergency PCI, the second at 2.9±1.5 
days, the third at 9.6±2.3 days and the fourth 213±27 days following PCI. 102 (85%) CMR 
scans had evaluable T2* data and 117 (98%) had evaluable T2 data.  
4.6.2 Patient characteristics 
The clinical characteristics are shown in table 4-1. Based on T2*-CMR, 101 (41%) patients 
had IMH. Male sex, anterior infarction, TIMI flow ≤1 before PCI and inflammation were 
more common in patients with myocardial haemorrhage. Heart failure during index 
admission was also more common in patients with myocardial haemorrhage, indicated by 
the higher NT-proBNP level and more Killip heart failure class >2 at presentation. In 
addition, patients with myocardial haemorrhage had less resolution of ST-segment 
elevation post-PCI.  
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The characteristics of the serial imaging cohort were similar to the main study population 
and are described in table 4-2. 
4.6.3 Myocardial haemorrhage is associated with myocardial infarct characteristics 
The CMR findings at 2 days post-MI and 6 month later are shown in table 4-3. Clinical 
cases are shown in figure 4-2. Compared to patients without myocardial haemorrhage, 
patients with myocardial haemorrhage had a larger LV mass, larger LV volumes, and 
lower LV ejection fractions early post-MI and at 6 months. The initial area-at-risk, infarct 
size and microvascular obstruction were also larger and there was less myocardial salvage 
in patients with myocardial haemorrhage, (p<0.001, respectively, table 4-3). 
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Figure 4-1 Study flow diagram 
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Table 4-1 Clinical and angiographic characteristics of 245 patients with acute STEMI who had CMR at baseline with evaluable T2* maps. 
Characteristics*  All Patients 
n = 245 
Haemorrhagic 
infarct (T2*core +) 
n = 101 
Non-haemorrhagic 
infarct (T2*core -) 
n = 144 
p value 
Clinical      
Age, years  58 (11) 59 (12) 58 (11) 0.745 
Male sex, n (%)  187 (76) 84 (83) 103 (72) 0.047 
BMI, (kg/m2)  28 (5) 28 (5) 28 (5) 0.848 
History       
Hypertension, n (%)  77 (31) 37 (37) 40 (28) 0.163 
Current smoking, n (%)  153 (62) 70 (69) 83 (58) 0.081 
Hypercholesterolemia, n (%)  68 (28) 31 (31) 37 (26) 0.469 
Diabetes mellitus‡, n (%)  28 (11) 15 (15) 13 (9) 0.220 
Previous angina, n (%)  31 (13) 15 (15) 16 (11) 0.437 
Previous myocardial infarction, n (%)  17 (7) 8 (8) 9 (6) 0.619 
Previous PCI, n (%)  13 (5) 10 (10) 3 (2) 0.009 
Presenting characteristics      
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Heart rate, bpm  78(16) 80 (17) 77 (16) 0.202 
Systolic blood pressure, mmHg  136 (25) 136 (23) 136 (26) 0.887 
Diastolic blood pressure, mmHg  80 (14) 82 (14) 79 (14) 0.074 
Time from symptom onset to reperfusion, min  176 (123, 324) 207 (125, 364) 171 (124, 303) 0.161 
Ventricular fibrillation†, n (%)  15 (6) 7 (7) 8 (6) 0.788 
Heart failure, Killip class at presentation, n (%) I 171 (70) 59 (58) 112 (78) 
<0.001  II 57 (23.3) 26 (25.7) 31 (21.5) 
 III/IV 17 (7) 16 (16) 1 (1) 
Electrocardiogram      
ST segment elevation resolution post PCI, n (%)      
Complete, 70 %  107 (44) 31 (31) 76 (53) 
0.001 Partial, 30% to < 70%  99 (41) 48 (48) 51 (36) 
None, 30%  38 (16) 22 (22) 16 (11) 
Coronary angiography      
Reperfusion strategy, n (%)      
Primary PCI  229 (94) 92 (91) 137 (95) 
0.173 
Rescue PCI (failed thrombolysis)  10 (4) 7 (7) 3 (2) 
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Successful thrombolysis  6 (2) 2 (2.0) 4 (3) 
Number of diseased arteries¥, n (%) 1 132 (54) 58 (57) 74 (51) 
0.714 
 2 70 (29) 25 (25) 45 (31) 
 3 37 (15) 16 (16) 21 (15) 
 LM 6 (2) 2 (2) 4 (3) 
Culprit artery, n (%)  Left anterior descending 96 (39) 46 (46) 50 (35)  
 Left circumflex 48 (20) 26 (26) 22 (15) 0.003 
 Right coronary 101 (41) 29 (29) 72 (50)  
TIMI coronary flow grade pre-PCI, n (%) 0/1 180 (74) 88 (87) 92 (64) 
<0.001 
 2/3 65 (27) 13 (13) 52 (36) 
TIMI coronary flow grade post-PCI, n (%) 0/1 3 (1) 2 (2) 1 (1) 
 
0.658 
 2 11 (5) 5 (5) 6 (4) 
 3 231 (94) 94 (93) 137 (95) 
Initial blood results on admission      
C-reactive protein, (mg/L) 
 
 
3.0 (2.0, 7.0) 3.0 (2.0, 7.0) 3.0 (2.0, 7.0) 0.116 
Leucocyte cell count (x109L)  12.5 (3.5) 13.7 (3.8) 11.6 (3.1) <0.001 
  
115 
 
Neutrophil count (x109L)  9.7 (3.3) 11.0 (3.5) 8.8 (2.9) <0.001 
Monocytes (x109L)  0.9 (0.4) 1.0 (0.5) 0.8 (0.3) <0.001 
NT-proBNP index admission, pg/mL  767 (363, 1635) 1117 (646, 1647) 606 (300, 1414) 0.007 
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Table 4-2 Clinical and angiographic characteristics of the 30 patients in the longitudinal clinical study stratified by the presence of haemorrhage on day 3 
CMR. 
Characteristics*  All Patients 
n = 30 
Myocardial 
hemorrhage      
(T2*core +) 
n = 13 (43%) 
No myocardial 
hemorrhage           
(T2*core -) 
n = 17 (57%) 
p value 
Clinical      
Age, years  54 (10) 53 (11) 55 (9) 0.602 
Male sex, n (%)  25 (83) 10 (77) 15 (88) 0.628 
BMI, (kg/m2)  28 (5) 27 (5) 29 (4) 0.257 
History       
Hypertension, n (%)  8 (27) 3 (23) 5 (29) 1.000 
Current smoking, n (%)  21 (70) 10 (77) 11 (65) 0.691 
Hypercholesterolemia, n (%)  13 (43) 6 (46) 7 (41) 1.000 
Diabetes mellitus‡, n (%)  2 (7) 1 (8) 1 (6) 1.000 
Previous angina, n (%)  3 (10) 2 (15) 1 (6) 0.565 
Previous myocardial infarction, n (%)  1 (3) 0 (0) 1 (6) 1.000 
Previous PCI, n (%)  1 (3) 0 (0) 1 (6) - 
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Presenting characteristics      
Heart rate, bpm  77 (17) 81 (14) 75 (19) 0.340 
Systolic blood pressure, mmHg  141 (26) 143 (16) 139 (33) 0.712 
Diastolic blood pressure, mmHg  84 (12) 86 (11) 83 (13) 0.472 
Time from symptom onset to reperfusion, min  156 (112, 243) 137 (112, 274) 161 (118, 206) 0.837 
Ventricular fibrillation†, n (%)  1 (3) 0 (0) 1 (6) 1.000 
Heart failure, Killip class at presentation, n (%) I 22 (74) 9 (69) 13 (76) 
0.811  II 7 (23) 3 (23) 4 (24) 
 III/IV 1 (3) 1 (8) 0 (0) 
Electrocardiogram      
ST segment elevation resolution post PCI, n (%)      
Complete, 70 %  15 (50) 1 (8) 1 (6) 
1.000 Partial, 30% to < 70%  13 (43) 6 (46) 7 (41) 
None, 30%  2 (7) 6 (46) 9 (53) 
Number of diseased arteries¥, n (%) 1 14 (47) 4 (31) 10 (58) 
0.298  2 11 (37) 6 (46) 5 (29) 
 3 5 (17) 3 (23) 2 (12) 
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 LM 0 (0) 0 (0) 0 (0) 
Culprit artery, n (%)  LAD 9 (30) 5 (38) 4 (24)  
 LCX 10 (33) 6 (46) 4 (24) 0.112 
 RCA 11 (37) 2 (15) 9 (53)  
TIMI coronary flow grade pre-PCI, n (%) 0/1 24 (80) 12 (92) 12 (71) 
0.196 
 2/3 6 (20) 1 (8) 5 (29) 
TIMI coronary flow grade post-PCI, n (%) 0/1 0 (0) 0 (0) 0 (0)  
1.000  2 2 (7) 1 (8) 1 (6) 
 3 28 (93) 12 (92) 16 (94) 
Initial blood results on admission      
Neutrophil count (x109L)  10.1 (3.1) 11.3 (3.0) 9.3 (3.0) 0.083 
NT-proBNP, pg/mL  588 (306, 1541) 864 (655, 1637) 529 (301, 1254) 0.841 
*P-values were obtained from t-tests or Mann-Whitney test as appropriate for continuous variables, and Fisher’s tests for categorical variables.  
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Table 4-3 Baseline and 6-month CMR findings of the entire patient population and according 
to the presence of myocardial haemorrhage. 
Characteristics* All 
 Patients 
n = 245 
Haemorrhagic 
infarct 
(T2*core +) 
n = 101 
Non-haemorrhagic 
infarct        
(T2*core -) 
n = 144 
p value 
CMR findings 2 days post-MI     
LV ejection fraction, % 55 (10) 51 (10) 57 (8) <0.001 
LV end-diastolic volume, ml 153 (34) 164 (34) 145 (32) <0.001 
Men 161 (32) 171 (31) 153 (32) <0.001 
Women 124 (23) 127 (26) 123 (22) 0.534 
LV end-systolic volume, ml 71 (26) 82 (27) 64 (22) <0.001 
Men 76 (26) 86 (27) 68 (23) <0.001 
Women 55 (15) 61 (16) 53 (14) 0.037 
LV mass, g 135 (38) 147 (39) 127 (35) <0.001 
Men 146 (34) 154 (38) 140 (30) 0.006 
Women 99 (24) 111 (26) 94 (21) 0.01 
Oedema and infarct characteristics 
Area at risk, % LV mass 33 (12) 39 (11) 29 (10) <0.001 
Infarct size, % LV mass 19 (14) 29 (12) 12 (10) <0.001 
Myocardial salvage, % of LV 
mass 
19 (9) 18 (8) 20 (10) 0.064 
Myocardial salvage index, %  61 (24) 46 (17) 71 (17) <0.001 
Late microvascular 
obstruction present, n (%) 
133 (54 %) 101 (100%) 32 (22 %) <0.001 
Late microvascular 
obstruction, % LV mass 
0.5 (0.0, 4.2) 5.3 (2.1, 9.5) 0.0 (0.0, 0.0) <0.001 
T2 hypointense core present, 
n (%) 
161 (66%) 101 (100%) 60 (42%) <0.001 
CMR findings 6 months post-MI (n = 228) 
LV ejection fraction, % 61 (9) 56 (10) 65 (7) <0.001 
Change in LV ejection 
fraction at 6 months from 
baseline, % 
7 (8) 5 (7) 8 (8) 0.005 
LV end-diastolic volume, ml 160 (42) 180 (49) 146 (30) <0.001 
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Men 169 (42) 188 (48) 154 (29) <0.001 
Women 128 (23) 133 (20) 127 (24) 0.066 
Change in LV end-diastolic 
volume at 6 months from 
baseline, ml 
6 (28) 15 (30) 1 (22) <0.001 
LV end-systolic volume, ml 64 (33) 82 (40) 52 (20) <0.001 
Men 69 (35) 86 (42) 55 (21) <0.001 
Women 48 (17) 62 (13) 43 (15) <0.001 
Change in LV end-systolic 
volume at 6 months from 
baseline, ml 
-7 (22) 0 (26) -12 (18) <0.001 
LV mass, g 119 (30) 127 (30) 114 (28) 0.001 
Men 128 (27) 133 (2) 123 (26) 0.007 
Women 91 (18) 95 (17) 90 (18) 0.270 
Infarct size, % LV mass 13 (10) 21 (10) 8 (7) <0.001 
*P-values were obtained from t-tests or Mann-Whitney test as appropriate for continuous 
variables, and Fisher’s tests for categorical variables. 
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Figure 4-2 Examples of acute reperfused STEMI patients with and without evidence of 
myocardial haemorrhage on day 2 CMR 
Three patients with acute STEMI treated by primary PCI using the same anti-thrombotic 
strategies. Each patient had normal TIMI grade 3 flow at the end of PCI. Cardiac MRI 
was performed for each patient 2 days post-reperfusion. (a) Patient with no evidence of 
myocardial haemorrhage or microvascular obstruction. T2 within the injury zone (middle 
left) measured 67.8 ms. T2* within the injury zone (middle right) measured 39 ms. Acute 
infarct size revealed by late gadolinium enhancement (LGE) (right) was 24%. The LVEF 
and LV end-diastolic volume were 51% and 132 ml, respectively. Analysis of the repeat 
MRI scan after 6 months follow-up indicated that the final infarct size was 18% of LV mass 
and the LV end-diastolic volume had reduced to 109 ml. This patient had an 
uncomplicated clinical course.  (b) Patient with T2 hypointense core and microvascular 
obstruction, in the absence of haemorrhage. T2 mapping (middle left) revealed a 
hypointense region within the infarct core (green arrow), corresponding to the the area of 
microvascular obstruction (MVO) on contrast-enhanced MRI (right; green arrow). T2 
within the infarct core measured 53 ms, which was substantially lower than the T2 value 
measured at the periphery of the infarct zone (72 ms). T2* within the injury zone measured 
36 ms (middle right). Acute infarct size revealed by LGE (right) was 19%. The LVEF and 
end-diastolic volume were 52% and 158 ml, respectively. Six month follow-up CMR 
revealed infarct size was 15% of left ventricular mass and there was an increase in the LV 
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end-diastolic volume to 171 ml. This patient had no adverse events during follow-up.  (c) 
Patient with myocardial haemorrhage. T2 mapping (middle left) revealed a hypointense 
region within the infarct core (red arrow), corresponding to the hypointense region on T2* 
map (middle right; red arrow) and the area of MVO on contrast-enhanced MRI (right; red 
arrow). T2 within the infarct core measured 44 ms, which was substantially lower than the 
T2 value measured at the periphery of the infarct zone (61 ms). T2* within the infarct core 
measured 9 ms. Acute infarct size revealed by LGE (right) was 38%. MVO depicted as the 
central dark zone within the infarct territory (red arrow) was 13% of LV mass. The LVEF 
and end-diastolic volume were 40.8% and 190 ml, respectively. The final infarct size at 6 
months was 32% of LV mass and the LV end-diastolic volume had increased to 231 ml. 
This patient was re-hospitalised for new onset heart failure during follow-up and ICD 
implantation (after 8 months), following a deterioration in LVEF. 
4.6.4 Comparison of myocardial haemorrhage (T2* core), T2 hypointense core and 
microvascular obstruction 
A hypointense infarct core was detected with T2 mapping in 161 (66%) STEMI patients. 
Microvascular obstruction with early gadolinium- and late gadolinium enhancement CMR 
was revealed in 151 (62%) and 133 (54%) patients, respectively. All patients with 
myocardial haemorrhage, as defined by T2* imaging, had late microvascular obstruction 
and a hypo-intense core on T2 imaging. In contrast, 32 (13%) patients had late 
microvascular obstruction in the absence of myocardial haemorrhage and all of these 
patients had a hypo-intense core on T2 imaging. 28 (11%) patients had a T2 hypo-intense 
core without evidence of late microvascular obstruction or myocardial haemorrhage.   
The results of intra- and inter-observer agreement of T2 and T2* core measurements are 
shown in chapter 3, section 3.5.2. 
4.6.5 Myocardial haemorrhage and associations with clinical characteristics  
101 STEMI survivors had evidence of myocardial haemorrhage revealed by T2* mapping 
with CMR 2 days post-MI. The clinical characteristics that were univariably associated 
with the presence of myocardial haemorrhage, from binary logistic regression were: male 
gender (odds ratio (95% confidence interval (CI)): (1.97 (1.04, 3.71); p=0.037), history of 
previous PCI (5.16 (1.38, 19.27); p=0.015, current smoker (1.66 (0.97, 2.84); p=0.064), 
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Killip heart failure classification >2 (30.37 (3.93, 234.69); p=0.001), TIMI coronary flow 
2/3 pre-PCI (0.26 (0.13, 0.51); p<0.001), and 30% ST-segment resolution post-PCI (3.37 
(1.56, 7.26); p=0,002). 
In stepwise logistic regression using AIC, myocardial haemorrhage was independently 
associated with sex, smoking, history of previous PCI, TIMI coronary flow grade at initial 
angiography, ECG evidence of reperfusion injury and Killip class (all p<0.03) (table 4-4). 
Table 4-4 Associates of myocardial haemorrhage, as defined by T2* CMR, in multivariable 
stepwise regression analyses (n=245). 
Multiple stepwise regression Odds ratio (95% CI) p value 
A. Including patient characteristics and 
angiographic data 
  
Male 2.36 (1.15, 4.85) 0.019 
Previous PCI 5.92 (1.23, 28.56) 0.027 
Smoker 2.45 (1.21, 4.96) 0.013 
Killip class >2 15.13 (1.86, 123.12) 0.011 
TIMI flow >1 at initial angiography 0.27 (0.13, 0.56) <0.001 
30% ST-segment resolution post-PCI 3.08 (1.27, 7.50) 0.013 
Footnote: The odds ratio (95% confidence intervals) indicates the magnitude and direction 
for myocardial haemorrhage.   
4.6.6 Myocardial haemorrhage and adverse remodelling at 6-months 
At 6 months, LV end-diastolic volume increased on average (SD) by 6 (27) ml in 224 
patients with evaluable data (table 4-3). The average increase in LV end-diastolic volume 
at 6 months was greater in patients with myocardial haemorrhage compared to those 
without (15 (30) vs. 1 (22); p<0.001). Adverse remodelling, defined as an increase in LV 
end-diastolic volume by ≥20%, occurred in 27 (12%) patients and 17 (63%) of these 
patients had myocardial haemorrhage at baseline. 
The clinical characteristics that were univariably associated with adverse remodelling and 
their p-values that were included in the multivariable model were: age (p=0.804), male 
gender (p=0.811), body mass index (p=0.693), previous MI (p=0.306), diabetes mellitus 
(p=0.816), previous PCI (p=0.469), cigarette smoking (p=0.500), history of hypertension 
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(p=0.329), history of hypercholesterolaemia (p=0.774), history of angina (p=0.816), heart 
rate (p=0.167), systolic blood pressure at initial angiography (p=0.511), Killip class II vs. 
Killip class I (reference category) (p=0.046), Killip class III/IV vs. Killip class I (reference 
category) (p=0.031), symptom onset to reperfusion time (p=0.355), TIMI flow grade 2/3 
vs. grade 1 (reference category) at initial angiography (p=0.529), ST segment resolution 
(none vs. complete (reference category), and p=0.343; incomplete vs. complete (reference 
category), p=0.064). 
The presence of myocardial haemorrhage (binary) was multivariably associated with 
adverse remodelling, independent of baseline LV end-diastolic volume (odds ratio (95% 
CI): 2.64 (1.07, 6.49); p=0.035) (table 4-5). Patients with myocardial haemorrhage on MRI 
had significantly higher NT-proBNP results at 6 month follow-up, compared to patients 
without evidence of haemorrhage (247 (158, 570) vs. 108 (61, 226) pg/mL; p<0.001). 
In multivariable regression, T2* core (continuous, ms) was not associated with adverse 
remodelling. 
Table 4-5 Multivariable predictors of adverse LV remodelling at 6 months post-STEMI. 
Multiple stepwise regression Odds ratio (95% CI) p value 
Patient characteristics and angiographic findings*   
Myocardial haemorrhage 2.60 (1.16, 5.86) 0.021 
Patient characteristics, angiographic findings and 
LV end-diastolic volume 
  
Myocardial haemorrhage 2.64 (1.07, 6.49) 0.035 
Killip class 2 2.62 (1.04, 6.62) 0.041 
LV end-diastolic volume at baseline, ml 0.99 (0.97, 1.00) 0.043 
Footnote: The odds ratio (95% confidence intervals) indicates the magnitude and direction 
for adverse LV remodelling. 
4.6.7 Myocardial haemorrhage, microvascular obstruction, T2 hypointense core and 
LV outcomes at 6 months 
The relationships for the presence of myocardial haemorrhage, T2 map core and 
microvascular obstruction for LV outcomes, including LV end-diastolic volumes and LV 
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ejection fraction are shown in table 4-6. Myocardial haemorrhage is consistently associated 
with worse LV outcomes 6 months post-MI. 
Table 4-6 Relationships for the presence of myocardial haemorrhage (T2* core), T2 map 
core and microvascular obstruction, and left ventricular outcomes at baseline and follow-
up. 
 LVEDV 
baseline 
LVEDV 
6 months 
Change 
LVEDV 
Adverse 
remodelling 
LVEF at 
baseline 
LVEF    
6 months 
LVEF 
change 
T2* core 
(binary) 
Direction of 
relationship 
<0.001 
(+)ve 
<0.001 
(+)ve 
<0.001 
(+)ve 
0.021 
(+)ve 
<0.001 
(-)ve 
<0.001 
(-)ve 
0.006 
(-)ve 
T2 core 
(binary) 
Direction of 
relationship 
0.001 
(+)ve 
<0.001 
(+)ve 
0.003 
(+)ve 
0.023 
(+)ve 
<0.001 
(-)ve 
<0.001 
(-)ve 
0.010 
(-)ve 
MVO 
(binary) 
Direction of 
relationship 
<0.001 
(+)ve 
<0.001 
(+)ve 
<0.001 
(+)ve 
0.048 
(+)ve 
<0.001 
(-)ve 
<0.001 
(-)ve 
0.010 
(-)ve 
 
4.6.8 Myocardial haemorrhage and longer term health outcomes 
245 (100%) patients had longer term follow-up completed. The median duration of follow-
up was of 827 days. 8 (3.3%) patients died or experienced a heart failure event post-
discharge. The presence of myocardial haemorrhage (binary) was associated with 
cardiovascular cause of death or heart failure hospitalisation post discharge (hazard ratio 
12.9, 95% CI 1.6, 100.8; p=0.015). 
T2* core (continuous, ms) was not associated with health outcome. 
  
126 
 
4.6.9 Temporal evolution of myocardial haemorrhage and microvascular obstruction 
from acute reperfusion through to 6 months 
Intramyocardial haemorrhage occurred in 7 (23%), 13 (43%), 11 (33%), and 4 (13%) 
patients, versus microvascular obstruction in 18 (60%), 17 (57%), 10 (33%) and 0 patients 
at 4 - 12 hours, 3 days, 10 days and 7 months, respectively (table 4-7). The amount of 
microvascular obstruction (% LV mass) in patients with haemorrhagic infarction was at its 
greatest at 4 – 12 hours post-reperfusion and remained similar at day 3 CMR, then reduced 
by day 10  (table 4-8). In contrast, the amount of myocardial haemorrhage progressively 
increased from 4 – 12 hours with a peak at day 3 and decreased by day 10 (p=0.001) (table 
4-8).  The amount of T2 hypointense core (% LV mass) followed a similar pattern to 
haemorrhage. At 7 months, 4 (13%) patients had evidence of persisting haemorrhage, but 
none of the patients had microvascular obstruction. 
Table 4-7 CMR findings of serial imaging sub-group (n=30) at 4 time intervals post-
reperfusion.  
 
 
 
4 < 12 hours 
n = 30 
3 Days 
n = 30 
10 Days 
n =30 
6-7 months 
n =30 
LV ejection fraction, % 52 (9) 56 (9) 59 (8) 59 (8) 
LV end-diastolic volume, 
ml 158 (135, 184) 165 (129, 181) 164 (132, 194) 161 (120, 196) 
Area at risk, % LV mass 34 (10) 39 (12) 31 (12) - 
Infarct size, % LV mass 19 (13) 20 (13) 14 (10) 14 (10) 
Late microvascular 
obstruction present, n (%) 18 (60) 17 (57) 10 (33) 0 
Early microvascular 
obstruction, n (%) 20 (67) 17 (57) 15 (50) - 
T2 hypointense core 
present, n (%) 19 (63) 18 (60) 14 (47) 0 
Myocardial haemorrhage     
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Table 4-8 The temporal evolution of amount (% LV mass) of microvascular obstruction, T2 
hypointense core and myocardial haemorrhage in acute reperfused STEMI patients (n=13). 
Footnote: the amount of microvascular obstruction and T2 hypointense were calculated 
using full LV coverage, whereas myocardial haemorrhage is the average of basal, mid and 
apical slice acquisitions.  
4.6.10 Persistence of microvascular obstruction in relation to the presence of 
myocardial haemorrhage 
Microvascular obstruction resolved by day 10 in 8 (44%) patients, 2 (25%) of whom had 
evidence of myocardial haemorrhage. Whereas microvascular obstruction persisted at day 
10 in 10 (56%) patients, all (100%) of whom had evidence of haemorrhage. 
 
4.7 Discussion 
We have undertaken the largest clinical study to date of myocardial haemorrhage using 
diagnostic T2* CMR mapping in a relatively unselected STEMI population following 
emergency invasive management. We have also reported for the first time a serial imaging 
analysis for the evolution and time-course of myocardial haemorrhage and microvascular 
obstruction in the early reperfusion period. 
Our main findings are 1) the incidence of myocardial haemorrhage occurred in 41% of 
STEMI patients and the presence of myocardial haemorrhage was associated with the 
present, n (%) 7 (23) 13 (43) 11 (37) 4 (13) 
 
 
 
4 < 12 hours 3 Days 10 Days 6-7 months 
Late microvascular 
obstruction, % LV mass 
5.3 (2.1, 10.5) 5.4 (2.7, 8.4) 1.3 (0.1, 4.2) - 
T2 hypointense core, % 
LV mass 
6.0 (4.6, 8.7) 9.9 (6.6, 11.3) 3.3 (1.5, 6.4) - 
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clinical severity of MI and was associated with adverse LV remodelling, although when 
analysed in a continuous format, there was no relationship between T2* and remodelling. 
IMH was also associated with cardiovascular death and first hospitalisation for heart 
failure, 2) considering the time-course of myocardial haemorrhage in a sub-group of 
STEMI patients, CMR within 12 hours of emergency PCI revealed myocardial 
haemorrhage in approximately one quarter of the patients and the incidence nearly doubled 
by day 3, implying a hyper-acute phase followed by secondary haemorrhage, 3)  
myocardial haemorrhage was a secondary event, which dynamically increased, following 
the initial occurrence of microvascular obstruction, 4) the severity of microvascular 
obstruction affected its degree of persistence and the presence of haemorrhage 
differentiated persistent, structural microvascular destruction from functional, potentially 
reversible microvascular obstruction, 5) a hypointense infarct core on T2-mapping always 
occurred in the presence of microvascular obstruction and commonly in the absence of 
myocardial haemorrhage within 12 hours and 3 days post-MI, indicating that the presence 
of T2-core is more closely associated with microvascular obstruction than myocardial 
haemorrhage. 
Studies to date of reperfusion haemorrhage, have been limited by either the subjective 
nature of qualitative evaluation of haemorrhage or not using haemorrhage sensitive CMR 
sequences. Most clinical studies have used dark blood T2-weighted imaging to detect 
haemorrhage (Ganame et al., 2009, Beek et al., 2010, Bekkers et al., 2010a, Eitel et al., 
2011, Amabile et al., 2012, Husser et al., 2013), however, this qualitative technique is 
hampered by imaging artefact (Wince and Kim, 2010) and false-positive effects of 
microvascular obstruction (Cannan et al., 2010, Jackowski et al., 2006). Thus, it does not 
seem feasible to differentiate microvascular obstruction and haemorrhage based solely on 
T2-weighted imaging.  
T2-weighted imaging is also strongly influenced by oedema and the hyperintense signal 
from oedema may mask the hypointense signal from haemorrhage (Lotan et al., 1992), on 
the contrary T2* techniques are relatively insensitive to the effects of oedema (Kali et al., 
2013b). Quantitative T2 mapping addresses the limitations associated with T2-weighted 
techniques (Wince and Kim, 2010, Cannan et al., 2010, Jackowski et al., 2006, Lotan et al., 
1992), offers increased accuracy in the detection of myocardial oedema and may provide a 
more objective assessment of the infarct core because it directly measures T2 relaxation 
times (Giri et al., 2009, Verhaert et al., 2011, Ghugre et al., 2011, Zia et al., 2012, Ugander 
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et al., 2012, Hammer-Hansen et al., 2014, Nassenstein et al., 2014, Park et al., 2013), and 
T2*-mapping holds greater promise. 
The temporal evolution of myocardial haemorrhage and relationship with microvascular 
obstruction, in the early post-infarct period is incompletely understood. Experimental 
studies have inferred that haemorrhage occurs as a consequence of reperfusion (Pislaru et 
al., 1997), whereas other studies have implied that haemorrhage may be a secondary 
phenomenon due to progressive capillary breakdown (Fishbein et al., 1980, Payne et al., 
2011a, Robbers et al., 2013, Kumar et al., 2011). A recent experimental study by Robbers 
et al (Robbers et al., 2013) indicated that microvascular obstruction might be a modifiable 
precursor of haemorrhage, which represented irreversible microvascular destruction. Our 
serial imaging data support the notion that haemorrhage occurs as a complication of 
microvascular obstruction, since microvascular obstruction was at its greatest extent from 
the outset, while haemorrhage progressively increased from <12 hours to day 3 post-
reperfusion. Also, in accordance with other recent studies using T2* imaging to define 
haemorrhage (Kali et al., 2013b, Kumar et al., 2011, Zia et al., 2012, Kidambi et al., 2013, 
O'Regan et al., 2010, Mather et al., 2011b), we observed that haemorrhage only occurred 
within regions of microvascular obstruction. 
Previous studies using dark blood T2-weighted imaging to define haemorrhage showed 
that microvascular obstruction occurred commonly in the absence of a T2 hypointense core 
(Amabile et al., 2012, Eitel et al., 2011, Ganame et al., 2009, Kandler et al., 2014). In 
contrast, we observed that all patients with microvascular obstruction had a hypointense 
core on T2-mapping. Our results concur with the findings of one of only a few 
histologically confirmed postmortem analyses (Jackowski et al., 2006), which showed that 
a T2 hypointense core always represented microvascular obstruction, with or without 
haemorrhage.  
We also observed that a T2 hypointense core was more closely related to early 
microvascular obstruction, than late microvascular obstruction or haemorrhage. The 
occurrence of a T2 hypointense core on T2 maps in the absence of haemorrhage likely 
represents a reduction in the effective tissue water to the infarct core due to associated 
obstructed capillary flow (e.g. cellular debris and extrinsic oedema) and microvascular 
spasm, thereby reducing the supply of protons and subsequent reduction in T2 signal. 
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There are conflicting data regarding the temporal change in size of microvascular 
obstruction in the early reperfusion period. Canine studies (Wu et al., 1998a, Rochitte et 
al., 1998) have shown that the amount of microvascular obstruction increases in the first 48 
hours after reperfusion and then remains stable between 2 and 9 days. However there have 
not been any confirmatory studies in humans to demonstrate expansion of microvascular 
obstruction at any time-point post-reperfusion. Our findings indicate that the extent of 
microvascular obstruction remains stable between 4 – 12 hours and day 3, then decreases 
to day 10, which is in agreement with other clinical data, demonstrating that microvascular 
obstruction appears small at one week (Orn et al., 2009, Mather et al., 2011a).   
Persistent microvascular obstruction at 1 week appears to be a different entity to 
microvascular obstruction resolving the first week. Our study may explain the variability in 
time-course data of resolution of microvascular obstruction, since T2* imaging is able to 
differentiate structural microvascular destruction (i.e. haemorrhage) from potentially 
reversible, functional microvascular obstruction.  
Our results have important clinical implications. Reperfusion haemorrhage related effects 
on LV end-diastolic volume and LV ejection fraction occur early and significant changes 
can be observed within the first 10 days post-MI. These early changes result in long-term 
adverse remodelling and this could represent a high risk group that should be targeted for 
anti-remodelling therapy. In addition haemorrhage is a non-contrast CMR biomarker with 
potential to reflect the efficacy of novel therapeutic interventions in STEMI patients.    
4.7.1 Limitations 
A main limitation of our study is lack of pathological correlation of our imaging results. As 
a result of time constraints we only acquired 3 short-axis slices using T2* mapping and 
therefore minor degrees of haemorrhage could have been missed. We could also not 
compare the total amount of haemorrhage to total amount of microvascular obstruction or 
T2 hypointense core due to the limited T2* slice acquisition. In addition, the inclusion of 
thrombolysed patients may represent a confounder and the sample size of this sub-group is 
too small to draw any conclusions. There was a substantial proportion of artefacts with the 
T2* sequence, limiting quantification of haemorrhage in a high number of patients. The 
use of high-pass filtered processing may have helped to overcome these limitations 
(Goldfarb et al., 2013). In addition, a technique has been proposed for applying an 
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automated truncation method to pixel wise T2* mapping to improve image quality 
(Sandino et al., 2015). Despite the technical limitations, T2* seems to be the most sensitive 
cardiac MRI sequence to detect haemorrhage. 
4.7.2 Conclusion 
We found that myocardial haemorrhage occurs commonly and is a biomarker for 
prognostication in STEMI survivors. The severity of MVO affects its degree of persistence 
and T2* imaging differentiates persistent, structural microvascular injury from functional, 
potentially reversible MVO. Haemorrhage occurs in primary and secondary phases within 
the first 10 days post-MI and is a secondary phenomenon to the initial occurrence of 
microvascular obstruction. 
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5 Chapter 5: Myocardial haemorrhage after acute 
reperfused ST-elevation myocardial infarction evolves 
dynamically and contributes to the early bimodal 
pattern in myocardial oedema: advanced imaging and 
clinical significance
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5.1 Introduction 
In acute ST-elevation myocardial infarction (STEMI), myocardial haemorrhage is a 
complication that is associated with the duration of ischemia and reperfusion (Betgem et 
al., 2014, Kloner et al., 1974, Jaffe et al., 2008, Higginson et al., 1982), and is an adverse 
prognostic factor in the longer term (Ganame et al., 2009, Amabile et al., 2012, Eitel et al., 
2011, Husser et al., 2013). Myocardial haemorrhage is potentially a therapeutic target for 
novel interventions however the temporal evolution of myocardial haemorrhage and its 
association with other MI characteristics early post-MI are uncertain.  
Myocardial oedema is a consequence of ischemia and infarction and has functional 
importance, since oedema impairs myocyte contractility (Bragadeesh et al., 2008). The 
extent of oedema revealed by cardiac magnetic resonance (CMR) is a retrospective marker 
of the ischemic area-at-risk (Aletras et al., 2006, Berry et al., 2010, Garcia-Dorado et al., 
1993), which in turn is a prognostic determinant post-MI (Califf et al., 1985). For oedema 
to be taken as a retrospective marker of the area-at-risk, its initial size should be stable. 
Dall’Armelina et al (Dall'Armellina et al., 2011) reported that the area-at-risk was maximal 
and constant in size within the first 5 - 7 days post-MI but then decreased in size 
subsequently. Recently, Fernández-Jiménez et al (Fernandez-Jimenez et al., 2015) assessed 
myocardial oedema in a swine model of MI (with or without reperfusion) at 2 hours, 24 
hours, 4 days or 7 days (n=5 per group) using CMR and quantification of myocardial water 
content by post-mortem tissue desiccation. They found a bimodal pattern in myocardial 
oedema with high water content peaks at 2 hours and 7 days post-reperfusion and an 
intervening decrease in myocardial water content at 24 hours.  
Tissue haemorrhage is typically characterised by an acute primary phase and then 
potentially secondary haemorrhagic transformation in the sub-acute phase hours – days 
later (Fishbein et al., 1980, Alvarez-Sabin et al., 2013), and deoxyhemoglobin has 
paramagnetic effects that enable myocardial haemorrhage to be detected using T2- and 
T2*-weighted CMR (Anzalone et al., 2004, Payne et al., 2011a). Since myocardial 
haemorrhage is virtually universal in swine after 40 minutes of ischemia the observations 
by Fernández-Jiménez et al (Fernandez-Jimenez et al., 2015) could be explained by 
myocardial haemorrhage, however, the time-course and relationships between myocardial 
oedema and haemorrhage early post-MI in STEMI survivors are uncertain.  
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We hypothesized that 1) myocardial haemorrhage evolves progressively after acute STEMI 
with incident haemorrhage occurring in some patients immediately after reperfusion 
followed by a secondary phase of haemorrhage, 2) T2 and T2* signals within the infarct 
zone follow similar time-courses and 3) T2 signal is inversely associated with the amount 
of haemorrhage, whereas the extent of oedema (area-at-risk) is stable. 
5.2 Methods 
5.2.1 Study population and STEMI management 
To examine these hypotheses, we performed a comprehensive longitudinal CMR study of 
myocardial haemorrhage and oedema in a cohort of reperfused STEMI survivors in a 
single regional cardiac centre between 3 November 2011 and 18 September 2012. Thirty 
STEMI patients provided written informed consent and the eligibility criteria and acute 
STEMI management are as described in detail in chapter 2. 
5.2.2 CMR acquisition 
CMR was performed on 4 occasions (4 to 12 hours and approximately 3 days, 10 days and 
7 months) post-reperfusion as described in chapter 2. The imaging protocol which was the 
same between scans was performed as described in chapter 2. Briefly, this included cine 
CMR with steady-state free precession (SSFP), T2*-mapping, T2-mapping (Giri et al., 
2009, Verhaert et al., 2011), and delayed-enhancement phase-sensitive inversion-recovery 
pulse sequences (Kellman et al., 2002).  
CMR was also performed in 50 healthy volunteers of similar age and gender in order to 
obtain local reference values for myocardial T2 and T2* (chapter 2 and 3). 
5.2.3 CMR analyses 
The images were analysed on a Siemens work-station by observers with at least 3 years 
CMR experience (N.A., D.C., I.M., and S.R.). All of the images were reviewed by an 
experienced CMR cardiologist (C.B.). LV dimensions, volumes and ejection fraction were 
quantified using computer assisted planimetry (syngo MR®, Siemens Healthcare, 
Erlangen, Germany). The late gadolinium enhancement images were analysed by observers 
(N.A., I.M.) who were blinded to all of the other data. 
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T2 and T2* standardised measurements in myocardial regions of interest (defined as (1) 
remote myocardium, (2) injured myocardium and (3) infarct core) were performed as 
described in chapter 2.  
5.2.4 Myocardial Haemorrhage 
Myocardial haemorrhage was scored visually. On the T2* maps, a region of reduced signal 
intensity within the infarcted area, with a T2* value of <20 ms (Ghugre et al., 2011, 
Kandler et al., 2014, O'Regan et al., 2010, Anderson et al., 2001), was considered to 
confirm the presence of myocardial haemorrhage. 
5.3 Statistical analyses  
Categorical variables are expressed as number and percentage of patients. Most continuous 
variables followed a normal distribution and are therefore presented as means together with 
standard deviation. Those variables that did not follow a normal distribution are presented 
as medians with interquartile range.  Differences between independent groups were 
assessed using t-tests, Mann-Whitney tests, or Fisher’s tests where appropriate. Changes 
over time were assessed using generalized linear mixed effects models with subject ID as 
the only random effect. A p-value > 0.05 indicates the absence of a statistically significant 
effect. Random effects models were used to compute inter-and intra- rater reliability 
measures (intra-class correlation coefficient (ICC)) for the reliability of remote zone, 
infarct zone and infarct core T2 and T2* values measured independently by 2 observers in 
20 randomly selected patients from the cohort. 
5.4 Results 
Thirty STEMI patients (mean age 54 years, 83% male) (table 5-1) gave informed consent 
and underwent serial CMR at 1.5 Tesla on 4 occasions (figure 5-1). The CMR 
examinations were performed (mean±SD) 8.6±3.1 hours, 2.9±1.5 days, 9.6±2.3 days and 
213±27 days following primary PCI. Evaluable T2 and T2* data were available in 117 
(98%) and 102 (85%) CMR scans, respectively (figure 5-1). Information on vital status and 
SAEs were available in all of the participants. 
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Figure 5-1 Study flow diagram 
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5.4.1 Temporal evolution of myocardial haemorrhage following ischemia/reperfusion 
Myocardial haemorrhage occurred in 7 (23%), 13 (43%), 11 (33%), and 4 (13%) patients 
at 4 - 12 hours, 3 days, 10 days and 7 months, respectively (table 5-2). Clinical case 
examples are shown in figure 2. In patients with myocardial haemorrhage, the amount of 
haemorrhage (% LV) increased progressively from 4 – 12 hours with a peak at 3 days and 
then a decrease at 10 days (p=0.001) (table 5-2 and figure 3). The opposite pattern was 
seen with T2* core values, with a nadir at day 3 CMR (p=0.004) (table 5-3). 
5.4.2 Temporal evolution of myocardial oedema and the area-at-risk  
The extent of myocardial oedema (% LV) increased from the initial CMR scan 4 – 12 
hours post-MI to a maximum 3 days post-MI and then reduced at 10 days and 7 months 
post-MI. The AAR fluctuated in size in both groups with an increase from 4 – 12 hours to 
a maximum at 3 days followed by a modest reduction in size by day 10 and a marked 
reduction by 7 months when the oedema could not be reliably measured (table 5-2). 
The increase in the extent of oedema at 3 days mirrored the increase in haemorrhage at this 
time-point. In addition, the end-diastolic wall thickness measured in the infarct zone, 
followed the same temporal changes (table 5-4)
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Figure 5-2 CMR T2 mapping, T2* mapping and contrast enhanced images at 4 time-points 
post-reperfusion, from patients with and without myocardial haemorrhage, following 
emergency percutaneous coronary intervention (PCI). 
 
(a) Case 1 (no hemorrhage) 
 
 
Patient with no myocardial haemorrhage. T2 value within infarct zone measured 59 ms at 
8 hours post-reperfusion, 65 ms at day 3, 76 ms at day 10 and 50 ms 7 months post-MI. 
Late gadolinium enhancement (LGE) imaging revealed a sub-endocardial infero-lateral 
infarct, with no evidence of microvascular obstruction. There was no hypointense core on 
T2* maps. LV ejection fraction progressively increased from 56% to 69% and LV end-
diastolic volumes progressively reduced from 151 ml to 129 ml at 7 months. 
(b) Case 2 (hemorrhage) 
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Patient with myocardial haemorrhage. T2 maps reveal a hypo-intense infarct core, which 
corresponded to the hypointense core on T2* maps and to the region of microvascular 
obstruction. T2* within the infarct core measured 18 ms at 11 hours post-reperfusion, 7 ms 
at day 3, 13 ms at day 10 and 18 ms at 7-months post-MI. Corresponding T2 core 
measurements were 55 ms at 11 hours, 46 ms at day 3 and 58 ms at day 10. LGE imaging 
revealed a transmural antero-septal infarct, with extensive microvascular obstruction. LV 
ejection fraction did not improve and measured 46% on day 3 vs. 45% at 7 months. LV 
end-diastolic volumes progressively increased from 165 ml to 210 ml at 7 months. 
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Table 5-1 Clinical and angiographic characteristics of the 30 patients in the longitudinal clinical study. 
Characteristics*  All Patients 
n = 30 
No myocardial 
hemorrhage 
(T2*core -) 
n = 17 (57%) 
Myocardial 
hemorrhage 
(T2*core +) 
n = 13 (43%) 
p value 
Clinical      
Age, years  54 (10) 55 (9) 53 (11) 0.602 
Male sex, n (%)  25 (83) 15 (88) 10 (77) 0.628 
BMI, (kg/m2)  28 (5) 29 (4) 27 (5) 0.257 
History       
Hypertension, n (%)  8 (27) 5 (29) 3 (23) 1.000 
Current smoking, n (%)  21 (70) 11 (65) 10 (77) 0.691 
Hypercholesterolemia, n (%)  13 (43) 7 (41) 6 (46) 1.000 
Diabetes mellitus‡, n (%)  2 (7) 1 (6) 1 (8) 1.000 
Previous angina, n (%)  3 (10) 1 (6) 2 (15) 0.565 
Previous myocardial infarction, n (%)  1 (3) 1 (6) 0 (0) 1.000 
Previous PCI, n (%)  1 (3) 1 (6) 0 (0) - 
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Presenting characteristics      
Heart rate, bpm  77 (17) 75 (19) 81 (14) 0.340 
Systolic blood pressure, mmHg  141 (26) 139 (33) 143 (16) 0.712 
Diastolic blood pressure, mmHg  84 (12) 83 (13) 86 (11) 0.472 
Time from symptom onset to reperfusion, min  156 (112, 243) 161 (118, 206) 137 (112, 274) 0.837 
Ventricular fibrillation†, n (%)  1 (3) 1 (6) 0 (0) 1.000 
Heart failure, Killip class at presentation, n (%) I 22 (74) 13 (76) 9 (69) 
0.811  II 7 (23) 4 (24) 3 (23) 
 III/IV 1 (3) 0 (0) 1 (8) 
Electrocardiogram      
ST segment elevation resolution post PCI, n (%)      
Complete, 70 %  15 (50) 1 (6) 1 (8) 
1.000 Partial, 30% to < 70%  13 (43) 7 (41) 6 (46) 
None, 30%  2 (7) 9 (53) 6 (46) 
Number of diseased arteries¥, n (%) 1 14 (47) 10 (58) 4 (31) 
0.298  2 11 (37) 5 (29) 6 (46) 
 3 5 (17) 2 (12) 3 (23) 
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 LM 0 (0) 0 (0) 0 (0) 
Culprit artery, n (%)  LAD 9 (30) 4 (24) 5 (38)  
 LCX 10 (33) 4 (24) 6 (46) 0.112 
 RCA 11 (37) 9 (53) 2 (15)  
TIMI coronary flow grade pre-PCI, n (%) 0/1 24 (80) 12 (71) 12 (92) 
0.196 
 2/3 6 (20) 5 (29) 1 (8) 
TIMI coronary flow grade post-PCI, n (%) 0/1 0 (0) 0 (0) 0 (0)  
1.000  2 2 (7) 1 (6) 1 (8) 
 3 28 (93) 16 (94) 12 (92) 
Medical therapy      
ACE-inhibitor or ARB  30 (100) 17 (100) 13 (100) - 
Beta-blocker  30 (100) 17 (100) 13 (100) - 
Initial blood results on admission      
Neutrophil count (x109L)  10.1 (3.1) 9.3 (3.0) 11.3 (3.0) 0.083 
NT-proBNP, pg/mL  588 (306, 
1541) 
529 (301, 1254) 864 (655, 1637) 
0.841 
Footnote: *P-values were obtained from t-tests or Mann-Whitney test as appropriate for continuous variables, and Fisher’s tests for categorical 
variables.  
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Table 5-2 Comparison of CMR findings in patients with myocardial haemorrhage (day 3) vs. patients without myocardial haemorrhage (day 3). CMR scans 
were obtained < 12 hours, 3 days, 10 days, and 7 months post-reperfusion. 
 
 4 - 12 hours 3 days 10 days 7 months P-value* 
Myocardial 
haemorrhage Yes No Yes No Yes No Yes No All Yes No 
LV ejection fraction, % 50 (7) 54 (10) 52 (8) 58 (8) 56 (9) 61 (7) 55 (8) 62 (7) <0.001 <0.001 <0.001 
LV end-diastolic 
volume, ml 160 (36) 160 (31) 163 (33) 161 (30) 169 (35) 160 (31) 176 (35) 154 (31) 0.698 0.001 0.377 
Area at risk, % LV 
mass 39 (9) 31 (9) 44 (8) 35 (13) 36 (9) 28 (13) - - <0.001 <0.001 0.029 
Infarct size, % LV mass 29 (13) 12 (8) 30 (12) 12 (7) 22 (9) 9 (5) 22 (9) 8 (4) <0.001 <0.001 <0.001 
T2 hypointense core, n 
(%) 7 (100) 12 (52) 13 (100) 5 (29) 10 (91) 4 (21) 1 (25) 0    
Myocardial 
haemorrhage, n (%) 7 (100) 23 (100) 13 (100) 17 (100) 11 (100) 19 (100) 4 (100) 26 (100)    
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Footnote: *Generalised linear mixed effects models were used to obtain p-values. P-values are not presented for categorical data, since the model is not 
supported for this function. 
 
Table 5-3 T2 and T2* relaxation times in the ischemic and remote zones for the serial imaging subset (n=30), at multiple time intervals post-reperfusion, 
stratified by the presence of haemorrhage on day 3. 
Timing of MRI 
 
4 < 12 hours 
n = 30 
3 days 
n = 30 
10 days 
n =30 
7 months 
n =30 
   
IMH (day 3)* Yes No Yes No Yes No Yes No All Yes No 
T2* infarct zone, ms 29.2 (5.8) 37.7 (3.3) 26.6 (4.8) 39.6 (3.5) 28.6 (3.3) 37.0 (4.3) 29.2 (4.0) 32.7 (2.0) 0.018 0.095 <0.001 
T2* infarct core, ms 17.8 (6.0) - 14.1 (4.1) - 16.7 (5.9) - 18.9 (6.2) - - <0.001 - 
T2* remote zone, ms 31.9 (2.0) 32.4 (1.8) 32.9 (1.9) 32.3 (2.0) 32.6 (1.6) 32.0 (1.3) 32.4 (2.3) 32.3 (1.6) 0.478 0.361 0.876 
T2 infarct zone, ms 62.8 (6.7) 62.1 (2.9) 61.4 (4.1) 64.4 (4.9) 68.1 (3.7) 65.9 (5.3) 54.0 (2.8) 52.0 (3.2) <0.001 <0.001 <0.001 
T2 infarct core, ms 55.5 (6.9) 54.2 (2.6) 51.8 (4.6) 54.4 (4.5) 59.2 (3.6) 59.2 (4.4) - - <0.001 0.008 0.057 
T2 remote zone, ms 48.5 (2.5) 48.5 (2.0) 49.3 (1.7) 48.7 (2.1) 50.5 (2.4) 49.2 (2.1) 50.3 (1.6) 50.0 (1.4) <0.001 0.002 0.003 
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Footnote:  The T2* infarct core values are given for only those patients that had a T2* hypointense core to measure (n = 7 at < 12 hours, n = 13 at day 
3, n = 11 at day 10 and n = 4 at 7 months). 
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Table 5-4 Temporal change in infarct zone end-diastolic wall thickness at serial time-points post-MI. 
Footnote: Data given as mean (standard deviation). P-values obtained from ANOVA. 
Timing of MRI 
 
4 < 12 hours 
n = 30 
3 days 
n = 30 
10 days 
n =30 
7 months 
n =30 
   
IMH (day 3) Yes No Yes No Yes No Yes No All Yes No 
Infarct zone, end-
diastolic wall 
thickness, mm 
1.14 (0.39) 1.10 (0.18) 1.22 (0.36) 1.17 (0.17) 1.08 (0.31) 1.09 (0.20) 0.78 (0.22) 0.91 (0.18) <0.0001 0.007 0.001 
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5.4.3 Temporal evolution of T2 relaxation times and myocardial haemorrhage  
The temporal evolution of T2 values within the infarct zone varied in association with T2* 
values. In patients with myocardial haemorrhage a bimodal time-course in T2 values was 
observed within the area-at-risk (p=0.006) and the infarct core (p=0.008) (table 5-3, figure 
5-3 and 5-4). By contrast, this pattern differed in patients without myocardial haemorrhage 
in whom T2 values increased progressively up to 10 days post-MI (p=0.042). By 7 months, 
T2 values had fallen in both groups, however, in patients with myocardial hemorrhage, T2 
values still remained higher in the infarct zone compared to T2 values in the remote zone 
(p=0.001) and those of healthy volunteers (p<0.001). They also tended to be higher than 
T2 values in the infarct zone of patients without haemorrhage (p=0.059; table 5-3).  
T2 values in the myocardial remote zone increased over time in both patients with and 
without myocardial haemorrhage (p=0.002 and p=0.003, respectively), but to a greater 
extent in patients with haemorrhage (table 5-3). 
5.4.4 Intra- and inter-observer agreement of T2 and T2* measurements 
The results for intra-class correlation coefficient for reliability of T2 and T2* 
measurements and Bland-Altman plots are shown in chapter 3, section 3.5.2.  
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Figure 5-3 Time course of T2 values in the early reperfusion period in patients with and 
without myocardial haemorrhage and evolution of haemorrhage (% LV mass) in the early 
reperfusion period. 
 
A 
 
B 
 
Time-course of CMR T2 relaxation times and myocardial haemorrhage (% LV mass) 
during the first 10 days after ischemia/reperfusion. Patients without haemorrhage have a 
progressive rise in T2 relaxation times during the first 10 days post-reperfusion, whereas 
patients with haemorrhage have a bimodal pattern. Myocardial haemorrhage peaks on day 
3 post-reperfusion. Baseline T2 values are taken from age and sex-matched healthy 
volunteers (n = 50). 
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Figure 5-4 T2 values within the infarct core and infarct zone follow a bimodal pattern with 
the nadir associated with peak haemorrhage 
 
The bimodal pattern in T2 relaxation times in the early reperfusion period is explained by 
the evolution of myocardial haemorrhage. 
 
5.4.5 Temporal relationships between intra-myocardial haemorrhage and left 
ventricular outcomes from < 12 hours to 7 months post-reperfusion 
Overall, LV mass decreased from 140±26 g 3 days post-MI to 119±26 g 7 months post-MI 
(p=0.003). By 7 months post-MI, LV ejection fraction tended to increase (56±9% vs. 59±8 
%, p=0.061) and infarct size (% of LV mass) tended to be less (20±13% vs. 14±10%; 
p=0.10). 
Three days post-MI, compared to patients without hemorrhage, patients with hemorrhage 
had a larger initial area-at-risk (46 (36, 50) vs. 31 (26, 44); p=0.007) and a lower LV 
ejection fraction (52 (47, 55) vs. 55 (54, 64); p=0.042) (table 5-2). 
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LV end-diastolic volume increased over time in patients with myocardial haemorrhage 
(p=0.001; table 5-2). By contrast, LV end-diastolic volume reduced over time in patients 
without haemorrhage (table 5-2). Day 3 post-MI, infarct size was greater in the patients 
with haemorrhage compared to patients without haemorrhage (p<0.001; table 5-2). 
5.4.6 T2* relaxation times in the myocardial remote zones and in healthy volunteers 
T2* values in the remote zone did not change over time (p=0.361 for patients with 
myocardial haemorrhage; p=0.876 for patients without haemorrhage) and these values 
were similar to T2* values in healthy controls (chapter 3, table 3-7). At 7 months, in 
patients with myocardial haemorrhage 3 days post-MI, T2* values in the infarct zone 
remained reduced compared with the remote zone, whereas in patients without 
haemorrhage, T2* values in the infarct zone were similar to T2* values in the remote zone 
(table 5-3). 
5.5 Discussion 
We have undertaken the first longitudinal study of myocardial haemorrhage in the early 
reperfusion period involving serial CMR on 4 occasions in STEMI survivors.  
Our main findings are (1) the incidence of myocardial haemorrhage was 43%, (2) 
approximately one quarter of the patients had evidence of myocardial haemorrhage 4 - 12 
hours post-MI and the incidence nearly doubled by 3 days, (3) T2* values within the 
haemorrhagic core followed a similar pattern to T2 values, with a nadir in both on day 3, 
(4) during the first 10 days post-reperfusion, T2 values within the infarct zone and 
hypointense core had a bimodal distribution in patients with myocardial haemorrhage 
whereas T2 values had a unimodal progressive increase in patients without myocardial 
haemorrhage, (5) changes in T2 values were inversely related to the occurrence and extent 
of haemorrhage, (6) the extent of oedema (area at risk, % LV mass) stayed fairly constant 
in size in both groups for the first 3 days and by day 10 was slightly less, (7) myocardial 
haemorrhage was associated with sustained reductions in LV ejection fraction and adverse 
LV remodelling from baseline through to 7 months.  
Based on these observations, we conclude that myocardial haemorrhage increases 
progressively after reperfusion with a primary hyperacute phase < 12 hours post-MI 
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culminating in a peak 3 days later. The temporal changes in T2 relaxation times are 
inversely associated with myocardial haemorrhage. Our results provide further evidence 
that myocardial haemorrhage is an adverse prognostic complication post-MI, but the 
secondary phase between days 1 and 3 suggests there may be a therapeutic window to 
prevent haemorrhage should targeted therapies become available in the future. 
Our data complement the myocardial oedema time-course study by Fernández-Jiménez et 
al (Fernandez-Jimenez et al., 2015). They described a bimodal pattern of myocardial 
oedema with peaks of percentage myocardial water content and T2 values acutely at 2 
hours post-reperfusion and 7 days later associated with an intervening decrease in 
myocardial water content at 24 hours. They concluded that myocardial oedema occurred in 
a two "waves", one occurring abruptly after reperfusion and a second "deferred wave of 
oedema" appearing progressively and becoming maximal around 7 days. There could be 
different explanations for the “second wavefront of oedema” including, first, an increase in 
the absolute amount of water or, second, a reduction in infarct tissue mass and a relative 
increase in percentage water, or finally, an increase in the wet weight of tissue due 
progressive myocardial hemorrhage or hemorrhagic transformation (Fernandez-Jimenez et 
al., 2015). Our analysis supports this possibility. Oxidative denaturation of haemoglobin 
evolves over 1 – 3 days (Anzalone et al., 2004) and the product, deoxyhemoglobin, has 
paramagnetic effects that destroy T2 signal. Our results are consistent with concomitant 
oxidative denaturation and paramagnetic destruction of T2 signal within the infarct core 
consistent with earlier pre-clinical (Ghugre et al., 2011) and clinical (Zia et al., 2012) 
observations. Therefore, the peak in myocardial haemorrhage that we observed 3 days 
post-MI likely explains the reductions in co-localized T2 values at this time-point, in turn 
explaining the bimodal distribution in T2 values that was observed by Fernández-Jiménez 
et al (Fernandez-Jimenez et al., 2015).  
The increase in the incidence of hemorrhage over time in some individuals is consistent 
with haemorrhagic transformation reflecting the natural history of wound-healing after 
tissue infarction, especially in reperfused patients treated with anti-thrombotic therapies 
(Anzalone et al., 2004, Fishbein et al., 1980, Alvarez-Sabin et al., 2013). On day 3 CMR, 5 
patients without evidence of haemorrhage on T2* imaging had a hypointense cores on T2 
maps. The mean T2 core value for these patients was greater than for patients with 
haemorrhage (54.5±4.5 ms vs. 51.8±4.6 ms; p=0.268). The hypointense core on T2 maps 
in the absence of haemorrhage likely represents a reduction in the amount of tissue water 
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within the infarct core due to cellular debris and obstructed capillary flow (Verhaert et al., 
2011). The observation that the mean T2 core value is lower in patients with haemorrhage 
is consistent with the additional effect of paramagnetic depletion of T2 signal.  
Our results have important clinical implications. First, the results translate experimental 
concepts proposed by Fernández-Jiménez et al (Fernandez-Jimenez et al., 2015) into 
clinical observations in patients. Second, our results should be helpful to plan the timing of 
CMR imaging post-MI for clinical and research purposes and indicate that the extent of 
edema reduces after 3 days post-MI. Third, our results provide further information on the 
adverse prognostic associations between myocardial haemorrhage and reductions in LV 
systolic function and adverse LV remodelling, consistent with previous studies (Beek et 
al., 2010, Eitel et al., 2011, Ganame et al., 2009, Kidambi et al., 2013). Finally, our results 
confirm that infarct pathologies evolve progressively post-MI and therefore, potentially, 
may be amenable to targeted preventative therapeutic interventions. Robbers et al (Robbers 
et al., 2013) proposed that myocardial haemorrhage was the final consequence of severe 
microvascular thrombosis and that therapeutic interventions that restored microvascular 
perfusion might in turn prevent myocardial haemorrhage. Conceivably, intra-coronary 
thrombolysis administered early after reperfusion and before stent implantation might 
reduce coronary thrombus burden and distal clot embolization, lyse microvascular thrombi 
and restore microvascular perfusion early post-MI. We are currently examining this 
hypothesis in a randomized, double-blind, placebo-controlled, parallel group trial of low-
dose adjunctive alteplase during primary PCI (T-TIME; NCT02257294).  
5.5.1 Limitations 
We do not have pathological validation of our imaging results. Although pre-clinical 
studies enable pathological validation (Fernandez-Jimenez et al., 2015, Ghugre et al., 
2011), the corollary is a stepped reduction in sample size and statistical power (n=20 at 2 
hours post-MI vs. n=5 at 7 days post-MI (Fernandez-Jimenez et al., 2015)). The sample 
size in our cohort was preserved during follow-up. Although CMR was not possible before 
STEMI, we think it is reasonable to believe that there was no haemorrhage present in the 
STEMI patients before the event, implying a 'zero baseline', since remote T2 and T2* 
values in STEMI patients were similar to those measured in healthy individuals. We 
acknowledge that the differences in T2 (ms) and T2* are within the inter-observer range of 
values and that our findings do not confirm causality. 
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5.6 Conclusion 
We have performed a comprehensive longitudinal clinical study of myocardial 
haemorrhage and oedema in a cohort of reperfused STEMI survivors. Myocardial 
haemorrhage peaked at day 3 post-MI in reperfused STEMI patients, and the temporal 
changes in oedema may be a secondary process. 
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6 Chapter 6: Prognostic significance of infarct core 
pathology in ST-elevation myocardial infarction 
survivors revealed by quantitative T2-mapping 
cardiac magnetic resonance
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6.1 Introduction  
Cardiac magnetic resonance (CMR) with T2-mapping is a recent advance for quantifying 
the extent and nature of ischaemic myocardial injury (Hammer-Hansen et al., 2014, 
Ugander et al., 2012, Verhaert et al., 2011, Giri et al., 2009) that has potential to extend 
what is known based on qualitative T2-weighted CMR (Garcia-Dorado et al., 1993, 
Higgins et al., 1983, McNamara et al., 1985). T2-weighted CMR enables detection of acute 
myocardial infarction (MI) and discrimination of acute from chronic MI (Abdel-Aty et al., 
2004, Cury et al., 2008), and qualitative T2-weighted CMR delineates the ischaemic area-
at-risk (Berry et al., 2010, Payne et al., 2011b, Aletras et al., 2006, Garcia-Dorado et al., 
1993) and myocardial salvage, which is marker for the efficacy of reperfusion (Friedrich et 
al., 2008, Eitel et al., 2010).  
Although qualitative T2-weighted CMR with dark blood turbo spin echo techniques has 
been the standard method for imaging myocardial oedema this method is hampered by 
image artefacts that limit quantitative assessment of heart injury (Wince and Kim, 2010, 
Kellman et al., 2007). Since the signal intensity is not linearly related to pathology, only 
the extent of oedema can be measured. Quantitative T2 mapping, which allows direct 
determination of T2 relaxation times, overcomes many of the inherent limitations 
associated with dark blood T2-weighted CMR and may allow for a more objective 
assessment of the infarct core (Giri et al., 2009, Verhaert et al., 2011, Ghugre et al., 2011, 
Zia et al., 2012, Ugander et al., 2012, Nassenstein et al., 2014, Park et al., 2013). 
A hypointense core within the hyperintense infarct zone revealed by T2-weighted CMR is 
a common observation that in some (Basso et al., 2007, Payne et al., 2011a), but not all 
(Cannan et al., 2010, Jackowski et al., 2006), studies corresponds with histology evidence 
of myocardial haemorrhage. Some studies have shown that T2 hypointense infarct cores 
are associated with adverse remodelling (Ganame et al., 2009, Husser et al., 2013) and 
adverse clinical outcome (Amabile et al., 2012, Eitel et al., 2011), whereas others have 
shown that there is no prognostic significance beyond microvascular obstruction (Beek et 
al., 2010, Bekkers et al., 2010a). 
In order to resolve this uncertainty, we studied the clinical associates and prognostic 
significance of a T2 hypointense core, revealed by quantitative T2 mapping. 
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6.2 Methods 
6.2.1 Study population and STEMI management 
We performed a prospective CMR cohort study in a single regional cardiac centre between 
11 May 2011 and 22 November 2012. Three hundred and forty three STEMI patients 
provided written informed consent to undergo CMR 2 days and 6 months post-MI. The 
eligibility criteria and acute STEMI management are as described in detail in chapter 2. 
6.2.2 CMR acquisition 
CMR was performed as described in detail in chapter 2. The imaging protocol included 
cine MRI with steady-state free precession (SSFP), T2-mapping with full LV coverage 
(Giri et al., 2009, Verhaert et al., 2011), T2*-mapping (3 short-axis slices: base, mid and 
apex, incorporating infarct zone), and delayed-enhancement phase-sensitive inversion-
recovery pulse sequences (Kellman et al., 2002). Patients and healthy volunteers 
underwent the same imaging protocol except that healthy volunteers <45 years did not 
receive gadolinium. 
6.2.3 CMR analyses 
T2 values were measured in myocardial regions of interest defined as: (1) remote 
myocardium, (2) injured myocardium and (3) infarct core, as previously described in detail 
in chapter 2.  
The infarct zone region-of-interest was defined as myocardium with pixel values (T2) >2 
SD from remote myocardium on T2-weighted CMR (Giri et al., 2009, Verhaert et al., 
2011). The infarct core was defined as an area in the centre of the infarct territory having a 
mean T2 value of at least 2 standard deviations (SDs) below the T2 value of the periphery 
of the area-at-risk. The rest of the analyses are described in detail in chapter 2. 
6.2.4 Health outcomes 
We pre-specified adverse health outcomes that are pathophysiologically linked with 
STEMI. The primary composite outcome was all-cause death or heart failure 
hospitalisation (chapter 2).  
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Research staff screened for events from enrolment by checking the medical records and by 
contacting patients and their primary and secondary care physicians, as appropriate. Each 
event was reviewed by a cardiologist who was independent of the research team and 
blinded to all of the clinical and CMR data. The adverse events were defined according to 
standard guidelines (Thygesen et al., 2012) and categorised as having occurred during the 
index admission or post-discharge. All study participants were followed-up for a minimum 
of 18 months after discharge. 
6.2.5 Statistical analyses 
Categorical variables are expressed as number and percentage of patients. Most continuous 
variables followed a normal distribution and are therefore presented as means together with 
standard deviation. Those variables that did not follow a normal distribution are presented 
as medians with interquartile range.  Differences between groups were assessed using one-
way ANOVA, Kruskal-Wallis test or Fisher’s where appropriate. Univariable and 
multivariable logistic regression analyses were performed to identify predictors of T2 
hypointense core.   
Kaplan-Meier and Cox proportional hazards methods were used to identify potential 
clinical predictors of all-cause death/heart failure events, including patient characteristics 
and CMR findings. A p-value > 0.05 indicates the absence of a statistically significant 
effect. 
6.3 Results 
Of 372 STEMI patients referred for emergency reperfusion therapy, 324 underwent CMR 
at 1.5 Tesla 2.2±1.9 days and all (100%) of these patients had evaluable T2-maps. 300 
patients (93%) had repeat CMR 6 months later (figure 6-1). All patients (n=324) with 
CMR had vital status assessed at least 18 months after enrolment (figure 6-1). 
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Figure 6-1 Study flow diagram 
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6.3.1 Patient characteristics 
The characteristics of the patients (n=324) are shown in table 6-1, including the patients 
with T2 hypointense infarct cores. The mean (standard deviation) age was 59 (12) years 
and 74% were male. 236 (73%) patients had an occluded culprit artery (TIMI coronary 
flow grades 0/1) at initial angiography.  
Table 6-1 Baseline clinical and angiographic characteristics of patients with acute STEMI 
and a CMR, with evaluable T2 map, at baseline. 
Characteristics*  All STEMI 
patients 
n=324 
Clinical   
Age, years  59.30 (11.49) 
Male sex, n (%)  237 (73.1%) 
BMI, (kg/m2)  28.79 (4.76) 
History   
Hypertension, n (%)  105 (32.4%) 
Current smoking, n (%)  196 (60.5%) 
Hypercholesterolemia, n (%)  94 (29.0%) 
Diabetes mellitus‡, n (%)  34 (10.5%) 
Previous angina, n (%)  40 (12.3%) 
Previous myocardial infarction, n (%)  25 (7.7%) 
Previous PCI, n (%)  18 (5.6%) 
Presenting characteristics   
Heart rate, bpm  78 (17) 
Systolic blood pressure, mmHg  132 (25) 
Diastolic blood pressure, mmHg  79 (14) 
Time from symptom onset to reperfusion, min  253 (212) 
Ventricular fibrillation†, n (%)  21 (6.5%) 
Heart failure, Killip class at presentation, n (%) I 233 (71.9%) 
 II 68 (21%) 
 III 17 (5.2%) 
 IV 6 (9.1%) 
ECG   
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ST segment elevation resolution post PCI, n (%)   
Complete, 70 %  148 (45.8%) 
Partial, 30% to < 70%  127 (39.3%) 
None, 30%  48 (14.9%) 
Coronary angiography   
Reperfusion strategy, n (%)   
Primary PCI  302 (93.2%) 
Rescue PCI (failed thrombolysis)  14 (4.3%) 
Successful thrombolysis  8 (2.5%) 
Number of diseased arteries¥, n (%) 1 174 (53.7%) 
 2 105 (32.4%) 
 3 45 (13.9%) 
Culprit artery, n (%)  Left anterior descending 121 (37.3%) 
 Left circumflex 59 (18.2%) 
 Right coronary 144 (44.4%) 
TIMI coronary flow grade pre-PCI, n (%) 0/1 236 (72.8%) 
 2 58 (17.9%) 
 3 30 (9.3%) 
TIMI coronary flow grade post-PCI, n (%) 0/1 4 (1.2%) 
 2 15 (4.6%) 
 3 305 (94.1%) 
Footnote: TIMI = Thrombolysis in Myocardial Infarction grade, PCI = percutaneous 
coronary intervention. Killip classification of heart failure after acute myocardial 
infarction: class I - no heart failure, class II - pulmonary rales or crepitations, a third 
heart sound, and elevated jugular venous pressure, class III - acute pulmonary edema, 
class IV - cardiogenic shock. * Data are given as n (%) or mean (SD). ‡ Diabetes mellitus 
was defined as a history of diet-controlled or treated diabetes. † Successfully electrically 
cardioverted ventricular fibrillation at presentation or during emergency PCI procedure. ¥ 
Multivessel coronary artery disease was defined according to the number of stenoses of at 
least 50% of the reference vessel diameter, by visual assessment and whether or not there 
was left main stem involvement. 
6.3.2 CMR findings 
Initial CMR findings following hospital admission 
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The CMR findings and clinical cases are shown in table 6-2 and figure 6-2, respectively. 
At baseline, the mean myocardial infarct size was 18 ±14% of LV mass. Native T2 within 
the infarct core (53.9±4.8 ms) was higher than in the remote zone (49.7±2.1 ms; p<0.01) 
but lower than in the area-at-risk (62.9±5.1 ms) (p<0.01).  
Figure 6-2 Acute STEMI cases, with and without T2 hypointense infarct core, revealed by 
CMR 2 days post-MI 
 
(a) Patient with no T2 hypointense infarct core and no microvascular obstruction. (b) 
Patient with both T2 hypointense infarct core (middle image, red arrows) and 
microvascular obstruction (right image, red arrows) 
 
Table 6-2 Comparison of CMR findings at baseline in STEMI patients and healthy volunteers 
and 6-month CMR findings in STEMI patients. 
Characteristics* STEMI 
patients 
n=324 
Healthy 
volunteers 
n=50 
p value 
CMR findings 2 days post-MI 
LV ejection fraction, % 55.0 (9.6) 67.2 (4.5) <0.0001 
LV end-diastolic volume, ml    
Men 161.3 (33.3) 167.8 (31.6) 0.329 
Women 125.0 (25.4) 134.1 (23.0) 0.104 
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LV end-systolic volume, ml    
Men 75.3 (26.6) 56.8 (14.9) <0.0001 
Women 55.1 (18.0) 43.6 (12.3) <0.001 
LV mass, g    
Men 144.54 (32.7) 124.5 (22.7) <0.001 
Women 99.1 (23.3) 92.0 (20.4) 0.151 
Oedema and infarct characteristics    
Area at risk, % LV mass 31.9 (11.9) -  
Infarct size, % LV mass 18.0 (13.5) -  
Myocardial salvage, % of LV mass 13.9 (8.8)   
Myocardial salvage index, % of LV mass 49 (30)   
Early microvascular obstruction present, n (%)    
Late microvascular obstruction present, n (%) 164 (50.6) -  
Late microvascular obstruction, % LV mass 2.9 (5.0) -  
Myocardial haemorrhage, n (%)    
Myocardial native  T2 values    
T2 remote myocardium (all subjects), ms 49.7 (2.1) 49.5 (2.5) 0.511 
Men, ms 49.6 (2.0) 48.5 (2.1) 0.014 
Women, ms 50.1 (2.1) 50.5 (2.5) 0.390 
T2 area-at-risk, ms 62.9 (5.1) - - 
T2 hypointense core present, n (%) 197 (61) - - 
T2 hypointense infarct core, ms 53.90(4.8) - - 
T2 of infarct tissue surrounding core, ms 68.5 (6.3)   
CMR findings 6 months post-MI (n = 300) 
LV ejection fraction, % 61.9 (9.4)   
LV end-diastolic volume, ml    
Men 168.6 (42.0)   
Women 127.3 (28.6)   
LV end-systolic volume, ml    
Men 68.0 (34.2)   
Women 46.3 (17.5)   
LV mass, g    
Men 127.5 (26.5)   
Women 92.0 (19.6)   
Footnote: * Data are given as n (%) or mean (SD). Abbreviations: LV = left ventricle 
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T2 maps were acquired with full LV coverage. In one patient, area at risk could not be 
measured due to SSFP off-resonance artefact. All other T2 maps were suitable for 
analysis. Infarct zone T2 values were higher in infarct tissue than infarct core (p<0.001) 
and remote myocardium (p<0.001).  
6.3.3 Comparison of T2 hypointense core and microvascular obstruction 
197 (61%) STEMI patients had a T2 hypointense core. Microvascular obstruction with 
early gadolinium- and late gadolinium enhancement CMR was revealed in 186 (57%) and 
164 (51%) patients, respectively.  All patients with late microvascular obstruction had 
evidence of a hypointense core on T2 imaging. 33 (10%) patients had a T2 hypointense 
core in the absence of late microvascular obstruction. 185 (99%) patients with early 
microvascular obstruction had a T2 hypointense core. Only 12 (4%) patients had a T2 
hypointense core without evidence of early microvascular obstruction. The negative- and 
positive predictive values for T2 hypointense core and microvascular obstruction are 
summarised in table 6-3. In patients with both late microvascular obstruction and a T2 
hypointense core (n = 164), the median (IQR) amount of T2 core (%LV mass) was greater 
than the median amount of microvascular obstruction (%LV mass) (5.2 (2.9, 9.2) vs. 3.5 
(1.7, 8.4); p=0.006).
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Table 6-3 Negative- and positive predictive values of T2 infarct core for microvascular 
obstruction and myocardial haemorrhage disclosed by a T2* core. 
 Native T2 infarct 
core absent 
Native T2 infarct 
core present 
 
Myocardial 
haemorrhage 
   
Myocardial 
haemorrhage 
absent 
84 60 
Specificity 58.3% 
95% CI (49.8, 66.5) 
Myocardial 
haemorrhage 
present 
0 101 
Sensitivity 100% 
95% CI (96.4, 100) 
 NPV 100% 
95% CI (95.7, 100) 
PPV  63.7% 
95% CI (54.8, 70.2) 
 
Early MVO    
Early MVO absent 126 12 Specificity 91.3% 
95% CI (89.6, 96.8) 
Early MVO present 1 185 Sensitivity 99.5% 
95% CI (97.0, 99.9) 
 NPV 99.2% 
95% CI (95.7, 99.9) 
PPV 93.9% 
95% CI (89.6, 96.8) 
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Late MVO    
Late MVO absent 127 33 Specificity 79.4% 
95% CI (72.3, 85.4) 
Late MVO present 0 164 Sensitivity 100%  
95% CI (97.8, 100) 
 NPV 100% 
95% CI (97.1, 100)  
PPV 83.3% 
95% CI (77.3, 88.2) 
 
95% CI – 95% confidence interval; MVO – microvascular obstruction; NPV – negative 
predictive value; PPV – positive predictive value. The CMR approaches for delineation of 
early MVO, late MVO and myocardial haemorrhage are described in the Methods 
(chapter 2). 
6.3.4 Comparison of T2 hypointense core and myocardial haemorrhage 
T2*-maps were available in 245 patients at baseline. Myocardial haemorrhage was 
revealed in 101 (41%) patients, all of whom had a corresponding T2 hypointense core 
(table 6-3). However, 64 (26%) patients had a T2 hypointense core in the absence of 
myocardial haemorrhage. 
6.3.5 T2 values in STEMI patients vs. healthy controls 
Fifty aged-matched healthy volunteers (52% male, 54±13 years) were included (table 3-7, 
chapter 3). The mean remote zone native T2 at the mid-ventricular level was higher in 
male STEMI patients than in male volunteers. The myocardial remote zone T2 values were 
similar in female patients and volunteers (section 3.6.1, chapter 3). 
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6.3.6 Intra- and inter-observer agreement of T2 measurements 
The results for intra-class correlation coefficient for reliability of T2 measurements and 
Bland-Altman plots are shown in chapter 3, section 3.5.2.  
6.3.7 Infarct core native T2: associations with clinical characteristics and 
inflammation 
T2 core (ms) was univariably associated with LVEF at baseline (0.31 (0.04, 0.58); 
p=0.023) but not at 6 months. T2 core was not associated with LV end-diastolic volume at 
baseline or at 6 months (table 6-4).  
In multivariable linear regression, native T2 in the infarct core was negatively associated 
with heart rate, Killip class and peak neutrophil count at presentation (all p<0.05) (table 6-
4). 
Table 6-4 Predictors of native T2 (ms) in the infarct core (n=197 subjects) in univariable and 
multivariable stepwise regression analyses. 
Univariable associations coefficient (95% CI) p value 
Hypertension -1.70 (-3.14, -0.27) 0.020 
Heart rate, min -0.04 (-0.09, -0.00) 0.048 
Killip class 4 -5.53 (-9.43, -1.63) 0.006 
Maximum log CRP -0.96 (-1.53, -0.40) <0.001 
Maximum leucocyte count, (x109L) -0.22 (-0.42, -0.02) 0.028 
Maximum neutrophil count, (x109L) -0.26 (-0.47, -0.04) 0.018 
Maximum monocyte count, (x109L) -0.26 (-0.47, -0.04) 0.018 
Change in log CRP from baseline* -0.21 (-0.53, -0.07) 0.003 
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Change in monocyte count, (x109L) -0.26 (-0.47, -0.04) 0.018 
Multiple stepwise regression coefficient (95% CI) p value 
A. Including patient characteristics and 
angiographic data 
  
Hypertension -1.49 (-2.92, -0.06) 0.041 
Heart rate, beats per min -0.04 (-0.08, -0.00) 0.056 
Killip class 4 -5.01 (-8.92, -1.10) 0.012 
B. Including patient characteristics, 
angiographic data, and change in log 
CRP* 
  
Change in log CRP from baseline* -0.17 (-0.34, 0.00) 0.050 
Killip class 3 -3.30 (-6.40, -0.20) 0.037 
C. Including patient characteristics, 
angiographic data, and maximum 
leucocyte count* 
  
Heart rate, beats per min -0.05 (-0.10, -0.00) 0.037 
Killip class 3 -3.08 (-5.96, -0.20) 0.036 
Killip class 4 -5.67 (-10.34, -0.99) 0.018 
Maximum leucocyte count, (x109L) -0.27 (-0.51, -0.03) 0.027 
D. Including patient characteristics, 
angiographic data, and maximum 
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neutrophil count* 
Heart rate, beats per min -0.05 (-0.01, -0.00) 0.048 
Killip class 3 -3.14 (-6.02, -0.26) 0.033 
Killip class 4 -5.66 (-10.33, -0.98) 0.018 
Maximum neutrophil count, (x109L) -0.28 (-0.53, -0.03) 0.028 
E. Including patient characteristics, 
angiographic data, and maximum 
monocyte count* 
  
Heart rate, beats per min -0.05 (-0.01, -0.00) 0.058 
Killip class 3 -2.78 (-5.69, 0.12) 0.060 
Killip class 4 -4.88 (-9.66, -0.09) 0.046 
Maximum monocyte count, (x109L) -2.51 (-4.67, -0.35) 0.023 
Footnote: The coefficient (95% confidence intervals) indicates the magnitude and direction 
of the difference in infarct core T2 (ms) for the patient characteristic (binary or 
continuous). For example, on average, infarct core native T2 (ms) is lower (-0.04 (-0.09, -
0.00) for each 1 beat per min increase in heart rate. 
For univariable analyses, all variables in Table 1 were tested and also the following 
baseline CMR parameters: area-at-risk, LV ejection fraction, LV end-diastolic volume, LV 
end-systolic volume and infarct size. Selected patient characteristics are shown. Separate 
multivariable analyses were performed for patient characteristics, angiographic data and 
CMR data. CMR parameters, which were all highly correlated with one another, were 
included separately in multiple stepwise regression models with patient characteristics and 
angiographic data to reduce multicollinearity.  
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6.3.8 Infarct core tissue characteristics and left ventricular outcomes  
At 6 months, LV end-diastolic volume increased on average (SD) by 5 (25) ml in 295 
patients with evaluable data (table 6-2). Adverse remodelling, defined as an increased LV 
end-diastolic volume by ≥20% at 6-months from baseline, occurred in 34 (11%) patients 
and 23 (68%) of these patients had both microvascular obstruction and T2 hypointense 
core at baseline. Native T2 in the infarct core was not associated with adverse remodelling.  
The area-at-risk revealed by T2-mapping CMR was associated with LVEF at follow-up (-
0.16 (-0.27, -0.04); p=0.07) and with LV end-diastolic volume at follow-up (0.83 (0.46, 
1.19); p<0.001), independent of LVEF (p<0.01) and LV end-diastolic volume at baseline 
(p<0.001). 
6.3.9 Infarct core tissue characteristics and longer term health outcomes  
324 (100%) patients had longer term follow-up information. The median duration of 
follow-up was of 860 days (minimum - maximum post-discharge censor duration 597 - 
1162 days). Thirty four (10.5%) patients died or experienced a heart failure event. These 
events included 6 cardiovascular deaths, 4 non-cardiovascular deaths and 25 episodes of 
heart failure (Killip Class 3 or 4 heart failure (n=23) or defibrillator implantation n=2). 
Fourteen (4.3%) patients died or experienced a heart failure hospitalisation post-discharge.  
T2-core (1 ms change) was associated with a reduced risk of all-cause death or heart 
failure hospitalisation (hazard ratio 0.786, 95% CI 0.658, 0.939; p=0.008) including after 
adjustment for LVEF at baseline (p=0.017) or LV end-diastolic volume at baseline 
(p=0.009) (figure 6-3; table 6-5).  
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Figure 6-3 Kaplan-Meier survival plot for T2 core; patients grouped as thirds 
 
Kaplan-Meier survival curves for 197 STEMI patients grouped according to the native T2 
value in the infarct core with patients grouped by thirds and all-cause death or first heart 
failure hospitalisation (n=14) after discharge from hospital to the end of follow-up (censor 
time 860 (597 to 1162) days).   Infarct core native T2 values in the lowest tertile were 
associated with all-cause death or heart failure hospitalization; p=0.047. 
Table 6-5 Relationships for infarct core T2 relaxation time (ms) revealed by CMR at baseline 
in 197 STEMI patients with an infarct core and all-cause death or first hospitalisation for 
heart failure post-discharge. 
Associations Hazard ratio (95% CI) p value 
Univariable associations   
Infarct core native T2, (for a 1 ms difference) 0.786 (0.658, 0.939) 0.008 
LVEF at baseline, (for a 1% difference) 0.938 (0.890, 0.989) 0.017 
Model A  
Infarct core native T2, (for a 1 ms difference) 0.799 (0.664, 0.961) 0.017 
LVEF at baseline, (1% difference) 0.945 (0.882, 1.012) 0.107 
14 (4.3%) patients experienced all-cause death or heart failure hospitalisation post-
discharge discharge (median (range) follow-up duration of 860 days (597 to 1162) days). 
Given the limited number of adverse events, the models were specified to assess the 
prognostic relationships of infarct core native T2 with LV function, LV volume and infarct 
characteristics that were measured at approximately the same time 2 days after hospital 
admission. 
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6.4 Discussion 
We have presented the largest ever single centre CMR study in acute STEMI survivors. 
The main findings of our study are: 1) T2-maps that were of diagnostic quality were 
obtained in all (100%) of the STEMI survivors early post-MI, and the T2 measurements 
were reliable; 2) Infarct core pathology delineated by a central zone of reduced T2 was 
associated with heart rate, acute systemic inflammation, as revealed by log CRP and the 
circulating concentrations of neutrophils and monocytes, and heart failure; 3) Myocardial 
haemorrhage always occurred in the presence of a T2 hypointense core, however 60 (37%) 
patients had a T2 hypointense core in the absence of haemorrhage 4) Infarct core native T2 
was associated with LVEF early post-MI; 5) Infarct core pathology revealed by native T2 
was independently associated with all-cause death or heart failure hospitalisation during 
longer term follow-up; 6) Microvascular obstruction always occurred in the presence of a 
T2 hypointense core. 
Previous studies using dark blood T2-weighted imaging to evaluate the infarct core showed 
that microvascular obstruction occurred commonly in the absence of a T2 hypointense core 
(Amabile et al., 2012, Eitel et al., 2011, Ganame et al., 2009). In contrast, we have 
observed that all patients with microvascular obstruction had a hypointense core on T2-
mapping. This disparity may be explained by differences in measurement sensitivity 
between quantitative T2-mapping and qualitative T2-weighted CMR methods (Giri et al., 
2009, Nassenstein et al., 2014, Park et al., 2013, Verhaert et al., 2011).  Our results are 
consistent with post-mortem histology (Jackowski et al., 2006) that found a T2 hypointense 
core always represented microvascular obstruction, with or without haemorrhage.  
We also observed that a T2 hypointense core was more closely related to early 
microvascular obstruction (sensitivity 99.5% and specificity 91.3%) than late 
microvascular obstruction (sensitivity 100% and specificity 79.4%). This observation is 
consistent with previous studies that found significant correlation between the extent of 
hypointense core on T2-weighted imaging and the extent of microvascular obstruction by 
early gadolinium enhancement (Ganame et al., 2009, Mather et al., 2011b, O'Regan et al., 
2009). A study by O’Regan et al (O'Regan et al., 2010), using T2-weighted imaging and a 
haemorrhage sensitive T2* technique, showed that late microvascular obstruction was 
highly associated with the extent of haemorrhage, defined by T2* imaging (r2=0.87, 
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p<0.001), but the correspondence with early microvascular obstruction was weaker 
(r2=0.3, p<0.003).  This result supports the notion that the occurrence of a T2 hypointense 
core revealed by T2 mapping likely represents, at one end of the spectrum, intra-
myocardial haemorrhage in patients with severe reperfusion injury and microvascular 
destruction, and at the other end of the spectrum, functional microvascular obstruction, 
with preserved endothelial integrity.  
The paramagnetic effects of myocardial haemorrhage resulting in shortening of T2-
relaxation times and thus a haemorrhagic infarct core will cause a hypointense zone on T2-
weighted CMR (Basso et al., 2007, Bradley, 1993). In addition, functional microvascular 
obstruction (e.g. cellular debris and extrinsic oedema) may reduce the capillary flow and 
the effective tissue water content within the infarct core thereby reducing the supply of 
protons and subsequent reduction in T2 signal. 
Consistent with other studies, we found that a T2 values within the infarct core were 
associated with adverse clinical outcome (Amabile et al., 2012, Eitel et al., 2011, Husser et 
al., 2013). Since signal intensity values in qualitative T2-weighted CMR are not clinically 
meaningful, the quantitative nature of T2 mapping adds incremental prognostic value over 
and above the binary classification of oedema by qualitative T2-weighted imaging. 
There are few clinical studies using T2 mapping to assess ischaemic-reperfusion injury. A 
small study by Park et al. (Park et al., 2013), including 20 STEMI patients, found that the 
mean T2 value of remote myocardium was 50.3 (3.2) ms, which is in accordance with our 
result of 49.7 (2.1) ms. They excluded areas of microvascular obstruction when measuring 
T2 values in the infarct zone, which may explain why they found a T2 value of 67.9 (9.3) 
ms, compared to our T2 infarct zone value of 62.9 (5.1)  ms, which encompassed the entire 
area-at-risk, including microvascular obstruction. Our findings are also in line with other 
small studies including Giri et al. (Giri et al., 2009) (remote myocardium = 50.5 (3.5) ms 
and infarct zone = 66.7 (1.9) ms), although there is no mention of whether microvascular 
obstruction was included in the infarct zone measurement. Verhaert et al. (Verhaert et al., 
2011) noted that the T2 value within the infarct core, corresponding with the area of 
microvascular obstruction, was lower than the T2 value of surrounding infarcted tissue and 
measured 58.7 (6) ms, which was higher than our value of 53.9 (3.8) ms. However, their 
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study included 27 acute MI patients, 6 of whom were non-STEMIs and 7 of whom who 
were not revascularised. 
T2 mapping resulted in evaluable data in all patients, owing to the relative insensitivity to 
motion artefacts. This is in part due to the integrated motion correction algorithm, which 
makes it particularly useful in this patient cohort, in whom poor breath holding and 
arrhythmia are prevalent. Since native T2 core can be determined without contrast, this 
prognostic parameter may be especially useful in patients with relative contraindications to 
intravenous gadolinium contrast. 
6.4.1 Limitations 
We lack pathological correlation of our imaging results and T2* values. The number of 
adverse events limited the number of variables that could be included in the multivariable 
models. 
6.5 Conclusion 
A hypointense infarct core revealed by T2-mapping was common and independently 
associated with all-cause death or heart failure hospitalisation post-discharge. Quantitative 
T2-mapping is a robust, reliable and prognostically informative imaging biomarker in STEMI 
patients undergoing CMR. 
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7 Chapter 7: Prognostic significance of infarct core 
pathology revealed by quantitative non-contrast T1-
mapping, in comparison to contrast cardiac magnetic 
resonance imaging in reperfused ST-elevation 
myocardial infarction survivors 
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7.1 Introduction 
Myocardial infarct size [(Holman et al., 1978, Pfeffer and Braunwald, 1990)] and 
microvascular obstruction [(van Kranenburg et al., 2014, Eitel et al., 2010, Eitel et al., 
2011, Wu et al., 1998b, Hombach et al., 2005)] revealed by contrast-enhanced cardiac 
magnetic resonance (CMR) reflect the efficacy of reperfusion therapy and are 
prognostically important findings in survivors of ST-elevation myocardial infarction 
(STEMI).  
Human tissue has fundamental magnetic properties, including the longitudinal (spin-
lattice) relaxation time (native T1 in milliseconds). Native T1 is influenced by water 
content, binding with macromolecules (water mobility), and cell content [(Mathur-De Vre, 
1984, Cameron et al., 1984)]. Native T1 CMR does not involve an intravenous contrast 
agent. Tissue water content increases as a result of ischemia, resulting in longer T1 times 
being a biomarker of more severe myocardial injury in localized myocardial regions 
[(Williams et al., 1980, Been et al., 1988, Higgins et al., 1983, Yang et al., 2007, 
Dall'Armellina et al., 2013, Dall'Armellina et al., 2012, Messroghli et al., 2003, Messroghli 
et al., 2007b, Ugander et al., 2012)]. 
The clinical significance of tissue changes within the infarct core in patients with acute 
reperfused STEMI has not been directly assessed. We hypothesised that baseline native T1 
values would be 1) inversely associated with the severity of MI, including microvascular 
obstruction, 2) independently associated with left ventricular (LV) remodelling, and 3) 
independently associated with pre-defined health outcomes. Should these hypotheses be 
confirmed then infarct core native T1 mapping without an intravenous contrast agent might 
have potential as an alternative biomarker to microvascular obstruction revealed by 
contrast-enhanced CMR. 
To investigate these hypotheses we measured native T1 in myocardial regions of interest in 
STEMI patients undergoing serial cardiac magnetic resonance (CMR) imaging 2 days and 
6 months post-MI. We assessed the clinical determinants of native T1 within the 
hypointense infarct core and subsequent LV remodelling and examined its association with 
all-cause death and first hospitalisation for heart failure. 
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7.2 Methods 
7.2.1 Study population and STEMI management 
We performed a prospective CMR cohort study in a single regional cardiac centre between 
14 July 2011 and 22 November 2012. Three hundred and forty three STEMI patients 
provided written informed consent to undergo CMR 2 days and 6 months post-MI. The 
eligibility criteria and acute STEMI management are described in detail in chapter 2. 
7.2.2 CMR acquisition 
CMR was performed, as described in detail in chapter 2. In brief, the imaging protocol 
included cine MRI with steady-state free precession (SSFP), native T1 mapping 
[(Messroghli et al., 2004, Messroghli et al., 2007b)], T2 mapping [(Giri et al., 2009, 
Verhaert et al., 2011)] (full LV coverage), T2*-mapping (3 short-axis slices), and delayed-
enhancement phase-sensitive inversion-recovery pulse sequences [(Kellman et al., 2002)].  
Native T1 maps were acquired in 3 short-axial slices (basal, mid and apical), using an 
optimised modified look-locker inversion-recovery (MOLLI) T1-mapping investigational 
prototype sequence [(Messroghli et al., 2004, Messroghli et al., 2007b)] before contrast 
administration. The prototype sequence did not involve motion correction. 
CMR was also performed in 50 healthy volunteers of similar age and gender in order to 
obtain local reference values for myocardial native T1 (chapter 2). 
7.2.3 CMR analyses 
Approach to analyses is described in detail in chapter 2.  
Each T1 map image was assessed for the presence of artefacts relating to susceptibility 
effects, or cardio-respiratory motion. Each colour map was evaluated against the original 
images. When artefacts occurred the affected segments were not included in the analysis.  
Native myocardial T1 was measured in regions of interest defined as (1) remote 
myocardium, (2) injured myocardium and (3) infarct core. The hypointense infarct core 
was defined as an area in the centre of the infarct territory having a mean T1 value of at 
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least 2 standard deviations (SDs) below the T1 value of the periphery of the area-at-risk 
[(Giri et al., 2009, Verhaert et al., 2011)]. The assessment of T1 maps and adjudication 
(present/absent) of a hypointense core was performed independently by D.C. 
7.2.4 Pre-specified health outcome 
Described in detail in chapter 2, including independent adjudication of SAEs by 
cardiologists blinded to all other clinical and CMR data. 
7.2.5 Statistical analyses 
As described in chapter 2, categorical variables are expressed as number and percentage of 
patients. Most continuous variables followed a normal distribution and are therefore 
presented as means together with standard deviation. Those variables that did not follow a 
normal distribution are presented as medians with interquartile range.  Differences in 
continuous variables between groups were assessed by the Student’s t-test or analysis of 
variance (ANOVA) for continuous data with normal distribution, otherwise the 
nonparametric Wilcoxon rank sum test or Kruskal-Wallis test. Differences in categorical 
variables between groups were assessed using a Chi-square test or Fisher’s test, as 
appropriate.  Correlation analyses were Pearson or Spearman tests, as indicated. Random 
effects models were used to compute inter-and intra- rater reliability measures (intra-class 
correlation coefficient (ICC)) for the reliability of infarct core native T1 values measured 
independently by 2 observers in 12 randomly selected patients from the cohort. 
Univariable and multivariable linear regression analyses were performed to identify 
associates of T1 values for (1) remote myocardium, (2) injured myocardium within the 
area-at-risk and (3) infarct core in all patients and (4) in patients without late microvascular 
obstruction.  In backward stepwise linear regressions, the Akaike information criteria 
(AIC) was used as a measure of the relative quality of the models for this dataset, and the 
model with the minimum AIC value was reported. The CMR parameters that were all 
highly correlated with one another were included in multiple stepwise regression models 
with patient characteristics, angiographic data and blood results separately in order to 
reduce multi-collinearity. Where standardised regression coefficients are reported, these 
are calculated by multiplying the unstandardised coefficient by the standard deviation of 
the predictor, then dividing by the standard deviation of the response. Potential non-linear 
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relationships between T1 values in regions of interest and LV ejection fraction and end-
diastolic volume were explored with restricted cubic splines and Loess plots. The 
relationships between the presence or absence of an infarct core revealed by native T1 
CMR compared with early MVO, late MVO, presence of T2 core, and myocardial 
haemorrhage were explored in sensitivity analyses. 
Receiver operating curve (ROC), Kaplan-Meier and Cox proportional hazards methods 
were used to identify potential clinical predictors of all-cause death/heart failure events and 
MACE, including patient characteristics, CMR findings and native T1. The net 
reclassification improvement (NRI) was calculated as described by Pencina et al [(Pencina 
et al., 2011)]. 
All p-values are 2-sided, and a p-value > 0.05 indicates the absence of a statistically 
significant effect.  Statistical analyses were performed using R version 2.15.1 or SAS v 
9.3, or higher versions of these programs. 
7.3 Results 
Of 343 STEMI patients referred for emergency reperfusion therapy, 300 underwent serial 
CMR at 1.5 Tesla 2.2±1.9 days and 6 months after hospital admission (figure 7-1). 292 
STEMI patients had a T1-map acquisition and 288 (99%) had evaluable T1 data (figure 7-
1). CMR follow-up at 6 months was achieved in 267 (93%) of the patients and the reasons 
for non-attendance are summarised in figure 7-1. Information on vital status and SAEs 
were available in all (100%) of the 288 participants. 
7.3.1 Patient characteristics 
Table 7-1 shows the characteristics of the patients, including the patients with a 
hypointense infarct core revealed by native T1 mapping (n=160 (56%), grouped by thirds 
of native T1).  
7.3.2 Intra- and inter-observer agreement of T1 measurements 
The results for intra-class correlation coefficient for reliability of T1 measurements and 
Bland-Altman plots are shown in chapter 3, section 3.5.2.  
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Figure 7-1 Study flow diagram 
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Table 7-1 Clinical and angiographic characteristics of 288 STEMI patients who had CMR with evaluable maps for myocardial native T1 magnetisation, 
including the subset of patients with an infarct core revealed by native T1 (all and categorized by tertiles of native T1). 
Characteristics*  All patients Patients with a 
native T1 infarct 
core  
Patients with a native T1 infarct core grouped by tertile 
of infarct core zone native T1 (ms) at baseline 
P-
value  
    T1 core ≤ 973 ms 974 < T1 core  
≤ 1010 ms 
T1 core > 1010 
ms 
 
  n = 288 n = 160 (56%) n = 54 (33%) n = 53 (33%) n = 53 (33%)  
Age, years  59 (11) 59 (11) 59 (11) 57 (11) 61 (11) 0.238 
Male sex, n (%)  211 (73) 123 (77) 46 (85) 37 (70) 40 (76) 0.144 
BMI, (kg/m2)  29 (5) 29 (5) 29 (4) 29 (5) 28 (5) 0.674 
Medical history        
Hypertension, n (%)  93 (32) 57 (36) 17 (32) 21 (40) 19 (36) 0.684 
Current smoking, n (%)  177 (62) 100 (62) 32 (59) 34 (64) 34 (64) 0.858 
Hypercholesterolaemia, n (%)  82 (28) 44 (28) 12 (22) 17 (32) 15 (28) 0.527 
Diabetes mellitus‡, n (%)  32 (11) 20 (12) 7 (13) 7 (13) 6 (11) 1.000 
Previous angina, n (%)  34 (12) 21 (13) 8 (15) 4 (8) 9 (17) 0.304 
Previous myocardial infarction, n 
(%) 
 
23 (8) 15 (9) 5 (9) 3 (6) 7 (13) 0.415 
Previous PCI, n (%)  16 (6) 14 (9) 4 (7) 3 (6) 7 (13) 0.414 
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Presenting characteristics        
Heart rate, bpm  78 (17) 78 (16) 80 (16) 79 (16) 76 (17) 0.401 
Systolic blood pressure, mmHg  136 (24) 136 (22) 137 (24) 140 (23) 131 (19) 0.095 
Diastolic blood pressure, mmHg  79 (14) 80 (14) 82 (14) 83 (13) 76 (13) 0.010 
Time from symptom onset to 
reperfusion, min 
 
174 (120, 311)* 188 (125, 388) 223 (145, 406) 163 (113, 313) 198 (128, 257) 0.268 
Ventricular fibrillation†, n (%)  20 (7) 10 (6) 3 (6) 2 (4) 5 (9) 0.518 
Heart failure, Killip class at 
presentation, n (%) 
I 205 (71%) 101 (63) 29 (54%) 38 (72%) 34 (64%)  
 II 64 (22%) 43 (27) 15 (28%) 14 (26%) 14 (26%) 0.059 
 III / IV 19 (7) 16 (10) 10 (18) 1 (2) 5 (9)  
ECG        
ST segment elevation resolution post 
PCI, n (%) 
       
Complete, 70 %  129 (45) 55 (35) 15 (28) 21 (40) 19 (36)  
Incomplete, 30% to < 70%  115 (40) 74 (46) 27 (50) 23 (44) 24 (45) 0.715 
None, 30%  43 (15) 30 (19) 12 (22) 8 (15) 10 (19)  
Reperfusion strategy, n (%)        
Primary PCI  268 (93) 148 (92) 49 (91) 49 (92) 50 (94)  
Rescue PCI (failed thrombolysis)  13 (4) 10 (6) 4 (7) 3 (6) 3 (6) 1.000 
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Successful thrombolysis  7 (2) 2 (1) 1 (2) 1 (2) 0 (0)  
Coronary angiography        
Number of diseased arteries¥, n (%) 1 156 (54) 89 (56) 156 (54) 156 (54) 156 (54)  
 2 89 (29) 44 (28) 90 (31) 90 (31) 90 (31) 0.436 
 3 42 (15) 24 (15) 42 (15) 42 (15) 42 (15)  
 LM 6 (2) 3 (2) 0 (0) 2 (4) 1 (2)  
Culprit artery, n (%)  LAD 108 (38) 60 (38) 22 (41) 19 (36) 19 (36)  
 LCX 51 (18) 31 (19) 10 (18) 12 (23) 9 (17) 0.915 
 RCA 129 (45) 69 (34) 22 (41) 22 (42) 25 (47)  
TIMI coronary flow grade pre-PCI, 
n (%)  
0/1 208 (72) 135 (84) 49 (91) 39 (74) 47 (89)  
 2 52 (18) 27 (13) 5 (9) 11 (21) 5 (9) 0.085 
 3 28 (10) 4 (2) 0 (0) 3 (6) 1 (2)  
TIMI coronary flow grade post-PCI, 
n (%) 
0/1 3 (1) 2 (1) 0 (0) 1 (2) 1 (2)  
 2 13 (4) 8 (5) 3 (6) 3 (6) 2 (4) 0.959 
 3 272 (94) 150 (94) 51 (94) 49 (92) 50 (94)  
Medical therapy        
ACE-I or ARB  285 (99) 159 (>99) 54 (100) 53 (100) 52 (98) 0.663 
Beta-blocker  278 (96) 158 (99) 53 (98) 52 (98) 53 (100) 1.000 
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Initial blood results on admission        
C-reactive protein, (mg/L) 
 
median 
(IQR) 
range 
3.0 (2.0 - 7.0) 
0 - 265.0 
4.0 (2.0, 8.0) 
1.0 -  265 
3.5 (2.0 - 11.0) 
1.0 - 125.0 
3.0 (1.0 – 6.2) 
1.0 - 92.0 
4.0 (2.0 - 7.0) 
1.0 - 265.0 
0.696 
Leucocyte cell count (x109L)  12.4 (3.5) 12.8 (3.6) 12.9 (3.5) 13.3 (3.5) 12.3 (3.6) 0.310 
Neutrophil count (x109L)  9.6 (3.2) 10.1 (3.3) 10.0 (3.4) 10.6 (3.4) 9.6 (3.0) 0.244 
Monocytes (x109L)  0.4 (0.4) 0.9 (0.4) 1.0 (0.4) 0.9 (0.3) 0.9 (0.5) 0.485 
NT-proBNP, pg/mL  824 (350, 1642) 1103 (628, 1849) 1456 (702, 2455) 980 (565, 1637) 1021 (529, 1436) 0.354 
Footnote: ACE-I or ARB = angiotensin converting enzyme inhibitor or angiotensin receptor blocker; LAD = Left anterior descending coronary artery; 
LCX = Left circumflex coronary artery; LM = left main coronary artery; RCA = right coronary artery; TIMI = Thrombolysis in Myocardial Infarction 
grade, PCI = percutaneous coronary intervention. Killip classification of heart failure after acute myocardial infarction: class I - no heart failure, class 
II - pulmonary rales or crepitations, a third heart sound, and elevated jugular venous pressure, class III - acute pulmonary edema, class IV - cardiogenic 
shock. * Data are reported as mean (SD), median (IQR), or N (%) as appropriate. P-values have been obtained from a one-way ANOVA or Fisher test. 
TIMI flow grades pre- and post-PCI were grouped 0/1 vs. 2/3 for this analysis. ‡ Diabetes mellitus was defined as a history of diet-controlled or treated 
diabetes. † Successfully electrically cardioverted ventricular fibrillation at presentation or during emergency PCI procedure. ¥ Multivessel coronary 
artery disease was defined according to the number of stenoses of at least 50% of the reference vessel diameter, by visual assessment and whether or not 
there was left main stem involvement. The blood results on admission and their changes during the first two days after admission are described in 
Supplementary Table 1. Missing data: Heart rate, n=1; Time from symptom onset to reperfusion, n=20; ST-segment resolution, n=1; CRP, n=7; 
leucocyte count, n=1. The patients are grouped according to tertile of T1 in hypo-intense core at baseline.
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7.3.3 Left ventricular function and pathology 
Initial CMR findings following hospital admission 
The CMR findings are summarised in table 7-2 and case examples are shown in figure 7-2. 
At baseline, the mean (SD) myocardial infarct size was 18 (14) % of LV mass. The 
average infarct core native T1 (996.9 (57.3)) was higher than native T1 in the remote 
myocardium (961 (25) ms; p<0.01) but lower than native T1 in the area-at-risk (1097 (52) 
ms; p<0.01). 
Figure 7-2 Acute STEMI cases with different infarct core T1 results revealed by CMR 2 days 
post-MI and divergent longer term clinical outcomes 
(a) Patient with no T1 hypointense infarct core and no microvascular obstruction. Native 
T1 within the injury zone (middle) measured 1211 ms. Acute infarct size revealed by late 
gadolinium enhancement (right) was 22.2%. The LVEF and LV end-diastolic volume were 
55.2% and 143.1 ml, respectively. Analysis of the repeat MRI scan after 6 months follow-
up indicated that the final infarct size was 15.6% of LV mass and the LV end-diastolic 
volume had reduced to 103.0 ml. This patient had an uncomplicated clinical course.    
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(b) Patient with both T1 hypointense infarct core and microvascular obstruction. T1 
mapping (middle) revealed a hypointense region within the infarct core, corresponding to 
the area of microvascular obstruction on contrast-enhanced MRI (right). Native T1 within 
the infarct core measured 1036 ms, which was substantially lower than the T1 value 
measured at the periphery of the infarct zone (1193 ms). Acute infarct size revealed by late 
gadolinium enhancement (right) was 33.0%. Microvascular obstruction depicted as the 
central dark zone within the infarct territory was 3.6% of LV mass. The LVEF and end-
diastolic volume were 45.8% and 199.3 ml, respectively. The final infarct size at 6 months 
was 22.6% of LV mass and the LV end-diastolic volume had increased to 221.8 ml. This 
patient was re-hospitalized for new onset heart failure during follow-up. (c) Patient with 
T1 hypointense infarct core, but no microvascular obstruction. T1 mapping (middle) 
revealed a hypointense region within the infarct core, with a T1 value of 998 ms, which 
was substantially lower than the T1 value measured at the periphery of the infarct zone 
(1113 ms). Acute infarct size revealed by late gadolinium enhancement (right) was 30.7%. 
The left ventricular ejection fraction and end-diastolic volume were 50.2% and 152.6 ml, 
respectively. Six month follow-up MRI revealed final infarct size was 22.1% of left 
ventricular mass and there was a significant increase in left ventricular end-diastolic 
volume to 182.4 ml. This patient had no adverse events during follow-up. 
  
186 
 
Table 7-2 Comparison of CM findings at baseline in 288 STEMI survivors and 6-month CMR findings in 267 STEMI patients. 
Characteristics* All patients Patients with a 
native T1 
infarct core  
Patients with a native T1 infarct core grouped by 
tertile of infarct core zone native T1 (ms) at 
baseline 
P-value 
 All patients Hypointense 
core 
≤ 973 ms 974 < T1 core 
≤ 1014 ms 
> 1014 ms  
         n = 288 n = 160 n = 54 n = 53 n = 53  
CMR findings 2 days post-MI        
LV ejection fraction, %  55 (10) 52 (9) 52 (10) 51 (8) 53 (10) 0.418 
LV end-diastolic volume, ml       
Men 162 (33) 168 (147, 187) 168 (22) 169 (36) 166 (30) 0.900 
Women 124 (25) 125 (113, 145) 122 (30) 134 (26) 126 (21) 0.497 
LV end-systolic volume, ml       
Men 73 (55, 94) 79 (64, 98) 75 (64, 94) 81 (74, 103) 76 (60, 100) 0.496 
Women 53 (41, 66) 64 (50, 69) 64 (57, 71) 66 (57, 70) 56 (45, 65) 0.383 
LV mass, g       
Men 142 (124, 159) 145 (130, 166) 149 (135, 170) 143 (126, 159) 141 (130, 160) 0.526 
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Women 97 (84, 108) 101 (89, 124) 103 (92, 113) 109 (93, 132) 97 (83, 101) 0.113 
Edema and infarct characteristics       
Area at risk, % LV mass 32 (12) 40 (11) 37 (11) 35 (10) 36 (11) 0.482 
Infarct size, % LV mass 16 (7, 27) 25 (16, 32) 25 (18, 34) 27 (18, 32) 22 (16, 32) 0.386 
Myocardial salvage, % of LV mass 18 (12, 24) 17 (12, 23) 18 (12, 24) 17 (10, 22) 16 (13, 22) 0.546 
Myocardial salvage index, % of LV mass 62 (44, 84) 49 (36, 62) 50 (40, 62) 46 (30, 62) 50 (40, 63) 0.590 
Late microvascular obstruction present, n (%) 145 (50) 23 (14) 49 (91) 45 (85) 43 (81) 0.356 
Late microvascular obstruction, % LV mass 0.1 (0.0, 3.5) 2.7 (0.8, 7.5) 5.2 (1.7, 10.5) 2.7 (0.9, 7.1) 1.7 (0.3, 4.7) 0.005 
Myocardial haemorrhage, n (%)* 96 (40) 94 (67) 34 (76) 35 (70) 25 (54) 0.086 
Myocardial native T1 values       
T1 remote myocardium (all subjects), ms 961 (25) 964 (26) 958 (28) 962 (20) 972 (28) 0.014 
Men, ms 959 (25) 962 (26) 955 (29) 959 (19) 973 (26) 0.004 
Women, ms 968 (25) 969 (26) 969 (22) 969 (22) 968 (36) 0.992 
T1 infarct zone, ms 1097 (52) 1093 (52) 1052 (37) 1088 (33) 1140 (22) <0.001 
T1 hypointense infarct core, ms 997 (57) 997 (57) 938 (30) 995 (12) 1060 (37) <0.001 
Myocardial native T2 values       
T2 infarct core (n=171, ms) 54 (5) 54 (5) 52 (4) 53 (4) 56 (5) <0.001 
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CMR findings 6 months post-MI (n=267)       
LV ejection fraction at 6 months, % 63 (57, 69) 60 (53, 65) 59 (53, 65) 59 (54, 64) 61 (54, 68) 0.542 
LV end-diastolic volume at 6 months, ml       
Men 165 (140, 193) 176 (155, 204) 188 (160, 209) 169 (153, 197) 171 (156, 196) 0.367 
Women 124 (110, 136) 120 (96, 139) 120 (96, 139) 130 (122, 153) 127 (118, 142) 0.338 
LV end-systolic volume at 6 months, ml       
Men 61 (43, 78) 69 (56, 95) 73 (58, 98) 69 (62, 84) 63 (53, 96) 0.667 
Women 43 (34, 58) 55 (44, 61) 45 (41, 56) 60 (50, 65) 53 (40, 57) 0.213 
Footnote: Abbreviations: LV = left ventricle, T1 = myocardial longitudinal relaxation time. Area-at-risk was measured with T2-mapping. Data are given 
as n (%) or mean (SD). P-values were obtained from one-way ANOVA, Kruskal-Wallis test, or a Fisher test. * Data are reported as mean (SD), median 
(IQR), or n (%) as appropriate. Data on T2*-CMR for myocardial haemorrhage were not available in 48 patients. 
Three T1 maps (basal-, mid-, and distal-ventricular levels) were measured in each patient (n=876 T1-maps overall) and 93% of these maps were suitable 
for analysis. Overall, 20 (6.8%) patients had poor quality T1 maps and 4 (1.3%) patients had no evaluable T1 maps (Figure 2). In all, 42 (4.8%) T1 
maps were unsuitable for analysis because of SSFP off-resonance artefacts and 19 (2.2%) T1 maps were affected by motion artefacts. T1 values were 
higher in infarct tissue surrounding the infarct core than within the infarct core (p<0.001) and remote myocardium (p<0.001).  
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7.3.4 Baseline associates of infarct core native T1 (hypothesis 1) 
The clinical characteristics that were univariably associated with infarct core native T1 
time (ms) and were included in the multivariable models were systolic blood pressure at 
initial angiography, mmHg (-0.45 (-0.85, -0.05); p = 0.026), LV ejection fraction (%) (0.94 
(-0.03, 1.91); p=0.057), infarct size (% LV mass) (-0.93 (-1.68, -0.18); p=0.016), minimum 
leucocyte count (x109L) (-3.97 (-6.93, -1.01); p=0.009), minimum neutrophil count 
(x109L) (-4.99 (-8.41, -1.56); p=0.005), maximum log CRP (-7.35 (-15.00, 0.31); 
p=0.060), maximum leucocyte count (x109L) (-2.53 (-5.09, 0.02); p=0.052), and 
maximum monocyte count (x109L) (-21.83 (-42.15, -1.51); p=0.035). 
In multivariable regression analysis, native T1 in the infarct core was inversely associated 
with TIMI coronary flow grades at the end of emergency PCI, Killip class and neutrophil 
count at initial presentation (all p<0.04), independent of LVEF, LV end-diastolic volume 
or infarct size (table 7-3). 
Infarct core native T1 (ms) was univariably associated with infarct core T2 (ms) (r=0.42; 
p<0.001) and infarct core T2* (ms) (r=0.36; p<0.0001). 
Table 7-3 Associates of infarct core native T1 time (for a 10 ms difference) in 160 STEMI 
survivors with infarct core pathology revealed by native T1 mapping with CMR 2 days post-
MI. 
Multiple stepwise regression (for a 10 ms 
difference in infarct core T1) 
coefficient (95% CI) p value 
A. Including patient characteristics and 
angiographic data* 
  
Systolic blood pressure at initial 
angiography, mmHg 
-0.05 (-0.09, -0.01) 0.007 
Killip class 3 or 4 -3.84 (-6.87, -0.80) 0.014 
TIMI flow grade 2 or 3 post-PCI -7.51 (-15.42, 0.40) 0.063 
B. Including patient characteristics, 
angiographic data, and minimum 
neutrophil count* 
  
Systolic blood pressure at initial -0.05 (-0.09, -0.01) 0.015 
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angiography, mmHg 
Killip class 3 or 4 -3.39 (-6.45, -0.33) 0.030 
TIMI flow grade 2 or 3 at the end of PCI -9.77 (-17.67, -1.87) 0.005 
Minimum neutrophil count, (x109L) -0.50 (-0.86, -0.15) 0.005 
C. Including patient characteristics, 
angiographic data, minimum neutrophil 
count*and T2 core (1 ms) 
  
T2 core (1 ms) 0.50 (0.32, 0.67) <0.001 
Neutrophils -0.39 (-0.71, 0.07) 0.016 
Gender (male) -2.32 (-4.25, 0.39) 0.019 
SBP -0.03 (-0.07, 0.00) 0.059 
TIMI 2/3 post-PCI -5.46 (-12.62, 1.70) 0.134 
Footnote: The coefficient (95% confidence intervals (CI)) indicates the magnitude and 
direction of the effect of the patient characteristic (binary or continuous) on the infarct 
core T1 (ms). For example, in models A and B, on average, infarct core native T1 (10 ms 
difference) is 0.50 lower for each 1 mmHg increase in SBP. 
* The clinical and angiographic characteristics that were assessed are listed in Table 1. 
The univariable associates with native T1 in the infarct core are described in the text. 
Separate multivariable analyses were performed for (A) patient characteristics and 
angiographic data and (B) CMR data. CMR parameters, which were all highly correlated 
with one another, were included separately in multiple stepwise regression models with 
patient characteristics and angiographic data to reduce multicollinearity.  
Similar results were obtained when area-at-risk, LV ejection fraction, LV end-systolic 
volume, and infarct size were included. Maximum leucocyte count (p=0.053) and 
maximum monocyte count (p=0.034) remained associates of infarct core native T1 after 
adjustment for LV end-diastolic volume. Similar results were also obtained in the 
multivariable model with LV end-diastolic volume for minimum leucocyte count (p=0.011). 
7.3.5 Relationships for native T1 infarct core versus infarct pathology, including 
microvascular obstruction, infarct core T2 and myocardial haemorrhage 
137 (86%) STEMI patients with a hypointense native T1 infarct core also had 
microvascular obstruction. In contrast, only 6.3% of those without hypointense infarct core 
had late microvascular obstruction. The negative- and positive predictive values of native 
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T1 infarct core for T2 core, early gadolinium enhancement, microvascular obstruction and 
myocardial haemorrhage disclosed by a T2* core are summarised in table 7-4. 
Table 7-4 Negative- and positive predictive values of T1 infarct core for microvascular 
obstruction, T2 core and myocardial haemorrhage disclosed by a T2* core. 
 Native T1 infarct 
core absent 
Native T1 infarct 
core present 
 
T2 core    
T2 core absent 111 2 Specificity 98.2 % 
95% CI (95.8, 
100.0) 
T2 core present 17 158 Sensitivity 90.3% 
95% CI (85.9, 
94.7) 
 NPV 86.7% 
95% CI (80.8, 
92.9) 
PPV 98.8% 
95% CI (97.0, 
100.0) 
 
Myocardial haemorrhage    
Myocardial haemorrhage 
absent 
97 47 Specificity 67.4% 
95% CI (60.5, 
74.8) 
Myocardial haemorrhage 
present 
2 94 Sensitivity 97.9% 
95% CI (95.2, 
100.0) 
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 NPV 97.9% 
95% CI (95.3, 
100.0) 
PPV 66.7% 
95% CI (59.4, 
74.2) 
 
Early MVO    
Early MVO absent 114 10 Specificity 91.9% 
95% CI (87.1, 
97.1) 
Early MVO present 14 150 Sensitivity 91.5% 
95% CI (87.3, 
95.7) 
 NPV 89.1%  
95% CI (83.8, 
94.6) 
PPV 93.8% 
95% CI (90.1, 
97.7) 
 
Late MVO    
Late MVO absent 120 23 Specificity 83.9% 
95% CI (78.4, 
89.7) 
Late MVO present 8 137 Sensitivity 94.5% 
95% CI (90.8, 
98.3) 
 NPV 93.8% 
95% CI (89.6, 
98.1) 
PPV 85.6% 
95% CI (0.80, 
0.91) 
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Footnote: 95% CI – 95% confidence interval; MVO – microvascular obstruction; NPV – 
negative predictive value; PPV – positive predictive value. The CMR approaches for 
delineation of early MVO, late MVO and myocardial haemorrhage are described in the 
Methods. 
7.3.6 Infarct core tissue characteristics as a marker of subsequent left ventricular 
remodelling (hypothesis 2) 
At 6 months, LV end-diastolic volume increased on average (SD) by 5 (25) ml in 262 
patients with evaluable data (table 7-2). Adverse remodelling occurred in 30 (12%) 
patients and 23 (77%) of these patients had a hypointense native T1 core at baseline. 
Infarct core native T1 (ms) was not associated with change in LV end-diastolic volume at 
follow-up (p=0.531). 
There were 20 clinical characteristics that were univariable associates of adverse LV 
remodelling, defined as an increase in LV end-diastolic volume ≥ 20% at 6 months from 
baseline. 244 STEMI participants had complete data for these clinical characteristics and 
paired CMR scans at baseline and follow-up, and 136 of these patients had a hypointense 
native T1 core. The univariable characteristics and their p-values that were included in the 
multivariable model were: infarct core native T1 (p=0.052), age (p=0.909), male sex 
(p=0.847), body mass index (p=0.366), previous myocardial infarction (p=0.364), diabetes 
mellitus (p=0.491), previous percutaneous coronary intervention (p=0.639), cigarette 
smoking (p=0.036), history of hypertension (p=0.463), hypercholesterolaemia (p=0.912), 
history of angina (p=0.972), heart rate (p=0.569), systolic blood pressure at initial 
angiography (p=0.718), Killip class II vs. Killip class I (reference category) (p=0.437), 
Killip class III/IV vs. Killip class I (reference category) (p=0.574), sustained ventricular 
arrhythmia (p=0.015), symptom onset to reperfusion time (p=0.793), TIMI flow grade 
2/3 vs. grade 1 (reference category) at initial angiography (p=0.648), ST segment 
resolution (none vs. complete (reference category), and p=0.966; incomplete vs. complete 
(reference category), p=0.089).  
In multivariable regression, native T1 (ms, continuous) within the hypointense core was 
inversely associated with adverse remodelling (table 7-5).  
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In a sensitivity analysis, the occurrence of a hypointense core within the infarct zone on T1 
mapping was associated with the odds ratio for being in the top quarter of an increase in 
LV end-diastolic volume at 6 months (native T1 core to predict Q4 (n=66) vs. Q1-3 
(n=196) (n=26 missing); odds ratio 0.994 (0.987, 0.999); p=0.048). 
Table 7-5 Multivariable associates of adverse LV remodelling revealed by CMR in STEMI 
survivors* after 6 months follow-up. 
Multivariable associations Odds ratio (95% CI) p value 
A Patient and angiographic characteristics  
Native T1 infarct core, per 10 ms 0.91 (0.82, 1.00) 0.061 
Current smoking 5.27 (1.07, 26.00) 0.041 
Sustained ventricular arrhythmia 16.06 (1.67, 154.43) 0.016 
Incomplete ST-segment resolution 3.29 (0.85, 12.78) 0.085 
B Patient and angiographic characteristics and infarct core native T2  
Native T2 infarct core, per 10 ms 1.01 (0.28, 3.67) 0.987 
Native T1 infarct core, per 10 ms 0.91 (0.81, 1.01) 0.073 
Current smoking 4.99 (0.99, 25.06) 0.051 
Sustained ventricular arrhythmia 15.26 (1.57, 148.71) 0.019 
Incomplete ST-segment resolution 3.18 (0.81, 12.43) 0.097 
C Patient and angiographic characteristics and myocardial haemorrhage 
Myocardial haemorrhage 0.57 (0.14, 2.41) 0.449 
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Native T1 infarct core, per 10 ms 0.90 (0.81, 1.01) 0.070 
Current smoking 4.78 (0.83, 27.52) 0.080 
Sustained ventricular arrhythmia 11.70 (0.94, 144.88) 0.055 
Incomplete ST-segment resolution 3.68 (0.90, 15.02) 0.069 
Footnote: The odds ratio (95% confidence intervals) indicates the magnitude and direction 
for adverse LV remodelling. For a 10 ms increase in native T1 the odds ratio for adverse 
LV remodelling reduced (0.91 (0.82, 1.00); p=0.061). For a 1 ms increase in native T1 the 
odds ratio for adverse LV remodelling reduced (0.99 (0.98, 1.00); p=0.061). 
* Twenty clinical characteristics at baseline that were univariable associates of adverse 
LV remodelling at 6 months post-MI were included in the multivariable model and these 
univariable associates are described in the text. 267 STEMI patients had CMR at 6 months 
and baseline and 23 of these patients had missing data of at least one of the univariable 
characteristics that were included in this multivariable model. C-statistic (area-under-the-
curve (AUC)) for the multivariable model in 244 subjects but not including native T1 core: 
0.95; C-statistic (AUC) for the model (above) including infarct core native T1 (n=136): 
0.81; net reclassification index for incremental addition of T1 core to the model: 0.31, p = 
0.184. 
When the multivariable model for adverse remodelling included infarct size, the area-
under-the curve (AUC) without native T1 core (continuous, ms) was 0.823 and the AUC 
with T1 core values included was 0.857. Inclusion of native T1 core values neither 
increased nor reduced the predictive value of this model (net reclassification index 
p=0.16).There was no threshold for native T1 core value in the infarct core in relation to 
its association with LV outcomes at baseline or during follow-up. 
7.3.7 Infarct core native T1 early post-MI and NT-proBNP, a biochemical measure of 
adverse outcome, at 6 months 
Biomarker blood samples were collected in the STEMI patients who had been enrolled 
during office hours and NT-proBNP results were available in 151 (52%) of 288 STEMI 
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patients overall. 81 of these STEMI patients had evaluable T1 CMR maps at baseline and 
an NT-proBNP result at 6 months, and 50 (62%) of these patients had a hypointense core 
disclosed by T1 mapping. The characteristics of these patients were similar to those of the 
whole cohort (tables not included).  
Native T1 within the infarct core and NT-proBNP were not associated at baseline. T1 
values within the infarct core at baseline were associated with log NT-proBNP (per 1 
pg/mL change) at 6 months (per 1 ms reduction in native T1: coefficient (95% CI) 0.01 
(0.01, 0.00); p=0.015) (n=50), independent of LV end-diastolic volume and NT-proBNP at 
baseline. 
7.3.8 Native T1 infarct core, microvascular obstruction, T2 core, myocardial 
haemorrhage and left ventricular outcomes at 6 months 
The relationships for infarct core native T1 (binary and continuous), T2 core (binary and 
continuous), microvascular obstruction (binary, % LV mass) and myocardial haemorrhage 
(binary and continuous) for LV outcomes, including LV end-diastolic volume and LV 
ejection fraction, are shown in table 7-6. Native T1 (ms) was not associated with LV 
volumes at follow-up. The presence of a hypointense infarct core disclosed by native T1 
and the presence and amount of microvascular obstruction were consistently and similarly 
associated with LV outcomes. Overall, there was no evidence of non-linearity between 
infarct core T1 (ms) and LV outcomes. Myocardial haemorrhage defined by T2* 
hypointense core was strongly associated with LV outcomes, including LVEDV and LVEF 
at 6-months. However, in multivariable regression, T2* (ms, continuous) was not 
associated with adverse remodelling or health outcome (all cause death or hospitalisation 
for heart failure). 
In multivariable regression, native T1 (ms, continuous) within the hypointense core was 
inversely associated with adverse remodelling. 
Table 7-6 The univariable relationships for infarct core characteristics revealed by native T1, 
T2, T2* and microvascular obstruction for LV outcomes at baseline and during follow-up in 
288 STEMI patients. 
  LVEDV at 
baseline 
LVEDV at 
6 months 
LVEF at 
baseline 
LVEF at 
follow-up 
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T1 core  Standardised β -0.042 -0.035 0.151 0.055 
(per 10 ms) P-value 0.596 0.520 0.057 0.485 
T1 core  β 16.410 13.80 -6.642 -4.652 
(binary) P-value <0.0001 <0.0001 <0.0001 <0.0001 
T2 core  
(per 10 ms) 
Standardised β 
P-value 
0.035 
0.653 
0.057 
0.282 
0.159 
0.037 
-0.033 
0.586 
T2 core 
 (binary) 
β 
P-value 
15.538 
<0.001 
12.875 
<0.0001 
-6.542 
<0.0001 
-4.494 
<0.0001 
Myocardial  Standardised β -0.158 -0.140 0.144 0.170 
haemorrhage            
(T2* core, per 10ms) 
P-value 0.115 0.038 0.151 0.023 
Myocardial 
haemorrhage 
(T2* core, binary) 
β 
P-value 
17.205 
<0.0001 
16.811 
<0.0001 
-6.374 
<0.0001 
-5.769 
<0.0001 
Microvascular 
obstruction  
Standardised β 0.186 0.209 -0.443 -0.283 
(% of LV mass) P-value 0.002 <0.0001 <0.0001 0.004 
Microvascular 
obstruction  
β 15.853 12.454 -6.620 -4.464 
(binary) P-value <0.001 <0.0001 <0.0001 <0.0001 
The relationships for infarct core native T1 relaxation time (per 10 ms), native T1 infarct 
core (binary), T2 core relaxation time (per 10 ms), T2 infarct core (binary), T2* core 
relaxation time (per 10 ms), myocardial haemorrhage (binary) and the presence and the 
amount of microvascular obstruction (n=145 STEMI patients) with LV outcomes are 
summarised by p-values and, for continuous predictors, standardised regression 
coefficients or odds ratios per standard deviation increase in native T1 (ms) or extent of 
microvascular obstruction (% of LV mass). Models with follow-up are adjusted for 
baseline.  Binary predictors are summarised by p-values and unstandardized regression 
coefficients or odds ratios. The odds ratio (p-values) for adverse remodelling and infarct 
core characteristics are: native T1 core (per 10 ms) are 0.939, p=0.122; native T1 core 
(present/absent): 2.692, p=0.016; T2 core (present/absent): 2.874, p=0.026; myocardial 
haemorrhage (present/absent): 2.556, p=0.025; microvascular obstruction (% LV mass): 
1.112, p=0.004; microvascular obstruction (present/absent) 1.883, p=0.115. 
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7.3.9 Infarct core tissue characteristics and health outcomes (hypothesis 3) 
All 288 patients had long term follow-up data completed. Thirty (10.4%) patients died or 
experienced a heart failure event. These events included 5 cardiovascular deaths, 3 non-
cardiovascular deaths and 22 episodes of heart failure (Killip Class 3 or 4 heart failure 
(n=20) or defibrillator implantation n=2). Thirteen (4.5%) patients died or experienced a 
first heart failure hospitalisation post-discharge, and 8 (61.5%) of these patients had a 
hypointense infarct core at baseline. 
Native T1 values (ms) within the hypointense infarct core (n=160 STEMI patients) were 
inversely associated with the risk of all-cause death or first hospitalization for heart failure 
post-discharge (for a 10 ms increase in native T1: hazard ratio 0.730, 95% CI 0.617, 0.863; 
p<0.001) including after adjustment for LVEF at baseline, LV end-diastolic volume at 
baseline, infarct core T2 (10 ms difference), and myocardial haemorrhage (figure 7-3; table 
7-7). Infarct core T1 retained its prognostic significance over and above infarct core T2 
and myocardial haemorrhage (table 7-7, models C – F). The net reclassification index for 
the inclusion of infarct core native T1 (ms) in a multivariable prognostic model for all-
cause death or heart failure post-discharge was 1.129 (95% CI 0.516, 1.742); p<0.001) 
(table 7-7). Using ROC analysis, the C-index for infarct core native T1 for all-cause death 
or heart failure was 0.806. The C-indexes for the prognostic model without and with infarct 
core native T1 (ms) were 0.715 and 0.931, respectively.  
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Figure 7-3 Kaplan-Meier survival curves for 160 STEMI patients grouped according to the 
native T1 value in the infarct core with patients grouped by thirds (lowest T1 tertile vs. 
tertiles 2 and 3) and all-cause death or first heart failure hospitalisation (n=13) after 
discharge from hospital to the end of follow-up (censor time 839 (598 to 1099) days).  Infarct 
core native T1 values in the lowest tertile were associated with all-cause death or heart 
failure hospitalisation. 
 
 
Table 7-7 . Relationships for infarct core T1 and T2 relaxation times (10 ms) revealed by 
CMR at baseline in 160 STEMI patients with an infarct core and all-cause death or first 
hospitalisation for heart failure post-discharge.  
Associations Hazard ratio (95% CI) p value 
Univariable associations   
Infarct core native T1, (for a 10 ms 
difference) 
0.730 (0.617, 0.863) <0.001 
Myocardial haemorrhage 2.488 (0.814, 7.609) 0.110 
LVEF at baseline, (for a 1% difference) 0.934 (0.885, 0.985) 0.013 
Peak log eosinophil count, x109/L 0.617 (0.432, 0.881) 0.008 
Model A  
Infarct core native T1, (for a 10 ms 
difference) 
0.744 (0.627, 0.883) <0.001 
LVEF at baseline, (1% difference) 0.938 (0.883, 0.996) 0.036 
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Model B   
Infarct core native T1, (for 10 ms difference) 0.737 (0.621, 0.875) <0.001 
Peak log eosinophil count, (1 x109/L) 0.728 (0.476, 1.114) 0.144 
Univariable associations   
Infarct core native T2, (for a 10 ms difference) 0.186 (0.032, 1.094) 0.063 
Model C  
Infarct core native T2, (for a 10 ms 
difference) 
0.244 (0.039, 1.528) 0.132 
LVEF at baseline, (for a 1% difference) 0.932 (0.870, 0.998) 0.044 
Model D   
Infarct core native T2, (for 10 ms difference) 0.203 (0.034, 1.297) 0.093 
Peak log eosinophil count, x109/L 0.681 (0.460, 1.007) 0.054 
Model E   
Infarct core T1, (for 10 ms difference) 0.738 (0.624, 0.873) <0.001 
Myocardial haemorrhage 1.965 (0.229, 16.864) 0.538 
Model F   
Infarct core T1, (for 10 ms difference) 0.752 (0.634, 0.893) 0.001 
Infarct core T2, (for a 10 ms difference) 0.428 (0.068, 2.683)  0.365 
Myocardial haemorrhage 1.485 (0.159, 13.879) 0.729 
Footnote: Thirteen (8.1%) patients experienced all-cause death or heart failure 
hospitalisation post-discharge discharge (median (range) follow-up duration of 841 (723 – 
945) days). Given the limited number of adverse events, the models were specified to 
assess the prognostic relationships of infarct core native T1 versus circulating markers of 
systemic inflammation, LV function, LV volume and infarct characteristics that were 
measured at approximately the same time 2 days after hospital admission. 
7.3.10 Prognostic importance of infarct core native T1: comparisons with microvascular 
obstruction and longer term health outcomes 
In a univariate Cox model that included infarct core native T1 (ms), native T1 core 
(binary), T2 core (ms), T2 core (binary), myocardial haemorrhage and the presence 
(binary) and amount of microvascular obstruction (% LV mass), only infarct core native 
T1 (ms) (p<0.001) and the amount of microvascular obstruction (% LV mass) (p<0.001) 
were associated with all-cause death or first heart failure hospitalisation after discharge. 
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7.4 Discussion 
The main findings of our study are: 1) native T1 mapping revealed without an intravenous 
contrast agent resulted in evaluable scans in a high percentage (93%) of STEMI survivors 
2 days post-MI; 2) acute culprit coronary artery blood flow and circulating measures of 
systemic inflammation at the time of the hospital admission were multivariable associates 
of native T1 within the hypointense infarct core revealed by T1 mapping 2 days later; 3) 
native T1 values (ms) within the infarct core were clinically meaningful since they tended 
to be associated with adverse remodelling, NT-proBNP concentrations at 6 months, and 
all-cause death or heart failure hospitalisation post-discharge during longer term follow-up; 
4) compared with infarct core T2 or myocardial haemorrhage revealed by T2* mapping, 
infarct core T1 was more consistently associated with LV surrogate outcomes and all-cause 
death or heart failure hospitalisation (table 7-7), implying T1 core is more closely linked 
with infarct pathology;; 5) compared with microvascular obstruction, a hypointense infarct 
core revealed by native T1 had similar prognostic significance for LV outcomes at 6 
months and for post-discharge cardiac events, including all-cause mortality and heart 
failure hospitalisation, in the longer term (tables 7-6 and 7-7). Finally, this study adds to 
the emerging literature on the prognostic value of quantitative native T1 CMR 
[(Banypersad et al., 2015)] and reaffirms the prognostic importance of MVO post-STEMI 
[(van Kranenburg et al., 2014)]. 
The results of this study extend what is known about infarct core pathology, and also 
provide a potential mechanistic explanation. Infarct size [(Holman et al., 1978, Pfeffer and 
Braunwald, 1990)] and pathology, including microvascular obstruction [(van Kranenburg 
et al., 2014)], haemorrhage [(Eitel et al., 2011)], and salvage [(Eitel et al., 2010)], predict 
cardiac morbidity and mortality post-MI. These pathologies are revealed by contrast-
enhanced CMR, and until recently, the assessment of infarct tissue without an intravenous 
contrast agent has been limited to T2-weighted and T2* imaging of myocardial 
haemorrhage [(Eitel et al., 2011, Yang et al., 2007, Payne et al., 2011b, Payne et al., 2011a, 
Robbers et al., 2013)]. T1-mapping methods, including MOLLI [(Messroghli et al., 2004, 
Messroghli et al., 2007b)] and shMOLLI [(Piechnik et al., 2010, Piechnik et al., 2013)], 
can now be integrated into clinical CMR protocols. Previous studies have assessed 
myocardial native T1 in experimental MI models ex vivo [(Higgins et al., 1983, Williams 
et al., 1980)], in vivo [(Yang et al., 2007)], or in proof-of-concept clinical studies involving 
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much smaller numbers of MI patients [(Dall'Armellina et al., 2013, Dall'Armellina et al., 
2012, Messroghli et al., 2003, Messroghli et al., 2007b, Been et al., 1988)]. Our study 
extends these findings in a much larger STEMI cohort and provides new evidence that T1 
core is more reflective of the severity of infarct injury and its prognostic importance than 
infarct core T2 and potentially also myocardial haemorrhage.  
We found that a hypointense infarct core revealed by native T1 mapping and 
microvascular obstruction revealed by late gadolinium imaging, assessed independently by 
different observers, co-existed in 86% of patients implying a common pathological basis.  
The positive predictive value of early (dynamic) microvascular obstruction for native T1 
infarct core was higher (93.8%) than that of late microvascular obstruction (85.6%). This 
difference can be explained by the occurrence of a hypointense T1 core in close association 
with microvascular obstruction in the early gadolinium enhancement imaging but a 
hypointense T1 core is less strongly associated with microvascular obstruction in the late 
gadolinium enhancement imaging. High negative predictive values were observed for both 
late microvascular obstruction and myocardial haemorrhage (T2* core) (93.8% and 97.9%, 
respectively) for a native T1 core. Early microvascular obstruction is to some extent a 
dynamic pathology since it may dissipate over time due to the contribution of reversible 
oedema and microvascular spasm. Native T1 is also affected by these pathologies, hence 
its closer association with early microvascular obstruction than with late microvascular 
obstruction which is a more persistent pathology because of its association with 
irreversible capillary destruction and intramyocardial haemorrhage (Robbers et al., 2013). 
This theory merits further assessment in pathology studies.  
Our study builds on the results from previous studies of infarct core pathology (Wu et al., 
1998b, van Kranenburg et al., 2014, Eitel et al., 2011). Dall’Armelina et al. studied 41 
acute MI patients and found that native T1 values correlated with the segmental extent of 
MI and LV function acutely and with improvements in LV function at 6 months 
(Dall'Armellina et al., 2012). However, their study had some limitations. There were no 
age- or sex-matched controls, the sample size was limited (n=32 STEMI patients) so 
multivariable analyses were not performed, and 17% of the cohort did not have follow-up 
imaging. In some of their analyses, segments with microvascular obstruction were not 
included, Our study differed in a number of important ways from that of Dall’Armelina et 
al. (Dall'Armellina et al., 2012). First, our STEMI cohort was 10-fold larger in size, and 
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7% had primary reperfusion therapy with thrombolysis. We used a different T1-mapping 
method and CMR was performed at 1.5 Tesla rather than 3.0 Tesla (which is associated 
with higher T1 values). We assessed T1 values in all patients and specifically focused on 
patients with microvascular obstruction rather than excluding them. We also performed 
multivariable analyses to assess the prognostic significance of T1 values for LV outcomes, 
independent of clinical characteristics, including LV volume and the ischaemic area-at-
risk. 
We have compared infarct core pathology delineated by native T1 mapping with 
microvascular obstruction, which is an established prognostic CMR biomarker post-MI 
[(van Kranenburg et al., 2014)]. Native T1 mapping is obtained without the use of an 
intravenous gadolinium-based contrast agent whereas microvascular obstruction is 
revealed by serial CMR imaging of EGE and LGE after intravenous contrast 
administration. We observed a high degree of concordance between the occurrence of a 
hypointense infarct core depicted by native T1 CMR (56%) and late microvascular 
obstruction (50%) as revealed by contrast-enhanced CMR. Although both a native T1 core 
and microvascular obstruction are depicted as a hypointense core within the hyperintense 
infarct zone (figure 7-2), the physics of these CMR techniques is entirely different. On the 
one hand, a hypointense infarct core depicted by non-contrast native T1 mapping is due to 
local destruction of the T1 magnetisation signal. On the other hand, microvascular 
obstruction (figure 7-2) is due to a failure of gadolinium contrast to penetrate within the 
infarct core hence the dark zone where gadolinium is absent within the infarct zone. Both 
CMR methods are T1-weighted but contrast kinetics are not relevant for native T1 
mapping since intravenous contrast is not administered. Accordingly, T1 mapping avoids 
the theoretical clinical risks and actual restrictions involved with gadolinium contrast-
based imaging of microvascular obstruction. 
Culprit artery coronary flow at the end of emergency PCI reflects the efficacy of coronary 
reperfusion, and reduced coronary flow initially independently predicted native T1 
relaxation time within infarct core as assessed by CMR 2 days later. Similar associations 
also exist for microvascular obstruction [(Amabile et al., 2010, van der Laan et al., 2012)], 
and in our study, both infarct core native T1 and microvascular obstruction were 
independently associated with circulating biomarkers of acute systemic inflammation. The 
occurrence of an infarct core disclosed by native T1 mapping, and the nature of the core 
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(i.e. the native T1 value), were associated with the initial severity of MI (i.e. Killip heart 
failure class), systemic inflammation (i.e. leucocyte counts), and LV remodelling and 
health outcomes in the longer term. We think that the prognostic significance of native 
T1values within the hypointense core are a distinctive attribute compared with 
microvascular obstruction since signal intensity values within microvascular obstruction 
are not clinically meaningful beyond binary categorisation (i.e. present / absent). The 
clinical utility of native T1 as a novel non-contrast imaging biomarker for prognosis and 
risk stratification post-MI merits further prospective assessment. 
The fact that infarct core pathology can be revealed without an intravenous contrast agent, 
and that this finding has similar prognostic significance with late microvascular 
obstruction, indicates that native T1 mapping could represent an alternative non-contrast 
CMR method for the assessment of infarct pathology in STEMI survivors. Intravenous 
gadolinium contrast represents a practical limitation for clinical CMR because of the risks 
associated with contrast allergy and advanced kidney disease. Since native T1 CMR 
mapping does not involve an intravenous contrast agent it is amenable to wider adoption. 
Furthermore, acquisition of the native T1 map does not prolong the CMR scan, in contrast 
to late gadolinium enhancement imaging for microvascular obstruction which is typically 
imaged 10 - 15 minutes after dosing [(Kramer et al., 2013)].  
7.4.1 Limitations 
We performed a single centre natural history study involving near-consecutive STEMI 
admissions. The STEMI patients in our natural-history study were recruited 24/7 therefore 
flow cytometry and routine NT-proBNP testing in all participants was not pragmatically 
possible. 
T1 assessment is sensitive to motion artefacts and imperfect breath holding, which may 
reduce image quality. A shortened version of this sequence (ShMOLLI) involving only 9 
heart beats has been developed, which shortens breath hold time and may help to account 
for these limitations [(Piechnik et al., 2010)]. Despite this, the MOLLI method has high 
precision reproducibility. Our T1 measurements are in good agreement with in vivo data 
published in the literature, including previous measurements using the ShMOLLI sequence 
[(Piechnik et al., 2010, Piechnik et al., 2013)].  
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The number of adverse events limited the number of variables that could be included in the 
multivariable models, however the associations between infarct core native T1 and a range 
of surrogate and clinical outcomes including adverse remodelling revealed by CMR, NT-
proBNP and the primary health outcome (all cause death / heart failure), supports the 
adverse prognostic importance of infarct core native T1. Our study does not permit 
inference on causality, and other interpretations of our data are, of course, possible, and 
further studies are warranted.  
7.5 Conclusions 
We found that infarct core pathology revealed by native T1 maps had similar prognostic 
value compared with microvascular obstruction revealed by late gadolinium enhancement 
CMR. Native T1 mapping is potentially widely applicable in clinical practice, not limited 
by renal disease, and so potentially could represent an alternative non-contrast CMR option 
for the assessment of infarct pathology
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8 Chapter 8: The index of microvascular resistance is an 
acute biomarker for myocardial haemorrhage and a 
clinical tool for risk stratification in reperfused 
survivors of acute-ST elevation myocardial infarction 
Introduction
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8.1 Introduction 
Despite the success of primary percutaneous coronary intervention (PCI) in achieving 
coronary reperfusion in most patients with acute ST-elevation myocardial infarction 
(STEMI), failure of myocardial reperfusion affects almost half of STEMI patients (Ahmed 
et al., 2013, Carrick and Berry, 2013, Frohlich et al., 2013, Cochet et al., 2009, Hombach 
et al., 2005). The index of microvascular resistance (IMR) measured at the end of PCI 
predicts the subsequent occurrence of microvascular obstruction one week post-STEMI 
(McGeoch et al., 2010), and adverse LV remodelling, heart failure and all-cause mortality 
in the longer term (Layland et al., 2013, Payne et al., 2012, Fearon et al., 2013). 
Accordingly, IMR has potential to identify higher risk STEMI patients at a very early time-
point for preventative therapies. 
Experimental studies in a pig model of reperfused MI identified myocardial haemorrhage 
two days post-MI as an irreversible but potentially preventable outcome (Robbers et al., 
2013). Using cardiac magnetic resonance (CMR) imaging, Robbers et al found that 
myocardial haemorrhage is preceded by microvascular obstruction which is characterised 
by fibrin-rich microvascular thrombi within intact capillaries. These results raised the 
question of whether IMR might be discriminative for microvascular obstruction (a 
therapeutic target) vs. myocardial haemorrhage (a manifestation of irreversible infarction). 
Accordingly, we aimed to assess whether IMR measured at the end of primary 
percutaneous coronary intervention (PPCI) might discriminate STEMI patients at risk of 
subsequent IMH. 
 
We hypothesised that IMR would be 1) more strongly associated with myocardial 
haemorrhage, reflecting severe microvascular damage, than other pathologies with a 
reversible component, such as microvascular obstruction and 2) independently associated 
with adverse outcome post-STEMI including left ventricular (LV) remodelling and pre-
defined health outcomes. 
To investigate these hypotheses we measured IMR at the end of emergency PCI in acute 
STEMI patients undergoing serial cardiac magnetic resonance (CMR) imaging 2 days and 
6 months post-MI. We assessed the clinical associates of IMR with infarct characteristics 
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and subsequent LV remodelling and examined its association with all-cause death and first 
hospitalisation for heart failure. 
8.2 Methods 
We performed a prospective single centre cohort study in 289 reperfused STEMI patients, 
as detailed in chapter 2. IMR measurement was not included in analyses if measured 
during the second procedure for the deferred patients in the deferred-stenting sub-study.  
8.2.1 Index of microvascular resistance following coronary reperfusion 
IMR and coronary flow reserve (CFR) were measured at the end of PPCI using guidewire 
based-thermodilution as described in detail in chapter 2. In brief, IMR is defined as the 
distal coronary pressure multiplied by the mean transit time of a 3 ml bolus of saline at 
room temperature during maximal coronary hyperemia, measured simultaneously (mmHg 
x s, or units) (Fearon et al., 2008, McGeoch et al., 2010, Payne et al., 2012). Coronary flow 
reserve is defined as the mean transit time at rest divided by the mean transit time during 
hyperaemia. Hyperemia was induced by 140 /kg/min of intravenous adenosine preceded 
by a 2 ml intracoronary bolus of 200 µg of nitrate. The mean aortic and distal coronary 
pressures were recorded during maximal hyperemia. In our study, the repeatability of IMR 
was assessed by duplicate measurements 5 minutes apart in a subset of 12 consecutive 
patients, in line with previous observations (Payne et al., 2012).  
Cardiac magnetic resonance (CMR) was assessed 2 days and 6 months as described in 
detail in chapter 2. In brief, Cine-CMR was used to measure LV ejection fraction and 
volumes. IMH was defined as a hypointense infarct core with a T2* value <20 ms. 
Microvascular obstruction (MVO) was defined as a hypointense infarct core as revealed by 
late gadolinium contrast-enhanced CMR.   
8.3 Results 
289 STEMI patients had culprit coronary artery IMR measured acutely and patients 
underwent CMR at 2.1±1.8 days and 6 months later. The median IMR [interquartile range] 
was 24 [15–44].  245 patients (86%) had evaluable T2*maps at baseline and 101 of these 
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patients (41%) had IMH. CMR follow-up at 6-months was achieved in 263 of the patients 
(91%) and all patients had longer-term health outcomes assessed. 
8.3.1 Repeatability of IMR measurements 
Repeated IMR measurements obtained by 4 different operators in 12 STEMI patients were 
highly correlated (r=0.99, P<0.001), with a mean difference between IMR measurements 
of 0.01 (mean standard error 1.59 [95% CI −3.52 to 3.54], p=0.48) (Payne et al., 2012). 
8.3.2 Relationships for IMR with IMH and MVO 
All of the patients with IMH had MVO, but 32 patients had MVO (13%) without IMH. 
IMR was higher in patients with IMH (37 [21 – 63]) than in patients without IMH (17 [12 
– 33]), including those that had MVO in the absence of IMH (17 [13 – 39]; p<0.0001).  
Using Receiver Operator Characteristic (ROC) analysis, the optimal cut-off for IMR in 
predicting IMH was 27 [area-under-the-curve (AUC) 0.73 (0.66, 0.79)]. The IMR cut-off 
for MVO was of 23.5 [AUC 0.68 (0.61, 0.75)]. IMR was more strongly associated with 
IMH (odds ratio 4.24 (2.38, 7.58); p<0.001) than for MVO (2.84 (1.70, 4.73); p<0.001).  
8.3.3 IMR and adverse remodelling at 6-months 
IMR measured acutely was independently associated with adverse remodelling at 6 months 
(1.01 (1.00, 1.03); p=0.006) and NT-proBNP at 6 months (4.64 (2.17, 7.12); p<0.001), 
including after adjustment for baseline LVEF and LVEDV (p=0.008).  
8.3.4 IMR and LV function at 6 months 
In multivariable regression IMR was inversely associated with LVEF at 6-months 
including after adjustment for baseline LVEF (regression coefficient -0.05 (95% CI -0.08, -
0.01); p=0.02). 
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8.3.5 IMR and longer-term health outcomes 
IMR was a weak multivariable associate of ACD/HF (n=30 events during admission and 
post-discharge (hazard ratio 1.016 (1.009, 1.023); p<0.001), whereas CFR was not (hazard 
ration 0.659 (0.382, 1.137); p=0.134). IMR values in the highest tertile were also 
associated with ACD/HF post-discharge (HR 3.30 (1.59, 6.86); p=0.001).  
8.3.6 The comparative clinical utility of IMR versus CFR for acute risk assessment in 
reperfused STEMI patients 
CFR was lower in patients with IMH (1.4 [1.0 – 1.8]) than in patients without IMH (1.7 
[1.4 – 2.5]), including those that had MVO in the absence of IMH (1.5 [1.1 – 1.8]; 
p<0.001). Both IMR and CFR were associated with LVEF at 6-months, after adjustment 
for baseline LVEF (p=0.001 and p=0.029, respectively). In multivariable analyses 
including other clinical and angiographic characteristics, only IMR was associated with 
LVEF at 6-months (regression coefficient -0.05 (95% CI -0.08, -0.01); p=0.02). In contrast 
to IMR, CFR was not associated with adverse remodelling at 6 months (p=0.117). 
8.4 Discussion 
The main findings of our study are: 1) IMR measured in the culprit coronary artery after 
reperfusion is more strongly associated with myocardial haemorrhage than microvascular 
obstruction in STEMI survivors 2 days later and 2) compared with CFR, IMR has stronger 
prognostic importance and greater potential clinical utility for risk assessment post-
STEMI. 
Our paper adds to the emerging literature on the prognostic value of IMR (Fearon et al., 
2013) and reaffirms the prognostic importance of myocardial haemorrhage post-STEMI 
(Eitel et al., 2011, Husser et al., 2013). 
Our results have important clinical implications: IMR adds early prognostic information at 
the time of emergency reperfusion and so has potential to stratify patients at risk of 
myocardial haemorrhage for more intensive therapy.  
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8.5 Limitations 
We performed a single centre natural history study involving near-consecutive STEMI 
admissions. 
T2* CMR is sensitive to motion artefacts and imperfect breath holding, which and may 
reduce image quality. Our T2* measurements are in good agreement with in vivo data 
published in the literature (Kali et al., 2013b, O'Regan et al., 2010). 
8.6 Conclusion 
IMR is more strongly associated with myocardial haemorrhage than microvascular 
obstruction, and is independently associated with adverse remodelling and LV ejection 
fraction at 6 months. Compared with CFR, IMR has stronger prognostic importance and 
greater potential clinical utility for risk assessment post-STEMI. Since IMH is a secondary 
phenomenon post-MI, IMR measured at the end of PPCI has potential to risk stratify 
STEMI patients for targeted therapy for microvascular obstruction to achieve myocardial 
reperfusion and prevent myocardial haemorrhage. 
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9 Chapter 9: A Randomised Trial of Deferred Stenting 
versus Immediate Stenting to Prevent No-Reflow in 
Acute ST-Elevation Myocardial Infarction (DEFER 
STEMI)
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9.1 Introduction 
Primary percutaneous coronary intervention (PCI) with stenting immediately after 
coronary reperfusion is the guideline-recommended treatment for acute ST-elevation 
myocardial infarction (STEMI) and is effective at reducing mortality (Keeley et al., 2003, 
Steg et al., 2012). However, a substantial proportion of patients with STEMI develop 
chronic cardiac failure owing to poor restoration of microvascular function and myocardial 
perfusion. This occurrence is called the ‘no-reflow’ phenomenon. No-reflow is defined as 
an acute reduction in myocardial blood flow despite a patent epicardial coronary artery 
(Jaffe et al., 2008). Although substantial evidence supports the concept that the 
pathophysiology of no-reflow involves microvascular obstruction secondary to distal 
embolization of clot, microvascular spasm and thrombosis (Jaffe et al., 2008); irreversible 
microvascular injury and subsequent intramyocardial haemorrhage are now also thought to 
be important factors in the process (Robbers et al., 2013). It is likely that microvascular 
obstruction precedes myocardial haemorrhage, by causing hypoxic disruption of 
microvascular integrity in the core of the infarct (Robbers et al., 2013, Fishbein et al., 
1980). 
Angiographic no-reflow (defined according to the TIMI coronary flow grade as 0 or 1) 
occurs in approximately 10% of cases of primary PCI and is a consequence of initial 
reperfusion or PCI procedures including stent deployment. An acute reduction in 
angiographic flow may be observed after stent deployment and expansion, suggesting that 
the negative effect on distal flow may be the consequence of increased atherosclerotic and 
thrombotic material embolization in the microvasculature. The risk factors associated with 
no-reflow include patient characteristics, such as increasing age and delayed presentation, 
and coronary characteristics such as a completely occluded culprit artery and heavy 
thrombus burden (Jaffe et al., 2008, Harrison et al., 2013, Morishima et al., 2000, 
Antoniucci et al., 2001, Ndrepepa et al., 2010). 
No therapies have been shown to prevent no-reflow and when it occurs, treatment by 
administration of vasodilator drugs (Vijayalakshmi et al., 2006) and intra-aortic balloon 
counter-pulsation therapy is empirical (Vijayalakshmi et al., 2006, Jaffe et al., 2008, Steg 
et al., 2012, Windecker et al., 2014). In primary PCI, stenting occurs immediately after 
coronary reperfusion at a time when clot burden may be greatest and vascular spasm due to 
  
214 
 
acute reperfusion injury may be pronounced. Thus, the rationale behind a deferred stenting 
strategy is that a period of time spent on the coronary care unit, with anticoagulant and 
antiplatelet therapies, reduces vascular reactivity and thrombus burden, such that deferred 
stenting is safe and effective. 
We hypothesised that after initial coronary reperfusion and normalisation of coronary 
blood flow, brief deferral of stenting might reduce the occurrence of angiographic no-
reflow, MVO and IMH, compared to usual care with immediate stenting and increase 
myocardial salvage. We investigated this hypothesis in a real-life clinical setting involving 
STEMI patients treated with primary PCI. 
9.2 Methods 
9.2.1 Trial design 
We performed a prospective randomised controlled parallel group trial in STEMI patients 
enrolled in a single centre between 11 March 2012 to 21 November 2012. The trial was a 
proof-of-concept trial nested in the larger prospective cohort study. 
9.2.2 Participants and eligibility criteria 
Patients at risk of no-reflow were selected if radial artery access was used and one or more 
of the following inclusion criteria were present:  
1) Clinical history (Jaffe et al., 2008, Morishima et al., 2000, Antoniucci et al., 2001, 
Ndrepepa et al., 2010, Vijayalakshmi et al., 2006): previous myocardial infarction, 
increased age (i.e. age ≥ 65 years), duration of symptoms > 6 hours; 
2) Culprit coronary artery abnormalities (Jaffe et al., 2008, Morishima et al., 2000, 
Antoniucci et al., 2001, Ndrepepa et al., 2010, Vijayalakshmi et al., 2006): an occluded 
artery (Thrombolysis in Myocardial Infarction (TIMI) grade 0/1 (1985)) at initial 
angiography, heavy thrombus burden (TIMI ≥ grade 2 (Gibson et al., 1996)), long lesion 
length (≥ 24 mm), small vessel diameter i.e. ≤ 2·5 mm; 
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3) Clinical signs of acute microvascular injury after initial reperfusion (Jaffe et al., 2008, 
Morishima et al., 2000, Antoniucci et al., 2001, Ndrepepa et al., 2010, Vijayalakshmi et 
al., 2006): persistent ST-elevation > 50%. 
The exclusion criteria were:  
1) Absence of normal (TIMI grade 3) coronary blood flow after initial reperfusion with 
aspiration thrombectomy with or without balloon angioplasty. The residual severity of the 
culprit stenosis was not relevant to participation provided TIMI grade 3 flow was evident; 
2) Cardiogenic shock; 
3) A contra-indication to magnetic resonance imaging (e.g. permanent pacemaker); 
4) Inability to give informed consent.  
9.2.3 Setting and PCI procedure 
Consecutive STEMI admissions were screened for these inclusion and exclusion criteria. 
During ambulance transfer to the hospital, the patients received 300 mg of aspirin, 600 mg 
of clopidogrel and 5000 IU of unfractionated heparin (Steg et al., 2012, Windecker et al., 
2014). A conventional approach to primary PCI was adopted in line with usual care in our 
hospital (Steg et al., 2012, Windecker et al., 2014). Conventional bare metal and drug 
eluting stents were used. Covered stents or investigational stents designed to reduce 
thrombus embolisation were not used (Stone et al., 2012a). The guideline to cardiologists 
recommended minimal intervention for initial reperfusion with aspiration thrombectomy 
only or minimal balloon angioplasty (e.g. a compliant balloon sized according to the 
reference vessel diameter and inflated at 4-6 atmospheres 1-2 times). Bail-out PCI because 
of coronary dissection or repeated angioplasty to minimize stenosis severity were not 
permitted and patients treated in this way were not eligible to participate. Provided TIMI 
grade 3 flow had been achieved with initial reperfusion therapy then the residual stenosis 
severity had no influence on eligibility. During PCI, glycoprotein IIbIIIa inhibitor therapy 
was initiated with high dose tirofiban (25 g/kg/bolus) followed by an intravenous infusion 
of 0.15 g/kg/min for 12 hours (Steg et al., 2012, Windecker et al., 2014). No reflow was 
treated according to contemporary standards of care with intra-coronary nitrate (i.e. 200 
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g) and adenosine (i.e. 30 – 60 g) (Steg et al., 2012, Windecker et al., 2014), as clinically 
appropriate. 
In patients with multivessel coronary disease, multivessel PCI was not recommended, in 
line with clinical guidelines (Steg et al., 2012, Windecker et al., 2014). The subsequent 
management of these patients was symptom-guided. 
9.2.4 Informed consent 
The amendment to the original study protocol to include the deferred stenting sub-study 
was approved by the West of Scotland Research Ethics Committee, reference 10-S0703-28 
(appendix 5). Witnessed informed consent was verbally obtained after coronary 
reperfusion in eligible patients in the cardiac catheter laboratory. When the patient returned 
to the Coronary Care Unit an amended Patient Information Sheet approved by the local 
ethics committee was provided (appendix 6) and written informed consent was then 
obtained (appendix 7).  The patients who were not randomised were included in a registry. 
9.2.5 Randomisation, implementation and blinding 
Randomisation took place immediately after obtaining verbal consent using a web-based 
computer tool with a concealed random allocation sequence provided by the independent 
clinical trials unit and implemented by the catheter laboratory physiologist. Randomisation 
was on a 1:1 basis between usual care with immediate stenting and deferred stenting.   
9.2.6 Interventions 
The deferred PCI strategy involved an intention-to-stent 4 to 16 hours after initial coronary 
reperfusion. This time interval was based on a balance between competing benefits and 
risks. A short minimum period (4 hours) was adopted given our concern about the 
theoretical time-related risk of coronary reocclusion. In practice, a guideline of at least 8 
hours was recommended for the deferred PCI to permit the beneficial effects of reperfusion 
and anti-thrombotic therapies and in order that all patients could be treated between 0700 – 
2300 hrs during the first 24 hours of admission to ensure that the second procedure 
occurred at a time which facilitated a rest period for the patient and the staff. Finally, an 
upper limit of 16 hours was set to minimise any prolongation of the hospital admission.  
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The treatment protocol for deferred patients included transfer to the Coronary Care Unit, 
continuous intravenous infusion of glycoprotein IIbIIIa inhibitor therapy (tirofiban, 0·15 
g/kg/min) and administration of subcutaneous low molecular weight heparin (enoxaparin, 
1 mg/kg 12 hourly) for up to 16 hours (extended tirofiban infusion chart protocol included 
in appendix 8). The radial artery sheath used for PCI was retained or removed according to 
operator and patient preference. Arterial blood pressure and the radial sheath site were 
monitored in the Coronary Care Unit. All patients also had continuous ECG monitoring in 
the Coronary Care Unit.  
Usual care included immediate stenting in the catheter laboratory and intravenous 
glycoprotein IIbIIIa inhibitor therapy for 12 hours (tirofiban, 0·15 g/kg/min). After the 
PCI procedure was completed the patients returned to the Coronary Care Unit and were 
treated with optimal secondary prevention measures (Steg et al., 2012). 
9.2.7 Primary outcome 
The primary outcome was the incidence of no/slow-reflow (Steg et al., 2012), defined as 
absent flow (TIMI flow grade 0), incomplete filling (TIMI flow grade 1) or slow-reflow 
but complete filling (TIMI 2) of the culprit coronary artery during or at the end of PCI as 
revealed by the coronary angiogram during the first or second procedure. The definition of 
no-reflow also required the absence of coronary dissection or obstruction (e.g. due to 
thrombus) that could cause a decrease in coronary blood flow (Jaffe et al., 2008).  
9.2.8 Secondary outcomes 
The secondary outcomes included angiographic, ECG and MRI parameters.  
9.2.9 Angiographic secondary outcomes 
The angiographic secondary outcomes were no-reflow (TIMI flow grade 0/1), final TIMI 
flow grade (1985), corrected TIMI frame count (Gibson et al., 1996), TIMI myocardial 
blush grade (Gibson et al., 2000), the occurrence of intra-procedural thrombotic events 
(McEntegart et al., 2012), (defined as the development of new or increasing thrombus, 
abrupt vessel closure, or distal embolisation occurring at any time during the procedure in 
the culprit vessel or any significant side branch measuring ≥ 2 mm). Embolisation was 
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defined as a distal filling defect with an abrupt 'cut-off' in one of the peripheral coronary 
artery branches of the infarct-related vessel, distal to the site of angioplasty (Windecker et 
al., 2014).  
The TIMI coronary flow grade (described in chapter 2) is straightforward to evaluate in the 
catheter laboratory hence TIMI flow grade was used as an eligibility criterion for 
participation in the study.  
Tissue myocardial perfusion (blush) grade 
Coronary angiography also provides other information on coronary blood flow and 
myocardial perfusion. The TIMI blush grade is an ordinal score for contrast washout at the 
end of the angiogram (Steg et al., 2012), and the TIMI blush grade is also predictive of 
prognosis (Gibson et al., 2000, van 't Hof et al., 1998). 
Table 9-1 Definitions of TIMI myocardial blush grade. 
TIMI Blush grade  
0 No myocardial blush 
1 Minimal blush and very slow clearing (e.g. present at beginning 
of next cine) 
2 Good blush with slow clearing of myocardial contrast (present at 
end of cine but gone at beginning of next) 
3 Good blush and normal clearing (i.e. gone by end of cine) 
 
TIMI frame count 
The TIMI frame count is a simple objective continuous variable index of coronary blood 
flow, representing the amount of time (in frames) for contrast dye to reach a standardized 
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distal landmark, corrected for vessel length (Gibson et al., 1996). The corrected TIMI 
frame count (CTFC) is predictive of prognosis (Gibson et al., 1996, Gibson et al., 1999).  
Method of CTFC 
The CTFC is the number of cine frames required for contrast to first reach standardized 
distal coronary landmarks in the culprit artery and was measured with a frame counter on a 
cine viewer (normal < 27 frames). In the left anterior descending artery this figure is 
corrected to account for increased vessel length and the frame count is divided by 1.7. A 
frame count of 100, a value that is the 99th percentile of patent vessels, was imputed to an 
occluded artery. CTFC is a measure of time, and data were converted when necessary 
according to film speed (e.g. 30 frames/s). The CTFC was divided by 30 to calculate the 
transit time for dye to traverse the length of the artery to the landmark in seconds and 
multiplied by 1000 to calculate the time in milliseconds. This was used along with the 
heart rate to calculate the fraction of a cardiac cycle required for dye to traverse the artery: 
fraction of cardiac cycle (CTFC/30 seconds) / (60s/heart rate). Calculation of the fraction 
of a cardiac cycle required for dye to traverse the culprit artery normalises the CTFC for 
heart rate.  
Intra-procedural thrombotic events 
An intra-procedural thrombotic event was defined as the development of new or increasing 
thrombus, abrupt vessel closure, no reflow or slow reflow, or distal embolization occurring 
at any time during the procedure (McEntegart et al., 2012). Embolisation was defined as a 
distal filling defect with an abrupt “cut-off” in one of the peripheral coronary artery 
branches of the infarct-related vessel, distal to the site of angioplasty. Each complication 
was assessed relative to the status of the previous frames. Thus, if thrombus was present at 
baseline but then resolved only to recur later, this was coded as an intra-procedural 
thrombotic event. Similarly, thrombus at baseline that qualitatively “grew” in subsequent 
frames was considered an intra-procedural thrombotic event. Conversely, baseline 
thrombus that persisted in size without growing, diminished, or resolved was not 
considered an intra-procedural thrombotic event. 
Comparison of stent strategy between procedures for the deferred group 
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In the deferred group, the intended stent strategy at the end of the first procedure was 
prospectively recorded and stent dimensions were compared to the actual stents used in the 
second procedure by the same operator. In addition, thrombus burden at the start of the 
second procedure was compared to the end of the first procedure.  All of the angiographic 
outcomes were adjudicated blind to treatment allocation by an independent central core 
laboratory.  
9.2.10 ECG secondary outcomes 
The ECG secondary outcomes included the occurrence of complete (70), partial (30% to 
< 70%) or no (30%) ST-segment resolution on the electrocardiogram (ECG) assessed 60 
minutes after reperfusion compared to the baseline ECG before reperfusion (Windecker et 
al., 2014, Steg et al., 2012). In addition, ST segment elevation was measured on the 
baseline ECG before reperfusion in order to estimate the extent of initial myocardial 
jeopardy with the Aldrich ST-elevation score (Aldrich et al., 1988).  
9.2.11 MRI secondary outcomes 
The MRI secondary outcomes included the occurrence of microvascular obstruction with 
late gadolinium enhancement on cardiac magnetic resonance imaging (MRI) 2 days after 
reperfusion (Kramer et al., 2013), final infarct size at 6 months (Kramer et al., 2013, 
Kellman et al., 2002), myocardial salvage (Berry et al., 2010, Payne et al., 2012, Giri et al., 
2009), and myocardial salvage index (Berry et al., 2010, Payne et al., 2012, Giri et al., 
2009) (both derived using final infarct size). Myocardial salvage (% left ventricular 
volume) was defined as the difference between the initial jeopardised area-at-risk revealed 
by T2-weighted MRI at baseline (Berry et al., 2010, Payne et al., 2012, Giri et al., 2009) 
and final infarct size revealed by contrast-enhanced MRI at 6 months (Berry et al., 2010). 
The myocardial salvage index was defined as infarct size at 6 months indexed to the initial 
area-at-risk (Payne et al., 2012). 
The ECG and MRI outcomes were also adjudicated blind to treatment allocation. 
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9.2.12 Safety outcomes 
The potential risks of the second catheterisation e.g. bleeding, contrast nephropathy, and 
procedure-related complications e.g. intra-procedural thrombotic events, and health 
outcomes were included as safety outcomes. 
Clinical outcome measures included the occurrence of heart failure, re-infarction, bleeding 
and cardiac death during the index admission and after discharge as defined in the Clinical 
Event Committee Charter (appendix 4). All potential clinical events were adjudicated 
blinded to treatment allocation by an independent Clinical Event Committee comprised of 
3 cardiologists from Ninewells Hospital, Dundee (J.I., A.D., S.H.T.) 
All study participants were followed-up for a minimum of 8 months after discharge. 
Information on adverse events was obtained by clinical review of the patients and primary 
and secondary care records during follow-up. 
9.2.13 Coronary angiogram acquisition and analyses 
Coronary angiograms were acquired during usual care with cardiac catheter laboratory X-
ray (Innova, GE Healthcare) and information technology equipment (Centricity, GE 
Healthcare). The angiograms underwent independent analysis in the Cardiovascular 
Research Foundation Angiographic Core Laboratory, New York, NY, USA by staff who 
were blinded to treatment assignment.  
I coded and de-identified the angiograms, then transferred the CDs by courier to be 
analysed at an independent core laboratory (Cardiovascular Research Foundation, New 
York, New York) by technicians blinded to randomization and clinical outcomes. 
Quantitative analyses of coronary, stent and thrombus dimensions were performed with 
Medis QAngio XA v7.2.34 (Medis Medical Imaging Systems, Leiden, Netherlands) image 
analysis software. In addition to routine pre- and post-procedural quantitative and 
qualitative assessments, additional analyses of every cineangiographic frame were 
performed. Intra-procedural complications were independently assessed for each 
angiographic run.  
Registry patients 
  
222 
 
The coronary angiograms of the non-randomised patients were analysed by 3 experienced 
interventional cardiologists (M.B., A.S., W.S.H.) who were independent of the lead site. 
All of the angiograms were independently and separately adjudicated by two cardiologists 
(M.B., A.S.) and disagreements were resolved by consensus established independently by a 
third cardiologist (W.S.H.). 
9.2.14 ECG and MRI acquisition and analyses 
A 12 lead electrocardiogram (ECG) was obtained before coronary reperfusion and 60 
minutes afterwards with Mac-Lab technology (GE Healthcare) in the catheter laboratory 
and a MAC 5500 HD recorder (GE Healthcare) in the Coronary Care Unit. The ECGs were 
acquired by trained cardiology staff. The ECGs were de-identified and transferred to the 
local ECG management system. The ECGs then underwent blinded analysis by R.W. who 
was trained by the University of Glasgow ECG Core Laboratory which is certified to ISO 
9001: 2008 standards as a UKAS Accredited Organization.  
 
Cardiac MRI was performed approximately 2 days after reperfusion and the sequence 
protocol is explained in detail in Chapter 2. In brief, the imaging protocol included cine 
MRI with steady state free precession, T2-weighted oedema imaging, T2* CMR and early 
and late gadolinium enhancement imaging. The initial area-at-risk was delineated with T2 
mapping MRI (Giri et al., 2009). Myocardial haemorrhage was defined as a hypointense 
region within the infarct core, with a T2* value <20 ms. Microvascular obstruction was 
defined as a central dark zone on early contrast enhancement imaging 1, 3, 5 and 7 minutes 
post-contrast injection and present within an area of late gadolinium enhancement (Kramer 
et al., 2013). Myocardial infarction was imaged using a segmented phase-sensitive 
inversion recovery turbo fast low-angle shot (Kellman et al., 2002).  The MRI scans were 
analysed by observers blinded to the treatment group allocation of the study participants. 
9.2.15 Sample size  
Based on a clinical audit in our hospital and a literature review (Morishima et al., 2000, 
Antoniucci et al., 2001, Ndrepepa et al., 2010), we estimated that the incidence of no/slow-
reflow (TIMI 2) during primary PCI would be 40% in selected patients with one or more 
of our predefined risk factors and 10% in the deferred PCI group. A minimum of 84 
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patients (n=42 per group) would provide 85% power to reject the null hypothesis with a 
type 1 error of 0·05.  
 
9.2.16 Statistical methods 
Means and standard deviations were used to summarise approximately Normally 
distributed continuous data.  Medians and interquartile ranges (IQR) or Geometric means 
and standard deviations were used to describe skewed continuous data. Counts and 
percentages were used to summarise categorical data.  All tests were two-tailed and 
assessed at the 5% significance level. Comparisons of continuous variables used paired or 
unpaired t-tests for Normally distributed data, or Wilcoxon tests or t-tests after logarithmic 
transformation for skewed data.  Differences in proportions were assessed using ordinal 
logistic regression with exact confidence intervals for odds ratios, or Mcnemar’s tests for 
paired comparisons.  Differences in ordinal data between groups were assessed using 
ordinal logistic regression with estimates of odds ratios and 95% confidence intervals. All 
statistical analyses were performed using R version 2.15.2 or SAS version 9.2 (or higher 
versions of these programs). 
The Robertson Centre for Biostatistics acted as an independent coordinating centre for 
randomisation and its statisticians conducted the analyses. The study was monitored for 
safety by the sponsor. All serious adverse events were prospectively reported to the 
Pharmacovigilance Unit of the Clinical Trials Unit. The trial was approved by the National 
Research Ethics Service (reference 10/S0703-28). The registry was approved by the 
hospital’s Caldicott Guardian and Clinical Governance office. The clinical trial registration 
number was NCT 01717573 and the trial sponsor was the National Waiting Times Centre 
Board, NHS Scotland. 
9.3 Results 
Four hundred and eleven patients were treated with primary PCI between 11 March 2012 
and 21st November 2012 and all of these patients were included in a registry (figure 9-1; 
table 9-2). Of these, 101 patients (mean age 60 years, 69% male) were randomised (n=52 
deferred group, n=49 immediate stenting; figure 9-1) by 8/13 (62%) cardiologists. The trial 
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stopped when all patients had a minimum follow-up period of six months and all 
randomised patients were included in the analysis. 
Figure 9-1 Study flow diagram 
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Table 9-2 Baseline clinical and angiographic characteristics of all-comers. 
  
Randomly assigned groups 
 
Registry§ 
n = 310 
Characteristics*  
Immediate 
Stenting 
n = 49 
Deferred 
Stenting 
n = 52 
 
Clinical     
Age, years  61·7 (12·2) 57·6 (10·9) 61·4 (12·9) 
Male sex, n (%)  36 (73·5%) 34 (65·4%) 196 (63·2%) 
Heart rate, bpm  83 (17) 77 (17) 83 (32) 
Systolic blood pressure, mmHg  138 (27) 141 (24) 131 (28) § 
Diastolic blood pressure, mmHg  79 (17) 83 (11) 77 (16) § 
Diabetes mellitus‡, n (%)  6 (12·2%) 7 (13·5%) 30 (9·7%) 
Previous myocardial infarction, n 
(%) 
 
2 (4·1%) 5 (9·6%) 
30 (9·7%) 
Previous percutaneous coronary 
intervention, n (%) 
 
2 (4·1%) 2 (3·8%) 
21 (6·8%) 
Heart failure, Killip class at 
presentation 
I 
II 
III 
35 (71·4%) 
13 (26·6%) 
1 (2·0%) 
38 (73·1%) 
12 (23·1%) 
2 (3·8%) 
- 
Procedure     
Time from symptom onset to 
reperfusion (first balloon or 
aspiration thrombectomy), min 
Time from symptom onset to 
reperfusion >12 hours, n (%) 
 
 
183 (131, 337) 
 
5 (10·2%) 
 
166 (124, 276) 
 
1 (1·9%) 
 
184 (124, 338) 
 
6 (5·9%) 
Coronary angiography     
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Randomly assigned groups 
 
Registry§ 
n = 310 
Characteristics*  
Immediate 
Stenting 
n = 49 
Deferred 
Stenting 
n = 52 
 
Number of diseased arteries, n (%) 1 
2 
3 
26 (55·3%) 
15 (31·9%) 
6 (12·8%) 
22 (45·8%) 
17 (35·4%) 
9 (18·8%) 
 
- 
Culprit artery, n (%) 
 
 
 
 
LAD 
LCX 
RCA 
VG 
LM 
18 (36·7%) 
6 (12·2%) 
25 (51·1%) 
0 (0·0%) 
0 (0·0%) 
15 (28·8%) 
11 (21·2%) 
25 (48·1%) 
1 (1·9%) 
0 (0·0%) 
131 (42·3%)§ 
42 (13·5%)§ 
132 (42·6%) 
2 (0·6%) 
3 (1·0%) 
TIMI coronary flow grade pre-PCI¥, 
n (%) 
0/1 
2 
3 
39 (79·6%) 
7 (14·3%) 
3 (6·1%) 
40 (76·9%) 
6 (11·5%) 
6 (11·5%) 
200 (64·5%)§ 
43 (13·9%) 
67 (21·6%)§ 
Lesion length§, mm  15·4 (11·2, 20·6) 13·5 (11·2, 17·8) - 
Coronary artery diameter at the start 
of the procedure§, mm 
 
  
 
- proximal to the culprit lesion  3·2 (0·7) 3·2 (0·6) - 
- distal to the culprit lesion  2·7 (0·6) 2·7 (0·6) - 
Thrombus present§, n (%)  47 (95·9%) 51 (98·1%) 284 (91·6%) 
Thrombus area§, mm2 
TIMI thrombus grade, n (%) 
 
0/1 
2 
3 
4 
13·0 (8·3, 20·2) 
21 (42·9%) 
6 (12·2%) 
10 (20·4%) 
12 (24·5%) 
19·9 (12·0, 1·3) 
22 (42·3%) 
6 (11·5%) 
7 (13·5%) 
17 (32·7%) 
- 
151 (48·9%) 
62 (20·1%) 
60 (19·4%) 
36 (11·7%) 
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Randomly assigned groups 
 
Registry§ 
n = 310 
Characteristics*  
Immediate 
Stenting 
n = 49 
Deferred 
Stenting 
n = 52 
 
Jeopardised myocardium by the 
ECG Aldrich score (% left ventricle) 
†14 
 
 
20 (17, 30) 
 
19 (15, 26) 
 
- 
Procedure details     
Aspiration thrombectomy, n (%)  42 (85·7%) 46 (88·5%) - 
Glycoprotein IIbIIIa inhibitor 
therapy, n (%) 
 
46 (98·9%) 51 (98·1%)  
Pre-dilatation, n (%)  36 (73·5%) 46 (88·5%) - 
Post-dilatation, n (%)  35 (71·4%) 30 (57·7%) - 
Final inflation pressure, kPa  17·4 (2·4) 16·4 (3·2) - 
Intra-coronary adenosine therapy, n 
(%) 
 
4 (8·2%) 3 (5·8%)  
Number of stents: 0 
                              1 
                              2 
                              3 
 
0 
39 (79·6%) 
9 (18·4%) 
1 (2·0%) 
3 (5·8%) 
33 (63·5%) 
16 (30·8%) 
0 
 
Contrast volume, ml  205 (172, 250) 278 (238, 312)  
Footnote: TIMI = Thrombolysis in Myocardial Infarction grade, ECG = 
electrocardiogram. * Means±SD or median (interquartile range) for normal and non-
normally distributed data, respectively.  ‡ Diabetes mellitus was defined as a history of 
diet-controlled or treated diabetes. Killip classification of heart failure after acute 
myocardial infarction: class I - no heart failure, class II - pulmonary rales or crepitations, 
a third heart sound, and elevated jugular venous pressure, class III - acute pulmonary 
oedema, class IV - cardiogenic shock. A diseased artery was defined as an epicardial 
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artery (≥ 2 mm) with one or more lesions ≥ 50% of the reference vessel diameter.  ¥ TIMI 
coronary flow grade pre-PCI was not evaluable in 1 patient in the immediate stenting 
group. Intra-coronary adenosine (10 – 30 g) was administered as bolus therapy during 
primary PCI as clinically-indicated for reduced coronary flow. The clinical and treatment 
characteristics of the patients included in the immediately stented group and the deferred 
group were similar except for total volume of contrast which was greater in the deferred 
group (p<0·0001). Procedure details and outcomes include the first and second procedure 
in the deferred stent group. Two deferred patients experienced culprit artery reocclusion 
before the planned second procedure. The coronary flow grades at the end of the first 
procedure and at the start of the second procedure differed in three other deferred patients 
as follows: two patients changed from TIMI flow grade 3 to TIMI 2 and one patient 
changed from TIMI flow grade 2 to TIMI 3. None of the patients received bail-out or 
covered stents.  
§ The following clinical characteristics differed between the registry patients and the 
randomly assigned patients who were enrolled in the trial: systolic blood pressure 
(p=0·003), diastolic blood pressure (p=0·022), TIMI thrombus grade 4 (p<0·0001) and 
TIMI flow grade pre-PCI (TIMI 0/1 p=0·015; TIMI 3 p=0·007). Quantitative coronary and 
ECG analyses were done in the randomised patients but not in the registry patients.  
 
Immediate vs. deferred stenting groups 
9.3.1 Angiographic findings 
The incidence of no/slow-reflow post stenting (primary end-point) was significantly lower, 
in the deferred stenting group: [odds ratio 0.16 (0.04, 0.59), p=0.006 (table 9-3)]. Distal 
embolisation and intra-procedural thrombotic events were also less frequent in the deferred 
stenting group (table 9-3). Post stenting, TIMI grade 3 flow and myocardial blush grades 
were higher in the deferred stenting group (table 9-3). Within the deferred stenting group 
there was a significant reduction in the proportion of patients with angiographic evidence 
of thrombus at the start of the second vs. the first procedure (98.1% vs. 62.7%; p<0.0001).  
Coronary thrombus area reduced significantly between the end of the first and start of the 
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second angiograms [geometric mean for the ratio of the thrombus areas (95% CI) 0.67 
(0.53, 0.85)].  
 
Table 9-3 Primary and secondary angiographic and ECG outcomes. 
             Randomly assigned 
groups 
  Registry, 
n = 310 
Outcome*  Immediate 
Stenting 
n = 49 
Deferred 
Stenting 
n = 52 
Odds ratio 
(95% CI) 
p 
value† 
 
 
Primary outcome       
No- or slow-reflow (TIMI 0 
to 2), n (%)¢ 
 
14 (28·6%) 3 (5·8%) 
0·16 (0·04, 
0·59) 
0·006 
45 
(14·5%) 
Secondary angiographic 
outcomes 
 
     
No-reflow (TIMI 0 or 1), n 
(%) 
 
7 (14·3%) 1 (2·0%) 
0·12 (0·01, 
1·04) 
0·054 
16 
(5·2%) 
Final TIMI coronary flow 
grade post-PCI, n (%)¥ 
3 
2 
0/1 
39 (79·6%) 
6 (12·2%) 
4 (8·2%) 
49 (98%) 
0 
1 (2·0%) 
0·08 (0·01, 
0·67) 
 
0·019 
273 
(88·6%) 
25 
(8·1%) 
10 
(3·2%) 
Final TIMI myocardial 
blush grade post-PCI, n 
(%)§ 
3 
2 
0/1 
26 (53·1%) 
18 (36·7%) 
5 (10·2%) 
39 (79·6%) 
9 (18·4%) 
1 (2·0%) 
 
0·28 (0·12, 
0·68) 
 
0·005 
 
 
- 
No- or slow-reflow (TIMI 0 
to 2), with MBG  1, n (%) 
 5 (10.2%) 1 (2.0%) 
0.18 (0.02, 
1.56) 
0.119  
 
No- or slow-reflow (TIMI 0 
to 2), with MBG  2, n (%) 
 12 (24.5%) 2 (3.9%) 
0.13 (0.03, 
0.60) 
0.009  
All intra-procedural 
thrombotic events, n 
 28 9 - - 68 
  
230 
 
Patients with at least one 
intra-procedural thrombotic 
event, n (%) 
 16 (32·7%) 5 (9·6%) 
0·22 (0·07, 
0·67) 
0·008 
63 
(20·3%) 
Distal embolisation, n (%)  
10 (20·4%) 1 (1·9%) 
0·08 (0·01, 
0·65) 
0·018 5 (1·3%) 
Other secondary outcome       
ECG: Resolution of ST 
segment elevation 60 min 
post PCI, n (%) 
 
    
 
- 
Complete, 70 %   19 (38·8%) 26 (50·0%)    
Partial, 30% to < 70%  
21 (42·9%) 15 (28·8%) 
0·77 (0·37, 
1·6) 
0·484  
None, 30%  9 (18·4%) 11 (21·2%)    
 
 
9.3.2 Comparison of stent strategy between procedures in the deferred group 
Compared with the intended stent strategy at the end of the first procedure, there was a 0.5 
mm increase in maximum stent diameter (p<0.0001) and 3 mm increase in total length 
(p=0.002), evaluated by the same operator for both procedures (table 9-4 and 9-5). Three 
deferred patients did not receive a stent. In one patient, repeat arterial access was not 
possible because of peripheral arterial disease. In the other two patients, the culprit lesions 
had only minimal residual stenoses.  
Table 9-4 Comparison of intended stenting strategy at the end of the first PCI procedure 
compared to the actual strategy during the second procedure in the deferred stent group. 
 Deferred stenting group 
n = 49 
 
Characteristic Procedure 1 Procedure 2 p value 
Maximum stent diameter, mm 3.0 (3.0, 3.5) 3.5 (3.0, 4.0) <0.0001 
Total stent length, mm 28 (18, 32) 28 (20, 40) 0.002 
Patients with an increase in maximum stent 
diameter for that procedure, n (%) 2 (4%) 36 (75%)  
Footnote: Three patients who did not receive a stent in the second procedure were 
excluded from the analysis. 
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Table 9-5 Median increase in stent diameter and length between procedures for the deferred 
stent group. 
 
 
 
 
 
9.3.3 MRI findings 
The MRI results 2 days and 6 months post-MI are described in table 9-6 and case examples 
are shown in figure 9-2. Compared with immediate stenting, myocardial salvage (% left 
ventricular mass) (19·7 (13·8, 26·0) vs.14·7 (8·1, 23·2); p=0·027) and salvage index (%) 
(68 (54, 82) vs. 56 (31, 72); p=0·031) at 6 months were greater in the deferred group. The 
incidence of both microvascular obstruction and myocardial haemorrhage were lower in 
the deferred PCI group, although this was not statistically significant.   
Table 9-6 Contrast-enhanced cardiac MRI findings during the index hospitalisation and after 
6 months follow-up. 
Characteristics* Immediate stenting Deferred PCI † p value 
MRI 2 days post-MI n = 47 n = 48  
Microvascular obstruction, n 
(%) 
29 (61·7) 23 (47·9) 0·155 
Myocardial haemorrhage, n 
(%)¥ 
19 (46.1) 14 (33.3) 0.225 
MRI 6 months post-MI n = 44 n = 45  
Characteristic  p value 
Median increase in maximum stent diameter in procedure 2 
versus procedure 1, mm 0.5 <0.0001 
Median increase in total stent length in procedure 2 versus 
procedure 1, mm 3 0.002 
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Characteristics* Immediate stenting Deferred PCI † p value 
Myocardial salvage, % left 
ventricular volume 
14·7 (8·1, 23·2) 19·7 (13·8, 26·0) 0·027 
Myocardial salvage index, % 56 (31, 72) 68 (54, 82) 0·031 
Infarct size, % of left 
ventricular volume 
14·3 (6·3 , 20·3) 9·0 (4·3 , 16·0) 0·181 
Footnote: * Means±SD and median (interquartile range) are used for normal and non-
normally distributed data. The initial area-at-risk (% of left ventricular volume) revealed 
by MRI 2 days post-MI was similar in patients randomised to immediate stenting (31·6 ( 
20·8 , 37·4 )) compared to in patients randomised to deferred PCI (28·4 (23·4 , 36·6); 
p=0.577). † Compared with the immediate stenting group, favorable directional changes 
were observed in the deferred PCI group for left ventricular end-systolic volume, left 
ventricular end-diastolic volume and ejection fraction, their changes at 6 months from 
baseline (data not shown). ¥Missing data: 6 patients in each group had non-evaluable T2* 
maps at baseline. The time from randomisation to MRI was 60 (18-97) hours and 55 (22-
90) hours in the immediate stenting and deferred groups, respectively. 
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Figure 9-2 Angiogram and MRI images from 2 patients with acute reperfused STEMI. One 
patient treated with a conventional primary PCI and the other with deferred PCI 
 
(a) Usual care with immediate stenting. The angiogram (left) revealed no-reflow (orange 
arrow, TIMI grade 1 flow) after stenting LAD. Cine MRI (middle left) revealed moderate 
left ventricular systolic dysfunction. Late gadolinium enhancement (LGE) imaging (middle 
right) revealed transmural infarction with microvascular obstruction (red arrows). There 
was minimal myocardial salvage because final infarct size nearly equalled area-at-risk 
(AAR) on T2 mapping (right). (b) Deferred PCI. The angiogram revealed brisk flow post-
stent. Cine MRI (middle left) again revealed moderate left ventricular systolic dysfunction, 
however this is consistent with largely stunned but viable myocardium, since this patient 
had minimal evidence of infarction on LGE imaging (middle right) and no microvascular 
obstruction. The ischaemic AAR was far greater than the final infarct size and therefore 
myocardial salvage was substantial. 
9.3.4 Adverse events and safety 
In hospital events after randomisation 
In the deferred stent group recurrent ST elevation myocardial infarction prior to stenting 
occurred in two patients. One patient had a severe intra-mural dissection within the culprit 
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lesion in the left anterior descending coronary artery associated with absent flow in a large 
diagonal side-branch. Five hours after initial reperfusion the patient experienced recurrent 
chest pain associated with anterior ST re-elevation. Repeat coronary angiography was 
performed within 30 minutes and confirmed re-occlusion of the culprit artery. The patient 
received a stent and his subsequent clinical course was uncomplicated.  A second patient 
who inadvertently had not received low molecular weight heparin therapy in the coronary 
care unit reinfarcted prior to stenting. This patient was treated with a stent within 30 
minutes of symptom onset and had an uncomplicated clinical course. One further patient 
experienced an abrupt culprit artery closure and intra-procedural thrombotic event due to a 
guidewire-related dissection.  
There were no bleeding events or in-hospital deaths. There was a greater volume of 
contrast used in the deferred group (278 ml (238, 312) vs. 205 ml (170, 250); p<0·0001). 
No cases of contrast nephropathy occurred. 
Post-discharge events 
The mean (SD) duration of follow-up was 352 (79) days from randomisation. Three 
patients in the deferred group and one patient in the immediate stenting group experienced 
a non-ST segment elevation myocardial infarction. Two additional patients in the 
immediate stenting group were hospitalised with unstable angina, one of who was treated 
with PCI. There was one non-cardiovascular death due to small cell lung carcinoma in the 
deferred group. 
9.4 Discussion 
The main findings of our study are that compared with standard care with immediate 
stenting, brief deferral of stenting after initial reperfusion, reduced angiographic no-reflow, 
tended to reduce intramyocardial haemorrhage and microvascular obstruction, and 
increased myocardial salvage. 
We implemented a novel strategy to prevent no-reflow in at-risk patients with STEMI 
undergoing primary PCI. A simple approach was adopted for treatment stratification and 
randomisation by the cardiologist. We identified patients with initial evidence of successful 
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reperfusion and with clinical risk factors for no-reflow, and from these patients the study 
participants were randomised to immediate stenting or to an intention-to-stent strategy 
within 4 - 16 hours including prolonged anti-thrombotic therapy. The strategy of deferred 
stenting in primary PCI represents a radical change from standard care.  
We have observed that deferred completion of PCI in selected STEMI patients reduced no-
reflow, distal embolisation and intra-procedural thrombotic complications compared to 
conventional treatment with immediate stenting. Final coronary flow grade and myocardial 
blush grade were also better in the deferred group. Two patients in the deferred group 
experienced early recurrent myocardial infarction before the second procedure. During 
longer term follow-up, myocardial salvage measured with cardiac MRI was significantly 
greater in the deferred group. The favourable effect on myocardial salvage is important. 
Salvage was objectively measured with MRI and was derived from results obtained after 6 
months follow-up indicating a beneficial treatment effect that is sustained over time. 
Finally, myocardial salvage is a prognostically validated surrogate outcome that is a major 
therapeutic target in primary PCI (Steg et al., 2012, Windecker et al., 2014). 
Our trial results reflect a balance of potential benefits and potential risks. The trial was 
conducted during usual care and our intervention was based on simple clinical eligibility 
criteria. The anti-thrombotic strategy involved a mechanical component (i.e. deferral of 
stent implantation to avoid/minimize thrombus embolisation) and a therapeutic component 
based on prolonged treatment with low molecular weight heparin (1 mg/kg) and 
glycoprotein IIb/IIIa inhibitor therapy during the interval between the first and second PCI 
procedure. Glycoprotein IIb/IIIa inhibitor therapy is an evidence-based anti-thrombotic 
treatment (Steg et al., 2012, Windecker et al., 2014) and was included in therapeutic 
strategy in order to reduce thrombus burden before stent implantation in the deferred group 
(Windecker et al., 2014). Although these treatments also increase the risk of bleeding, no 
bleeding problems occurred in the deferred group probably because radial artery access 
was used in all patients. Accordingly, our strategy has potential to be widely applicable. 
Our strategy was based on selection of patients with at least one clinical and/or 
angiographic risk factor for no-reflow (Morishima et al., 2000, Ndrepepa et al., 2010, 
Antoniucci et al., 2001). We felt that the intervention would not be appropriate in 'all 
comers' for three reasons. Firstly, the efficacy of deferred stenting was likely to be greatest 
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in the patients at highest-risk of no/slow-reflow. Secondly, the risk of recurrent myocardial 
infarction could not be mitigated in patients who were at low risk of no-reflow on clinical 
grounds. Thirdly, a strategy which involved all-comers would be difficult to implement 
due to the large number of additional second procedures.  
The clinical risk profiles of the randomised and registry patients differed. Compared with 
the registry patients, anterior myocardial infarction due to left anterior descending coronary 
artery thrombosis and an occluded culprit artery (TIMI 0/1) were much more common in 
the trial patients. Anterior myocardial infarction and an occluded culprit artery are both 
associated with large infarct size (Berry et al., 2010, Payne et al., 2012, Srinivasan et al., 
2009) and an adverse prognosis (Steg et al., 2012, Windecker et al., 2014). These baseline 
differences between randomized and registry patients can be explained by appropriate risk 
stratification and patient selection by the cardiologists at the time of primary PCI.  
In order to assess whether or not clinicians could stratify patients at risk of no-reflow, 
information on all-comers was collected and those not randomised were included in a 
registry. The incidence of no/slow-reflow in the registry patients was 14.5%, nearly half 
the incidence of this event observed in the immediately stented patients and over double 
the incidence of no- or slow-reflow in the deferred group. This indicates the patient 
selection approach correctly identified a sub-group of STEMI patients in whom the 
incidence of no/slow-reflow was lower (table 9-3).  
Our study was performed during normal emergency care and all-comers were 
prospectively screened and documented. However, as might be expected with a new 
intervention which represents a radical change from standard care, patient enrolment was 
influenced by physician preference and in the absence of clinical evidence to support this 
strategy, 5/13 cardiologists in our primary PCI service did not randomise any patients.  
Thrombus is mechanistically involved in no-reflow and stent implantation may cause distal 
embolisation of clot and microvascular thrombosis (Bekkers et al., 2010b, Niccoli et al., 
2009). Based on the rationale for our intervention, we examined whether coronary 
thrombus burden might be lower at the start of the second PCI compared to the start of the 
first procedure (when stenting is normally performed) and this indeed was the case. 
Furthermore, thrombus in the culprit artery had dissipated during the intervening period. 
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Thus, coronary stent implantation in the deferred group of patients occurred when 
thrombus burden was less, and so the substrate for distal embolisation and microvascular 
thrombosis had diminished. This may explain the lower incidence of no-reflow in the 
deferred group.  
Two patients in the deferred group had early recurrent myocardial infarction. One of these 
patients had a complex culprit lesion with an intra-mural dissection (Holmes et al., 1988) 
and persistently reduced side branch flow (TIMI grade 1). The other patient was a protocol 
violation as they had not received low molecular weight heparin after the initial procedure. 
Both patients were treated with PCI expeditiously and without complication. These events 
contain learning which should be used to optimize the design of a future clinical trial. For 
example, persistent flow reduction (TIMI 0/1) in the side branch of a culprit bifurcation 
lesion would be an exclusion criterion. Overall, the balance of the benefit of reduced no-
reflow versus the risk of recurrent myocardial infarction needs to be tested in a large 
multicentre randomised controlled trial. 
There were 5 patients in the usual care group compared with 1 in the deferred group that 
had a time from symptom onset to reperfusion greater than 12 hours. Given the small 
sample size, this may have affected the outcome, especially with regard to the difference in 
myocardial salvage at 6-months. In addition, 3 patients in the usual care group versus 1 in 
the deferred group never received Tirofiban, which may have confounded results. 
Therapeutic strategies for the prevention and treatment of no-reflow have been intensively 
investigated in recent years (Stone et al., 2012b, Vlaar et al., 2008, Steg et al., 2012, 
Vijayalakshmi et al., 2006). However, none of the previously studied interventions have 
improved clinical outcomes in large multicentre randomised trials.  Other clinical trials of 
deferred stenting in primary PCI are also underway including MIMI (NCT01360242), 
PRIMACY (NCT01542385), and DANAMI-3 (NCT01435408). The designs of these trials 
differ compared to DEFER-STEMI. For example, these trials involve a longer delay before 
stent implantation (i.e. at least 1 - 2 days), which theoretically increases the risk of 
recurrent myocardial infarction and bleeding, and prolongs hospital stay. Recent studies 
(Escaned et al., 2013, Kelbaek et al., 2013, Freixa et al., 2013, Isaaz et al., 2006), including 
three non-randomised case series (Escaned et al., 2013, Isaaz et al., 2006, Kelbaek et al., 
2013) and a systematic review (Freixa et al., 2013), reported results which support the 
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notion that deferred stenting may be safe in appropriately selected patients. Taken together 
with the trials that are currently recruiting, these recent publications highlight the rapidly 
growing interest in this new therapeutic approach in primary PCI. 
9.4.1 Implications for clinical practice 
Our strategy of deferred stenting in selected STEMI patients with risk factors for no-reflow 
represents a potential new treatment paradigm. The strategy involves a balance between 
competing risks and benefits that merits prospective evaluation in a large clinical trial. On 
the one hand, we have shown that deferred stenting reduces no-reflow and increase 
myocardial salvage. On the other hand, there may be an increased risk of early recurrent 
STEMI. A deferred stent strategy involves a second procedure and so procedure-related 
costs may be higher. Our study design timed the second procedure 4 - 16 hours after the 
first in order to keep the second procedure within working hours and so optimise 
feasibility. On the other hand, the strategy has the potential to reduce healthcare costs 
overall by reducing the clinical consequences of no-reflow (e.g. heart failure and its related 
cost burden).  Only a large clinical trial designed to assess patient experience, health 
outcomes, quality of life, and cost-effectiveness can address these uncertainties. 
9.4.2 Limitations 
Investigators and patients were unblinded in our study. For this reason, the primary and 
secondary outcomes underwent independent analysis blind to treatment group assignment 
in order to prevent ascertainment bias. Our estimates for the expected incidences of no-
/slow-reflow were slightly higher than the observed rates. The reasons for this may be 
multifactorial and may reflect the effect of core laboratory adjudication over investigator 
reported events. Our study design did not include an angiographic control in the immediate 
stenting group, but we do not think this is relevant since the occurrence of no-reflow and 
other angiographic sequelae, such as intra-procedural thrombotic events, is due to the 
effect of PCI. Although two patients experienced recurrent STEMI and the outcome of 
these patients was favourable, and the learning from these experiences will inform the 
design of a future trial.  Advanced peripheral vascular disease may limit vascular access 
for repeated procedures. Glycoprotein IIbIIIa inhibitor therapy and unfractionated heparin 
were used rather than bivalirudin (Steg et al., 2012), and the former anti-thrombotic 
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combination therapy remains widely used worldwide. Some of the registry patients were 
eligible for randomisation but were not included because of physician preference. We 
believe this behaviour is to be expected in a pragmatic trial with a disruptive intervention 
which conflicts with the standard of care, and demonstration of a treatment effect in the 
randomized patients arguably makes our trial results all the more striking.    
Some of the MRI and ECG parameters were numerically but not statistically different 
between treatment groups. We think this is related to the sample size, especially since the 
longer term MRI results confirmed greater myocardial salvage in the deferred group. 
9.5 Conclusions 
For the first time, we have conducted a proof-of-concept trial and found that deferred 
stenting in primary PCI reduced angiographic no-reflow, tended to reduce IMH and MVO, 
and increased myocardial salvage compared to conventional primary PCI with immediate 
stenting. Two patients had recurrent myocardial infarction which represents important 
balancing information on potential risks. The strategy is simple, pragmatic and potentially 
widely applicable. Our results support the rationale for a substantive multicentre clinical 
trial to assess the cost-effectiveness of early deferred completion of PCI after reperfusion 
versus conventional treatment in STEMI patients at risk of no-reflow.
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10 Chapter 10: Conclusions and future directions
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In summary, I found that myocardial haemorrhage defined by T2* mapping is a biomarker 
for prognostication in STEMI survivors. For the first time we have performed a serial 
imaging analysis for the evolution and time-course of IMH and MVO in the early 
reperfusion period. Hemorrhage occurs in primary and secondary phases within the first 10 
days post-MI and is a secondary phenomenon to the initial occurrence of microvascular 
obstruction. The dynamic evolution of haemorrhage suggests that microvascular damage 
may be modifiable. Therapeutic interventions designed to preserve microvascular integrity, 
given before or immediately after reperfusion, could prevent haemorrhage and this 
possibility merits prospective assessment in randomised controlled trials. 
This thesis also adds to the growing body of evidence for the clinical utility of quantitative 
assessment of relaxation times, using parametric mapping techniques. T2 mapping proved 
to be a robust sequence with evaluable images in all patients. T2 core represents a novel 
biomarker with potential for infarct characterisation and prognostication. Using a 
comprehensive multi-parameter CMR protocol we showed that a hypointense T2 core was 
more closely related with MVO than IMH.  
In chapter 7, I showed that infarct core pathology revealed by T1 mapping had superior 
prognostic value compared to infarct core T2 and myocardial haemorrhage, and similar 
prognostic value compared to MVO, an established prognostic CMR biomarker, revealed 
by contrast-enhanced CMR. T1 mapping is potentially widely applicable in this patient 
setting and avoids the theoretical risks and actual restrictions associated with contrast-
enhanced CMR, so could represent an alternative non-contrast CMR option for the 
assessment of infarct pathology. 
I have also demonstrated that IMR adds early prognostic information at the time of 
emergency reperfusion and has the potential to stratify patients at risk of IMH for more 
intensive therapy. 
Finally, for the first time we have found that a strategy of deferred stenting in selected 
patients reduced angiographic no-reflow in primary PCI and tended to reduce MVO and 
IMH. This intervention is pragmatic and potentially widely applicable. Our results support 
the rationale for a multicentre trial to assess the safety and cost-effectiveness of deferred 
stenting in primary PCI. 
  
242 
 
In addition to the DEFER-STEMI programme (Carrick et al., 2014), this thesis has 
stimulated the MRC-EME funded T-TIME Phase II trial (Clinicaltrials.gov 
NCT02257294). Conceivably, intra-coronary thrombolysis administered early after 
reperfusion and before stent implantation might reduce coronary thrombus burden and 
distal clot embolisation, lyse microvascular thrombi and restore microvascular perfusion 
early post-MI. We are currently examining this hypothesis in a randomised, double-blind, 
placebo-controlled, parallel group trial of low-dose adjunctive alteplase during primary 
PCI (T-TIME).  
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Appendix 2 – Patient information sheet 
 
Patient Information Sheet  
 
Project title: Detection and significance of heart injury in ST elevation MI  
 
You are being asked to take part in a clinical research study. Before you decide it is 
important for you to understand why the research is being done and what it will involve for 
you. Please take time to read the following carefully and discuss it with others if you wish. 
Please ask us if there is anything you are unclear about or if you would like more 
information. Take time to decide whether or not you wish to take part. 
What does the title mean and what is the purpose of the study? 
 
Treatment of heart attack (myocardial infarction) has traditionally concentrated on opening 
the large heart arteries, whether by “clot busting” medication or balloons and stents 
(angioplasty).  We now know that damage to the heart’s tiny blood vessels also occurs 
during heart attack and this can contribute to longer-term heart damage. We plan to take 
measurements, which represent damage to the heart’s small blood vessels during treatment 
for heart attack with angioplasty. We will then perform a special heart scan, an MRI scan, 
which would allow us to look at the blood supply to the heart, to look at the amount of 
damage to the heart as a whole and at the amount of damage to the small blood vessels. We 
would also like to obtain a blood and urine sample at the time of your admission to hospital 
and with each MRI scan in order to study some circulating cells and chemicals that may be 
involved in heart muscle and blood vessel repair. Our aim is to identify patients with 
significant damage to the hearts small blood vessels at the time of angioplasty therefore 
allowing us to identify future patients with treatment to minimise damage at the earliest 
opportunity.   
  Why have I been chosen? 
You have had a heart attack and you require an angiography procedure to look at the 
arteries that supply the heart.   
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Do I have to take part? 
 
No, it is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and will be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect 
the standard of care you receive. 
 
What will happen to me if I take part? 
 
During the angiography/angioplasty procedure we will make measurements that represent 
damage to the hearts small blood vessels. This involves injecting dye into the heart arteries 
under x-ray guidance allowing us to identify if any blockages are present. A tiny wire will 
be passed into the relevant heart artery allowing us to inflate balloons and deploy stents 
(like small scaffolds) over the blocked area. We will use a pressure and temperature 
sensitive guidewire during the procedure. This wire is routinely used in our clinical 
practice. The measurements will take an additional 10 minutes during the procedure and do 
not pose any additional risk to you. While these measurements are being taken a drug 
called adenosine is used to increase the blood flow through the heart arteries. 
 
You will have two heart MRI scans. One will occur within 48 hours after the 
angiography/angioplasty procedure and the other will be at around six months after your 
heart attack at a time that is convenient for you.  If you agree, we would also like you to 
have two other MRI scans after the angiography procedure in order to study how heart 
injury changes. These ‘extra’ MRI scans would take place on the day you are admitted to 
hospital, and after discharge day 7 to 10. 
The MRI scans last approximately one hour each. The scanner is basically tunnel shaped, 
like large “polo” mint, which is open at both ends. You are slid into the centre of the 
“polo” on a couch and the scans are taken. Some people find it a little enclosing but you 
can come out at any time. 
 
Before you go into the scanner, you will be invited to provide a urine sample. Following 
this, two small plastic tubes or cannulas (similar to that used when putting in a drip) will be 
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inserted into the veins in your arms by a doctor. We would like to draw about 40 millilitres 
(about 3 tablespoonfuls) of blood from one of the plastic cannulas, and also ask you to 
provide a urine sample. We will examine new cells, such as progenitor cells, that may be 
involved in heart blood vessel injury/repair. We will also measure some of the circulating 
growth factors (small chemicals in the blood) which stimulate the release of these cells. 
We will count the number of these cells in each blood sample, and also prepare DNA and 
RNA from these cells to examine whether the genetic make-up has any connection with 
heart muscle and blood vessel repair (as assessed by MRI). Small blood and urine samples 
will be stored in a freezer to be analysed at a later stage, particularly when new markers of 
disease will have been developed by us or by other scientists. Further approval will be 
required by the ethics committee for future studies with these samples. 
 
Following this, the cannula will permit us to inject gadolinium dye during your MRI scan. 
 
Gadolinium is a clear fluid like water. It is used in MRI scanning because it accumulates in 
abnormal tissue and “lights up” that area so the scanner can detect it. It is useful in telling 
us which parts of the heart are abnormal, if any. After a short while the gadolinium fades 
away and is removed from your body (within a few hours). There is a very small risk of 
kidney damage or allergy after gadolinium contrast administration. 
 
When you are in the scanner you will need to wear a pair of headphones. These are 
necessary because of the loud knocking noise that occurs when the pictures are being 
taken. The headphones allow you to listen to music of your choice (you may bring your 
own CD) and allow us to communicate with you throughout the scan. Whilst in the 
scanner, you will be given an emergency buzzer and can very quickly be taken out should 
you feel uncomfortable. During the scan you will be asked to hold your breath at times to 
improve the quality of the pictures. During the 2nd MRI visit you may bring a CD of your 
own choice or you can ask a relative to bring one in. 
 
Is there any long term follow up: There is no direct follow up once you have had a repeat 
scan at 6 months. However, in the future, we would like to obtain information on your 
future well-being from health records held by the National Health Service or Government 
(e.g. Registrar General). We would also like to obtain information on your drug therapy 
(medication). We can obtain this information through confidential electronic NHS and 
government records. This will not require us to contact you directly. 
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Women only: The effect of MRI scans on babies is unknown- for this reason, anyone who 
is pregnant or becomes pregnant during the study will be excluded. If you think you may 
be pregnant please inform the study doctor. 
 
What are the risks? 
 
There is no additional risk by taking these extra measurements during your angioplasty. 
The MRI scanner is very safe if you have not metal implants in your body.  
The dye used during the cardiac MRI scans is called gadolinium. It is generally harmless 
and will be washed out of your system by your kidneys. Side effects include mild headache 
and nausea. Rarely (less than 1 % of the time) low blood pressure and light-headedness 
occurs. Very rarely (less than one in a thousand), patients are allergic to the contrast agent. 
 
Senior doctors will be present during your angioplasty procedure and a senior doctor will 
be present during your cardiac MRI scans. The impact of any incidental finding will be 
followed up by referral to the appropriate specialist if not dealt with by cardiology staff. 
The amount of blood and urine drawn does not place you at any risk. 
 
We would like to involve medical and/or physics students in our research team in order 
that they learn about and engage in research in imaging and heart disease.  
 
What are the potential benefits of taking part? 
 
You are unlikely to benefit directly from taking part in the study but the information that 
we get may help to improve treatment of patients in the future. This will provide additional 
information about your health, which could influence your future treatment. While the 
blood and urine results may be useful for clinical research purposes, we do not anticipate 
these results to be useful for the treatment of your condition. 
 
What if something goes wrong? 
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If you are harmed by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you have grounds for a 
legal action but you may have to pay for it. Regardless of this, if you wish to complain, or 
have any concerns about any aspect of the way you have been approached or treated during 
the course of this study, the normal NHS complaints mechanisms will be available to you. 
 
Will my GP be informed? 
 
We will inform your GP that you have agreed to take part in this study. 
 
Will my taking part in this study be kept confidential? 
 
All information that is collected about you during the course of the research will be kept 
strictly confidential. Any information about you that leaves the hospital will have your 
name and address removed so that you cannot be recognised from it. Your personal 
information will be kept on file and stored in a secure place at the BHF Glasgow 
Cardiovascular Research Centre and in the Department of Cardiology. All examinations 
(including urine and blood results and gene data) will be labelled with a code and not with 
any personal details so that all analyses will be carried out anonymously. All information 
which is collected about you during the course or the research will be kept strictly 
confidential. Any information about you which leaves the hospital or the Clinical 
Investigation Unit will have your name and address removed so that you cannot be 
recognised from it. 
 
What will happen to the results of the research study? 
 
When the results become available they will be submitted to medical journals where they 
will be considered for publication. The final results will also be submitted to national and 
international medical conferences where they will be considered for publication. At the 
BHF Glasgow Cardiovascular Research Centre we will have events to inform the public 
about our ongoing research and about results from this and other studies. 
 
You will not be identified in any report or publication. 
If you would like a copy of the results, please ask your study doctor. 
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Who is organising and funding the research? 
This study is organised by doctors from the Department of Cardiology, Golden Jubilee 
National Hospital, and scientists from the BHF Glasgow Cardiovascular Research Centre 
at Glasgow University. The study is funded by charities and researchers will not receive 
any payment for conducting this study. 
 
Who has reviewed the study? 
The West of Scotland Research Ethics Committee and the National Waiting Times Board 
has reviewed this study. 
 
Who can I contact for further information? 
 
Study doctors: Dr David Carrick 
   Department of Cardiology 
Golden Jubilee National Hospital  
Telephone: 0141-951-5875 or 0141 951 5180 
 
Supervisor:  Dr Colin Berry 
 
Thank you for taking the time to read this patient information sheet. 
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Appendix 3 – Patient consent form 
          CONSENT FORM  
 
Title of project: 
 
Detection and significance of heart injury in ST elevation MI  
 
Name of researcher: Dr Colin Berry; Dr David Carrick   Please initial box 
 
 
1. I confirm that I have read and understand the information sheet for                                     
the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to                           
withdraw at any time without giving any reason, without my medical                              
care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked                                  
at by responsible individuals from the research team or from regulatory                  
authorities where it is relevant to my taking part in research. I give                           
permission for these individuals to have access to my records. 
 
4. I agree to take part in the above study.       
 
.                                                                                                                                                       
Name of patient         Date               Signature 
 
                 
Name of Person taking consent        Date               Signature 
(if different from researcher)                                                                        
 
 
 Researcher                 Date               Signature 
 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes
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Appendix 4 – Clinical event adjudication charter 
 
 
 
 
Clinical Event Adjudication Charter 
Detection and Significance of Heart Injury in ST Elevation Myocardial Infarction – 
The BHF MR-MI study 
NCT02072850 
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Rationale for the independent adjudication of clinical events 
As a measure of enhanced Pharmacovigilance (PV) and Good Clinical Practice, a 
cardiologist who was independent of the clinical research team was designated to review 
deaths (due to any cause) and specifically cardiovascular events of interest. At a high level, 
such events of interest will include death of any cause, non-fatal acute myocardial 
infarction, non-fatal stroke, hospitalization due to unstable angina, hospitalization due to 
heart failure and coronary revascularization procedures (i.e. percutaneous coronary 
intervention, coronary artery bypass grafting). The revascularization procedures will not be 
considered to be major adverse events of interest but will be reviewed by the independent 
clinician to ensure that events of interest (e.g. acute myocardial infarction) have not been 
missed. 
The clinician will review cases of interest to determine if they meet accepted diagnostic 
criteria. Causality assessments will not be made by the clinician, nor will the clinician 
possess governance authority. The cardiologist will be blinded regarding any information 
relating to the imaging measurements. 
All deaths and pre-specified major adverse cardiovascular events (i.e. “MACE”-type 
events) will be prospectively collected by investigators and classified independently by the 
independent cardiologist.  Details on these pre-specified events are listed in section 4. 
As noted above, events of interest will be identified primarily by the investigator, who may 
use an eCRF checkbox to mark any event as a “CV event of interest”. The study was under 
regulatory review by the National Research Ethics Service and the National Waiting Times 
Board (NWTB) which is the Sponsor.  
Objective of the Event Adjudication Charter 
The purpose of this document is to delineate the roles, responsibilities and procedures in 
regards to the adjudication of cardiovascular events occurring in the BHF MR-MI study. 
Study Coordinator 
The independent cardiologist is assisted by the study coordinator (Dr David Carrick, BHF 
Cardiovascular Research Centre, University of Glasgow; david.carrick@nhs.net) who is a 
registered physician based in the University of Glasgow and Golden Jubilee National 
Hospital and who has considerable previous experience in the conduct of clinical 
cardiology studies.   
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The coordinator will: 
Assist with preparation of the source clinical data 
Enter the classification verdicts of the independent cardiologist into the database 
Events to be reviewed by the independent cardiologist 
3.1 Deaths 
The independent cardiologist will review all reported deaths and classify the cause of death 
according to the following schema:  
Non-cardiovascular 
A definite non-cardiovascular cause of death must be identified.   
Cardiovascular (CV) 
Death due to acute myocardial infarction 
Death due to stroke 
Sudden cardiac death 
Other CV death (e.g. heart failure, pulmonary embolism, cardiovascular procedure-related) 
Undetermined cause of death (i.e. cause of death unknown) 
3.2 Non-fatal cardiovascular events 
The independent cardiologist will review and adjudicate the following reported non-fatal 
cardiovascular events: 
Acute myocardial infarction 
Hospitalization for unstable angina/other angina*/chest pain* 
Stroke/TIA/Other cerebrovascular events (i.e. subdural/extradural hemorrhage)** 
Heart failure requiring hospitalization 
Coronary revascularization procedures (i.e. percutaneous coronary intervention, coronary 
artery bypass grafting)*** 
Renal failure (>25% rise in creatinine from baseline or an absolute increase in serum 
creatinine of 0·.5 mg/dL (44 µmol/L) after a radiographic examination using a contrast 
agent (Barrett NEJM 2006;354:379-86) 
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Bleeding according to the ACUITY criteria (Stone Am Heart J 2004;148:764-75) 
Note: Other non-fatal cardiovascular events will not routinely be reviewed by the 
independent cardiologist. These events will be reviewed by trained and qualified clinical 
research staff in the Golden Jubilee National Hospital to ensure that potential 
cardiovascular events requiring adjudication are not missed.  If the review suggests that a 
potential cardiovascular event requiring adjudication may have been missed, further 
information will be requested, as required and, if necessary, the event will be allocated for 
adjudication.   
*Hospitalization for other angina or for chest pain are not study events of interest but such 
events will be reviewed by the independent cardiologist to ensure that acute myocardial 
infarction or hospitalization for unstable angina events have not been missed. 
**TIAs and other cerebrovascular events (subdural haemorrhage, extradural haemorrhage) 
will be reviewed to ensure that stroke events have not been missed. 
***Coronary revascularization procedures (i.e. percutaneous coronary intervention, 
coronary artery bypass grafting) are not study events of interest but will be reviewed by the 
independent cardiologist to sure that study events of interest (e.g. acute myocardial 
infarction, hospitalization for unstable angina) have not been missed. 
Adverse Event definitions  
For those event-types requiring adjudication, each event will usually be adjudicated on the 
basis of strict application of the endpoint definitions below.  However, the clinical 
likelihood that a suspected event has occurred will be individually assessed even in the 
absence of fulfilment of all of the criteria specified in the event-definition, recognizing that 
information may at times be difficult to interpret (e.g. the exact measurement of ECG 
changes may be imprecise) or unavailable.  
Overall, event definitions should align with the "Standardized definitions for endpoint 
events in cardiovascular trials' Hicks KA et al May 2011 and the "Third Universal 
Definition of Myocardial Infarction" Thygesen et al Eur Heart J 2012. 
4.1 Deaths 
In cases where a patient experiences an event and later dies due to that event, the event 
causing death and the death will be considered as separate events only if they are separated 
  
260 
 
by a change in calendar day.  If the event causing death and the death occur on the same 
calendar day, death will be the only event classified.  
4.1.1 Cardiovascular deaths 
Cardiovascular death includes death resulting from an acute myocardial infarction, 
sudden cardiac death, death due to heart failure, death due to stroke and death due to other 
cardiovascular causes as follows:  
Death due to Acute Myocardial Infarction refers to a death usually occurring up to 30 
days after a documented acute myocardial infarction (verified either by the diagnostic 
criteria outlined below for acute myocardial infarction, above, or by autopsy findings 
showing recent myocardial infarction or recent coronary thrombus) due to the myocardial 
infarction or its immediate consequences (e.g. progressive heart failure) and where there is 
no conclusive evidence of another cause of death. 
If death occurs before biochemical confirmation of myocardial necrosis can be obtained, 
adjudication should be based on clinical presentation and other (e.g. ECG, angiographic, 
autopsy) evidence. 
NOTE: This category will include sudden cardiac death, involving cardiac arrest, often 
with symptoms suggestive of myocardial ischemia, and accompanied by presumably new 
ST elevation*, or new left bundle branch block*, or evidence of fresh thrombus in a 
coronary artery by coronary angiography and/or at autopsy, but death occurring before 
blood samples could be obtained, or at a time before the appearance of cardiac biomarkers 
in the blood (i.e. myocardial infarction Type 3 – see section 4.2.1, below).  
*If ECG tracings are not available for review, the independent cardiologist may adjudicate 
on the basis of reported new ECG changes that have been clearly documented in the case 
records or in the case report form. 
Death resulting from a procedure to treat an acute myocardial infarction [percutaneous 
coronary intervention (PCI), coronary artery bypass graft surgery (CABG)], or to treat a 
complication resulting from acute myocardial infarction, should also be considered death 
due to acute myocardial infarction.  
Death resulting from a procedure to treat myocardial ischemia (angina) or death due to an 
acute myocardial infarction that occurs as a direct consequence of a cardiovascular 
investigation/procedure/operation that was not undertaken to treat an acute myocardial 
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infarction or its complications should be considered as a death due to other cardiovascular 
causes. 
Sudden Cardiac Death refers to a death that occurs unexpectedly in a previously stable 
patient. The cause of death should not be due to another adjudicated cause (e.g. acute 
myocardial infarction Type 3 – see section 4.2.1 below).   
The following deaths should be included. 
a. Death witnessed and instantaneous without new or worsening symptoms  
b. Death witnessed within 60 minutes of the onset of new or worsening symptoms unless a 
cause other than cardiac is obvious. 
c. Death witnessed and attributed to an identified arrhythmia (e.g., captured on an ECG 
recording, witnessed on a monitor), or unwitnessed but found on implantable cardioverter-
defibrillator review.  
d. Death in patients resuscitated from cardiac arrest in the absence of pre-existing 
circulatory failure or other causes of death, including acute myocardial infarction, and who 
die (without identification of a non-cardiac aetiology) within 72 hours or without gaining 
consciousness; similar patients who died during an attempted resuscitation. 
Unwitnessed death without any other cause of death identified (information regarding the 
patient’s clinical status in the 24 hours preceding death should be provided, if available)  
Death due to Heart Failure refers to a death occurring in the context of clinically 
worsening symptoms and/or signs of heart failure without evidence of another cause of 
death (e.g. acute myocardial infarction). 
Death due to heart failure should include sudden death occurring during an admission for 
worsening heart failure as well as death from progressive heart failure or cardiogenic shock 
following implantation of a mechanical assist device.  
New or worsening signs and/or symptoms of heart failure include any of the following:  
a. New or increasing symptoms and/or signs of heart failure requiring the initiation of, or 
an increase in, treatment directed at heart failure or occurring in a patient already receiving 
maximal therapy for heart failure  
Note: If time does not allow for the initiation of, or an increase in, treatment directed at 
heart failure or if the circumstances were such that doing so would have been inappropriate 
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(e.g. patient refusal), the adjudication will be based on the clinical presentation and, if 
available, investigative evidence. 
b. Heart failure symptoms or signs requiring continuous intravenous therapy (i.e. at least 
once daily bolus administration or continuous maintenance infusion) or chronic oxygen 
administration for hypoxia due to pulmonary oedema.  
c. Confinement to bed predominantly due to heart failure symptoms.  
d. Pulmonary oedema sufficient to cause tachypnoea and distress not occurring in the 
context of an acute myocardial infarction, worsening renal function (that is not wholly 
explained by worsening heart failure/cardiac function) or as the consequence of an 
arrhythmia occurring in the absence of worsening heart failure. 
e. Cardiogenic shock not occurring in the context of an acute myocardial infarction or as 
the consequence of an arrhythmia occurring in the absence of worsening heart failure.  
Cardiogenic shock is defined as systolic blood pressure (SBP) < 90 mm Hg for greater than 
1 hour, not responsive to fluid resuscitation and/or heart rate correction, and felt to be 
secondary to cardiac dysfunction and associated with at least one of the following signs of 
hypoperfusion:  
Cool, clammy skin or  
Oliguria (urine output < 30 mL/hour) or  
Altered sensorium or  
Cardiac index < 2·2 L/min/m2 
Cardiogenic shock can also be defined if SBP < 90 mm Hg and increases to ≥ 90 mm Hg 
in less than 1 hour with positive inotropic or vasopressor agents alone and/or with 
mechanical support.  
 Death due to Stroke refers to death after a documented stroke (verified by the diagnostic 
criteria outlined below for stroke or by typical post mortem findings) that is either a direct 
consequence of the stroke or a complication of the stroke and where there is no conclusive 
evidence of another cause of death. 
NOTE: In cases of early death where confirmation of the diagnosis cannot be obtained, the 
independent may adjudicate based on clinical presentation alone.  
  
263 
 
Death due to a stroke reported to occur as a direct consequence of a cardiovascular 
investigation/procedure/operation will be classified as death due to other cardiovascular 
cause. 
Death due to subdural or extradural haemorrhages will be adjudicated (based on clinical 
signs and symptoms as well as neuroimaging and/or autopsy) and classified separately by 
the CV-EAC.   
Death due to Other Cardiovascular Causes refers to a cardiovascular death not included 
in the above categories [e.g. pulmonary embolism, cardiovascular intervention (other than 
one performed to treat an acute myocardial infarction or a complication of an acute 
myocardial infarction – see definition of death due to myocardial infarction, above), aortic 
aneurysm rupture, or peripheral arterial disease]. Mortal complications of cardiac surgery 
or non-surgical revascularization should be classified as cardiovascular deaths.  
4.1.2 Non-cardiovascular deaths 
A non-cardiovascular death is defined as any death that is not thought to be due to a 
cardiovascular cause.  There should be unequivocal and documented evidence of a non-
cardiovascular cause of death. 
Further sub-classification of non-cardiovascular death will be as follows: 
Pulmonary  
Renal  
Gastrointestinal  
Infection (includes sepsis)  
Non-infectious (e.g., systemic inflammatory response syndrome (SIRS)) 
Malignancy  
Haemorrhage, not intracranial  
Accidental/Trauma   
Suicide  
Non-cardiovascular surgery  
Other non-cardiovascular, specify: ________________  
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4.1.3 Undetermined cause of death 
This refers to any death not attributable to one of the above categories of cardiovascular 
death or to a non-cardiovascular cause (e.g. due to lack of information such as a case where 
the only information available is “patient died”).  It is expected that every effort will be 
made to provide the adjudicating committee with enough information to attribute deaths to 
either a cardiovascular or non-cardiovascular cause so that the use of this category is kept 
to a minimal number of patients. 
4.1.4 Non-fatal Cardiovascular Events 
Date of onset 
For purposes of classification, when classifying events that are a cause of hospitalization, 
the date of admission will be used as the onset date.  In cases where the stated date of 
admission differs from the date the patient first presented to hospital with the event (e.g. 
because of a period of observation in an emergency department, medical assessment unit or 
equivalent), the date of initial presentation to hospital will be used (provided that the 
patient had not been discharged from hospital in the interim).  
For events where an admission date is not applicable (or not available), the date of onset as 
stated by the investigator will be used. 
4.2.1 Acute myocardial infarction 
Note on biomarker elevations: 
For cardiac biomarkers, laboratories should report an upper reference limit (URL). If the 
99th percentile of the upper reference limit (URL) from the respective laboratory 
performing the assay is not available, then the URL for myocardial necrosis from the 
laboratory should be used. If the 99th percentile of the URL or the URL for myocardial 
necrosis is not available, the MI decision limit for the particular laboratory should be used 
as the URL. 
Spontaneous acute myocardial infarction: 
A rise and/or fall of cardiac biomarkers (troponin or CK-MB) should usually be detected 
(see note below) with at least one value above the upper reference limit (URL) together 
with evidence of myocardial ischemia with at least one of the following: 
Clinical presentation consistent with ischemia 
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ECG evidence of acute myocardial ischemia (as outlined in Table 1, below) or new left 
bundle branch block (LBBB). 
Development of pathological Q waves on the ECG (see Table 2, below) 
 Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality 
Autopsy evidence of acute myocardial infarction 
If biomarkers are elevated from a prior infarction, then a spontaneous myocardial 
infarction is defined as:  
 
a. One of the following:  
o Clinical presentation consistent with ischemia  
o ECG evidence of acute myocardial ischemia (as outlined in Table 1, below) or new left 
bundle branch block. [The events committee will adjudicate in the context of the sequential 
ECG changes that are commonly seen in acute ST elevation/acute non-ST elevation 
myocardial infarction.] 
o New pathological Q waves (see Table 2, below).  [The events committee will adjudicate 
in the context of the sequential ECG changes that are commonly seen in acute ST 
elevation/acute non-ST elevation myocardial infarction.] 
o Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality  
o Autopsy evidence of acute myocardial infarction 
AND  
b. Both of the following:  
o Evidence that cardiac biomarker values were decreasing (e.g. two samples 3-6 hours 
apart) prior to the suspected acute myocardial infarction*  
o ≥ 20% increase (and > URL) in troponin or CK-MB between a measurement made at the 
time of the initial presentation with the suspected recurrent myocardial infarction and a 
further sample taken 3-6 hours later  
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*If biomarkers are increasing or peak is not reached, then a definite diagnosis of recurrent 
myocardial infarction is generally not possible. 
Percutaneous coronary intervention-related acute myocardial infarction  
Peri-percutaneous coronary intervention (PCI) acute myocardial infarction is defined by 
any of the following criteria. Symptoms of cardiac ischemia are not required.  
Biomarker elevations within 48 hours of PCI:  
• Troponin or CK-MB (preferred) > 5 x URL and  
• No evidence that cardiac biomarkers were elevated prior to the procedure;  
OR  
• Both of the following must be true:  
o ≥ 50% increase in the cardiac biomarker result  
o Evidence that cardiac biomarker values were decreasing (e.g. two samples 3-6 hours 
apart) prior to the suspected acute myocardial infarction  
New pathological Q waves or new left bundle branch block (LBBB).  
[If the PCI was undertaken in the context of an acute myocardial infarction, the events 
committee will adjudicate in the context of the sequential ECG changes that are commonly 
seen in acute ST elevation/acute non-ST elevation myocardial infarction.] 
Autopsy evidence of acute myocardial infarction  
Coronary artery bypass grafting-related acute myocardial infarction  
Peri-coronary artery bypass graft surgery (CABG) acute myocardial infarction is defined 
by the following criteria. Symptoms of cardiac ischemia are not required.  
Biomarker elevations within 72 hours of CABG: 
• Troponin or CK-MB (preferred) > 10 x URL and  
• No evidence that cardiac biomarkers were elevated prior to the procedure;  
OR  
• Both of the following must be true:  
o ≥ 50% increase in the cardiac biomarker result  
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o Evidence that cardiac biomarker values were decreasing (e.g. two samples 3-6 hours 
apart) prior to the suspected acute myocardial infarction  
AND  
One of the following:  
New pathological Q-waves (preferably with evidence of persistence) 
[If the CABG was undertaken in the context of an acute myocardial infarction, the events 
committee will adjudicate in the context of the sequential ECG changes that are commonly 
seen in acute ST elevation/acute non-ST elevation myocardial infarction.] 
New LBBB (preferably with evidence of persistence) 
Angiographically documented new graft or native coronary artery occlusion  
Imaging evidence of new loss of viable myocardium  
OR  
Autopsy evidence of acute myocardial infarction  
Note: For a diagnosis of acute myocardial infarction, a rise and/or fall of cardiac 
biomarkers should usually be detected.  However, myocardial infarction may be 
adjudicated for an event that has characteristics which are very suggestive of acute 
infarction but which does not meet the strict definition because biomarkers are not 
available (e.g. not measured) or are non-contributory (e.g. may have normalized). 
Suggestive characteristics are: 
Typical cardiac ischemic-type pain/discomfort  
(except for suspected acute myocardial infarction occurring in the context of PCI or CABG 
where this requirement need not apply) 
AND 
New ECG changes* or other evidence to support a diagnosis of acute myocardial 
infarction (e.g. imaging evidence of new loss of viable myocardium/new regional wall 
motion abnormality or angiography demonstrating occlusive coronary thrombus) 
*If ECG tracings are not available for review, the adjudication may be made on the basis 
of reported ECG changes that have been clearly documented in the case records or in the 
case report form. 
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Clinical classification of different types of myocardial infarction 
Myocardial infarctions will be clinically classified as: 
Type 1 
Spontaneous myocardial infarction related to ischemia due to a primary coronary event 
such as plaque erosion and/or rupture, fissuring, or dissection. 
Type 2 
Myocardial infarction secondary to ischemia due to either increased oxygen demand or 
decreased supply, e.g. coronary artery spasm, coronary embolism, anaemia, arrhythmias, 
hypertension, or hypotension. 
Type 3 
Sudden unexpected cardiac death, including cardiac arrest, often with symptoms 
suggestive of myocardial ischemia, accompanied by presumably new ST elevation, or new 
LBBB, or evidence of fresh thrombus in a coronary artery by angiography and/or at 
autopsy, but death occurring before blood samples could be obtained, or at a time before 
the appearance of cardiac biomarkers in the blood. 
Type 4a 
Myocardial infarction associated with PCI. 
Type 4b 
Myocardial infarction associated with stent thrombosis as documented by angiography or 
at autopsy. 
Type 5 
Myocardial infarction associated with CABG. 
Myocardial infarctions will be further sub-classified as: 
ST segment elevation myocardial infarction (STEMI). 
or 
Non-ST segment elevation myocardial infarction (NSTEMI). 
or 
Myocardial infarction, type (i.e. STEMI or NSTEMI) unknown.
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Table 1: ECG manifestations of acute myocardial ischemia (in absence of left 
ventricular hypertrophy and left bundle branch block) 
ST elevation 
New ST elevation at the J-point in two anatomically contiguous leads with the cut-off 
points: ≥ 0·2 mV in men (> 0·25 mV in men < 40 years) or ≥ 0·15 mV in women in 
leads V2-V3 and/or ≥ 0·1 mV in other leads. 
ST depression and T wave changes 
New horizontal or down-sloping ST depression ≥ 0·05 mV in two 
contiguous leads; and/or new T wave inversion ≥ 0·1 mV in two contiguous 
leads. 
The above ECG criteria illustrate patterns consistent with myocardial ischemia. In patients 
with abnormal biomarkers, it is recognized that lesser ECG abnormalities may represent an 
ischemic response and may be accepted under the category of abnormal ECG findings. 
 
Table 2: Pathological Q waves: 
Any Q-wave in leads V2-V3 ≥ 0·02 seconds or QS complex in leads V2 and V3 
Q-wave ≥ 0·03 seconds and ≥ 0·1 mV deep or QS complex in leads I, II, aVL, aVF, 
or V4-V6 in any two leads of a contiguous lead grouping (I, aVL, V6; V4-V6; II, III, 
and aVF) a 
A The same criteria are used for supplemental leads V7-V9, and for the Cabrera 
frontal plane lead grouping. 
4.2.2 Hospitalization for unstable angina 
For the diagnosis of hospitalization due to unstable angina there should be 
emergency/unplanned admission to a hospital setting (emergency room, observation or 
inpatient unit) that results in at least one overnight stay (i.e. a date change) with fulfilment 
of the following criteria: 
There should be: 
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1. Cardiac ischemic-type symptoms at rest (chest pain or equivalent) or an 
accelerating pattern of angina (e.g. exercise-related ischemic-type symptoms increasing in 
frequency and/or severity, decreasing threshold for onset of exercise related ischemic type 
symptoms) but without the fulfilment of the above diagnostic criteria for acute myocardial 
infarction.  
and 
2 The need for treatment with parenteral (intravenous, intra-arterial, buccal, 
transcutaneous or subcutaneous) anti-ischemic/antithrombotic therapy and/or coronary 
revascularization. 
and 
3a  ECG manifestations of acute myocardial ischemia (New ST-T changes meeting the 
criteria for acute myocardial ischemia - as outlined in Table 1, section 5.2.1). 
or 
3b  Angiographically significant coronary artery disease thought to be responsible for the 
patient’s presentation.  [If both invasive and CT angiographic imaging of the coronary 
arteries were performed, the results of the invasive coronary angiogram should take 
preference.] 
and 
4 The independent clinician should be satisfied that unstable angina was the primary 
reason for hospitalization. 
4.2.3 Hospitalization for other angina* 
For the diagnosis of hospitalization for other angina, there should be emergency/unplanned 
admission to a hospital setting (emergency room, observation or inpatient unit) that results 
in at least one overnight stay (i.e. a date change) with fulfilment of the following criteria: 
There should be: 
Typical cardiac ischemic-type symptoms but without the fulfilment of the above diagnostic 
criteria for acute myocardial infarction or unstable angina. 
and 
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2   The need for treatment with new or increased anti-angina therapy (excluding sublingual 
nitrate therapy).  
   and 
     3a    Investigations undertaken in view of the event (e.g. exercise ECG or stress 
myocardial perfusion scan) showing evidence of reversible myocardial ischemia.  
or 
      3b   Coronary angiography showing angiographically significant coronary disease 
thought to be responsible for the patient’s presentation. [If both invasive and CT 
angiographic imaging of the coronary arteries were performed, the results of the invasive 
coronary angiogram should take preference.] 
and 
4 The independent clinician should be satisfied that angina was the primary reason 
for hospitalization. 
4.2.4 Hospitalization for other chest pain* 
There should be: 
Emergency/unplanned admission to a hospital setting (emergency room, observation or 
inpatient unit) that results in at least one overnight stay i.e. a date change) due to chest pain 
but where the definitions (above) of acute myocardial infarction, hospitalization for 
unstable angina or hospitalization for other angina are not met.   
The independent clinician should be satisfied that chest pain was the primary reason for 
hospitalization. 
*These events are not study cardiovascular events of interest but the definitions provided 
for these events will be used by the independent clinician to categorise reported myocardial 
infarction, angina and chest pain events that do not meet the study definition of acute 
myocardial infarction or hospitalization for unstable angina. 
4.2.5 Stroke 
Stroke is defined as an acute episode of neurological dysfunction caused by focal or global 
brain, spinal cord, or retinal vascular injury. 
A   For the diagnosis of stroke, the following 4 criteria should usually be fulfilled: 
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1.  Rapid onset* of a focal/global neurological deficit with at least one of the 
following: 
Change in level of consciousness 
Hemiplegia 
Hemiparesis 
Numbness or sensory loss affecting one side of the body 
Dysphasia/aphasia 
Hemianopia (loss of half of the field of vision of one or both eyes) 
Complete/partial loss of vision of one eye 
Other new neurological sign(s)/symptom(s) consistent with stroke 
*If the mode of onset is uncertain, a diagnosis of stroke may be made provided that there is 
no plausible non-stroke cause for the clinical presentation. 
2.  Duration of a focal/global neurological deficit > 24 hours  
 or 
 < 24 hours if  
(i) this is because of at least one of the following therapeutic interventions: 
  (a) pharmacologic i.e. thrombolytic drug administration. 
(b)  non-pharmacologic i.e. neurointerventional procedure (e.g. intracranial 
angioplasty). 
or 
(ii) brain imaging available clearly documenting a new haemorrhage or infarct. 
or 
(iii) the neurological deficit results in death 
 
3.  No other readily identifiable non-stroke cause for the clinical presentation (e.g. 
brain tumour, hypoglycaemia, peripheral lesion). 
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4.  Confirmation of the diagnosis by at least one of the following**: 
neurology or neurosurgical specialist. 
brain imaging procedure (at least one of the following): 
CT scan. 
MRI scan. 
cerebral vessel angiography. 
Lumbar puncture (i.e. spinal fluid analysis diagnostic of intracranial haemorrhage). 
B If the acute neurological deficit represents a worsening of a previous deficit, this 
worsened deficit must have: 
Persisted for more than one week  
Or < one week if 
(i) this is because of at least one of the following therapeutic interventions: 
 (a) pharmacologic i.e. thrombolytic drug administration. 
(b) non-pharmacologic i.e. neurointerventional procedure (e.g. intracranial angioplasty). 
or 
(ii) brain imaging available clearly documenting an appropriate new CT/MRI finding. 
or 
(iii) the neurological deficit results in death 
Strokes will be further sub-classified as: 
Ischemic (non-haemorrhagic) stroke  
(i.e. caused by an infarction of central nervous system tissue) 
or 
Haemorrhagic stroke***  
(i.e. caused by non-traumatic intraparenchymal, intraventricular or subarachnoid 
haemorrhage) 
or 
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Stroke type (i.e. haemorrhagic or ischemic) unknown (i.e. when imaging/other 
investigations are unavailable or inconclusive).   
***Subdural and extradural haemorrhages will be adjudicated (based on clinical signs and 
symptoms as well as neuroimaging and/or autopsy) and classified separately. 
4.2.6. Heart Failure requiring hospitalization 
For the diagnosis of heart failure requiring hospitalization, there should be 
emergency/unplanned admission to a hospital setting (emergency room, observation or 
inpatient unit) that results in at least one overnight stay (i.e. a date change) with fulfilment 
of the following criteria: 
There should be: 
Clinical manifestations of new or worsening heart failure including at least one of the 
following: 
New or worsening dyspnoea on exertion 
New or worsening dyspnoea at rest 
New or worsening fatigue/decreased exercise tolerance 
New or worsening orthopnoea 
New or worsening PND (paroxysmal nocturnal dyspnoea) 
New or worsening lower limb or sacral oedema 
New or worsening pulmonary crackles/crepitations 
New or worsening elevation of JVP (jugular venous pressure) 
New or worsening third heart sound or gallop rhythm 
 
 And 
1 Investigative evidence of structural or functional heart disease (if available) with at 
least one of the following: 
Radiological evidence of pulmonary oedema/congestion or cardiomegaly. 
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Imaging ( e.g. echocardiography, cardiac magnetic resonance imaging, radionuclide 
ventriculography) evidence of an abnormality (e.g. left ventricular systolic dysfunction, 
significant valvular heart disease, left ventricular hypertrophy). 
 Elevation of BNP or NT-proBNP levels. 
 Other investigative evidence of structural or functional heart disease (e.g. 
evidence obtained from pulmonary artery catheterization).  
And 
3 Need for new/increased therapy* specifically for the treatment of heart failure  
including at least one of the following:  
New or increased oral therapy for the treatment of heart failure 
(See note on oral therapy, below) 
Initiation of intravenous diuretic, inotrope, vasodilator or other recognised intravenous 
heart failure treatment or up-titration of such intravenous therapy if already receiving it 
Mechanical or surgical intervention (e.g. mechanical or non-invasive ventilation, 
mechanical circulatory support, heart transplantation, ventricular pacing to improve cardiac 
function), or the use of ultrafiltration, hemofiltration, dialysis or other mechanical or 
surgical intervention that is specifically directed at treatment of heart failure. 
Note on oral therapy: In general, for an event to qualify as heart failure requiring 
hospitalization on the basis of oral heart failure therapy (i.e. in cases where none of the 
non-pharmacological treatment modalities listed above have been utilized), the new or 
increased oral therapy should include oral diuretics.  However, in special cases, other new 
or increased oral therapy (e.g. hydralazine/long acting nitrate, aldosterone antagonist) may 
be accepted provided that the adjudication committee is satisfied that: 
the new or increased oral therapy was primarily directed at treating clinical manifestations 
of new or worsening heart failure (rather than, for example, initiation or up-titration of 
heart failure therapy as part of the routine optimization of medical therapy) 
and 
the totality of the evidence indicates that heart failure, rather than any other disease 
process, was the primary cause of the clinical presentation. 
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*If time does not allow for the initiation of, or an increase in, treatment directed at heart 
failure or if the circumstances were such that doing so would have been inappropriate (e.g. 
patient refusal), the independent clinician will adjudicate on clinical presentation and, if 
available, investigative evidence. 
and 
4 The independent clinician should be satisfied that heart failure was the primary 
disease process accounting for the clinical presentation. 
4.2.7. Renal Failure requiring hospitalisation 
Contrast-induced nephropathy: is defined as either a greater than 25% increase of serum 
creatinine or an absolute increase in serum creatinine of 0·5 mg/dL after a radiographic 
examination using a contrast agent. 
4.2.8. Bleeding requiring hospitalisation 
Bleeding: is defined according to the ACUITY criteria: major bleed = intracranial or 
intraocular bleeding; bleeding at the site of angiography requiring intervention; a 
hematoma of 5 cm in diameter; a reduction in haemoglobin level of at least 4 g/dL in the 
absence of overt bleeding or 3 g/dL with a source of bleeding; or transfusion.  
6.1 Event identification  
The BHF MR-MI study will use paper-based and electronic data capture (EDC). Those 
events requiring independent validation (see section 4) will be reported by the Investigator 
via the EDC (electronic data capture) system. 
6.2 Incomplete event data 
If, having reviewed the event data pertaining to an event, the independent cardiologist 
deems that the information provided is insufficient for the purposes of event adjudication, 
an electronic request for further information detailing the information required will be 
made. The date of request will be recorded electronically and the event will be classified as 
not adjudicated/pending additional information.  
Clinical data to be provided 
The trial management team (including Prof Berry, Dr Carrick, Ms Joanne Kelly CRN) will 
provide event data for each potential cardiovascular event requiring adjudication to the 
independent cardiologist. 
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Data to be included for event classification will include: 
Subject study identification number and event details  
On request: Relevant de-identified CRF data (including any relevant event-specific CRFs 
e.g. the myocardial infarction/hospitalization for unstable angina/other angina/ 
chest pain event form). 
Supportive source documentation as required 
Baseline and subsequent scheduled ECGs obtained during study participation.   
All clinical data would be de-identified. 
De-identified Source Documentation 
The following source documents (if available) will be provided to the independent 
cardiologist as part of the standard  dossier contents for cardiovascular events requiring 
review/adjudication: 
Death  
Hospital Discharge Summary/Death Summary  
Autopsy Report  
Death Certificate 
Admission History & Physical (if applicable) 
Acute Myocardial Infarction/Hospitalization for Unstable Angina/Other Angina/Chest 
Pain  
Hospital Discharge Summary 
ECGs 
Pre-Randomization/Screening 
Baseline (prior to event but post-randomization) 
During Event 
Post-Event  
Relevant Procedure/Operation Reports  
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Relevant Laboratory Reports (e.g. that document the cardiac enzyme/marker 
measurements provided – peak values and pre-procedure and post-procedure values, where 
applicable) 
Reports for other investigations taken: 
PCI Report 
CABG Report 
Coronary Angiography Report  
Echocardiogram Report 
Exercise ECG Report  
Stress Myocardial Perfusion Scan Report  
Other investigation report undertaken to test for presence of reversible myocardial 
ischemia 
Admission History & Physical 
Stroke/TIA/Other cerebrovascular events 
Hospital Discharge Summary  
Neurology Consultation Report(s) 
Reports for other investigations undertaken: 
CT Brain Scan Report  
MRI Brain Scan Report 
Cerebral Angiography Report 
Lumbar Puncture Report 
Admission History & Physical 
Heart Failure requiring hospitalization 
Hospital Discharge Summary  
Chest X-Ray Report  
Prescription Sheets/Medication Administration Records 
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Echocardiogram Report  
Relevant Laboratory Reports (e.g. for peak BNP/NT-proBNP)  
Reports for other investigations undertaken: 
Cardiac Magnetic Resonance Imaging 
Radionuclide Ventriculogram Scan  
Pulmonary Artery Catherisation 
Admission History & Physical  
Coronary revascularization procedure 
Hospital Discharge Summary 
Relevant Procedure/Operation Reports  
Bleeding 
Hospital Discharge Summary 
Relevant Procedure/Operation Reports  
Hb 
Blood transfusion results 
Diagnostic and therapeutic procedures (e.g. gastroscopy). 
CEC Quality assurance 
For the purposes of quality assurance, 10 % of all events initially classified may be subject 
to review by the CEC again. If there are any discrepancies between the initial and the 
subsequent adjudication decisions, the Chairman and the Sponsor will discuss the steps 
necessary to ensure reconciliation and resolution of the issue. 
  
280 
 
Appendix 5 – Study amendment, ethical approval 
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Appendix 6 – Amended patient information sheet 
 
Version 1.4 February 2012               Patient Information Sheet  
 
Project title: Detection and significance of heart injury in ST elevation MI  
 
You are being asked to take part in a clinical research study. Before you decide it is 
important for you to understand why the research is being done and what it will involve for 
you. Please take time to read the following carefully and discuss it with others if you wish. 
Please ask us if there is anything you are unclear about or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
What does the title mean and what is the purpose of the study? 
Treatment of heart attack (myocardial infarction) has traditionally concentrated on opening 
the large heart arteries, whether by “clot busting” medication or balloons and stents 
(angioplasty).  We now know that damage to the heart’s tiny blood vessels also occurs 
during heart attack and this can contribute to longer-term heart damage. We plan to take 
measurements, which represent damage to the heart’s small blood vessels during treatment 
for heart attack with angioplasty. We will then perform a special heart scan, an MRI scan, 
which would allow us to look at the blood supply to the heart, to look at the amount of 
damage to the heart as a whole and at the amount of damage to the small blood vessels. We 
would also like to obtain a blood and urine sample at the time of your admission to hospital 
and with each MRI scan in order to study some circulating cells and chemicals that may be 
involved in heart muscle and blood vessel repair. Our aim is to identify patients with 
significant damage to the hearts small blood vessels at the time of angioplasty therefore 
allowing us to identify future patients with treatment to minimise damage at the earliest 
opportunity.   
During the angioplasty procedure, the cardiologist may feel that placing a stent in your 
heart artery might be harmful since blood flow might get worse, a situation known as ‘no 
reflow’. When no-reflow happens patients usually feel more unwell. The delayed stenting 
approach should allow the heart artery to begin healing and so delayed stenting might be 
safer. The purpose of the study is to work out if waiting for a few hours before placing a  
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stent in your heart artery might reduce the risk of ‘no-reflow’, compared to usual care with 
stenting at the time of the initial procedure. 
 
 Why have I been chosen? 
You have had a heart attack and you require an angiography procedure to look at the 
arteries that supply the heart. If you are asked to take part in the ‘stent later’ sub-study this 
is because your cardiologist feels you may be at risk of ‘no reflow’.   
 
Do I have to take part? 
No, it is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and will be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at anytime, or a decision not to take part, will not affect the 
standard of care you receive. 
 
What will happen to me if I take part? 
During the angiography/angioplasty procedure we will make measurements that represent 
damage to the hearts small blood vessels. This involves injecting dye into the heart arteries 
under x-ray guidance allowing us to identify if any blockages are present. A tiny wire will 
be passed into the relevant heart artery allowing us to inflate balloons and deploy stents 
(like small scaffolds) over the blocked area. We will use a pressure and temperature 
sensitive guidewire during the procedure. This wire is routinely used in our clinical 
practice. The measurements will take an additional 10 minutes during the procedure and do 
not pose any additional risk to you. While these measurements are being taken a drug 
called adenosine is used to increase the blood flow through the heart arteries. 
 
You will have an equal chance of being treated by stenting later (about 4 – 8 hrs) or usual 
care with stenting at the time of the initial angioplasty. Once the stent has been placed 
(either directly or after a few hours), you would then carry on with the study and usual 
care. 
 
You will have two heart MRI scans. One will occur within 48 hours after the 
angiography/angioplasty procedure and the other will be at around six months after your 
heart attack at a time that is convenient for you.  If you agree, we would also like you to  
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have three other MRI scans after the angiography procedure in order to study how heart 
injury changes. These ‘extra’ MRI scans would take place on the day you are admitted to 
hospital, on each of the first two days after admission and after discharge on day 5 - 7. 
 
The MRI scans last approximately one hour each. The scanner is basically tunnel shaped, 
like large “polo” mint, which is open at both ends. You are slid into the centre of the 
“polo” on a couch and the scans are taken. Some people find it a little enclosing but you 
can come out at any time. 
 
Before you go into the scanner, you will be invited to provide a urine sample. Following 
this, two small plastic tubes or cannulas (similar to that used when putting in a drip) will be 
inserted into the veins in your arms by a doctor. We would like to draw about 40 millilitres 
(about 3 tablespoonfuls) of blood from one of the plastic cannulas, and also ask you to 
provide a urine sample. We will examine new cells, such as progenitor cells, that may be 
involved in heart blood vessel injury/repair. We will also measure some of the circulating 
growth factors (small chemicals in the blood) which stimulate the release of these cells. 
We will count the number of these cells in each blood sample, and also prepare DNA and 
RNA from these cells to examine whether the genetic make-up has any connection with 
heart muscle and blood vessel repair (as assessed by MRI). Small blood and urine samples 
will be stored in a freezer to be analysed at a later stage, particularly when new markers of 
disease will have been developed by us or by other scientists. Further approval will be 
required by the ethics committee for future studies with these samples. 
 
Following this, the cannula will permit us to inject gadolinium dye during your MRI scan. 
 
Gadolinium is a clear fluid like water. It is used in MRI scanning because it accumulates in 
abnormal tissue and “lights up” that area so the scanner can detect it. It is useful in telling 
us which parts of the heart are abnormal, if any. After a short while the gadolinium fades 
away and is removed from your body (within a few hours). There is a very small risk of 
kidney damage or allergy after gadolinium contrast administration. 
 
 
When you are in the scanner you will need to wear a pair of headphones. These are 
necessary because of the loud knocking noise that occurs when the pictures are being 
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taken. The headphones allow you to listen to music of your choice (you may bring your 
own CD) and allow us to communicate with you throughout the scan. Whilst in the 
scanner, you will be given an emergency buzzer and can very quickly be taken out should 
you feel uncomfortable. During the scan you will be asked to hold your breath at times to 
improve the quality of the pictures. During the 2nd MRI visit you may bring a CD of your 
own choice or you can ask a relative to bring one in. 
 
Is there any long term follow up: There is no direct follow up once you have had a repeat 
scan at 6 months. However, in the future, we would like to obtain information on your 
future well being from health records held by the National Health Service or Government 
(e.g. Registrar General). We would also like to obtain information on your drug therapy 
(medication). We can obtain this information through confidential electronic NHS and 
government records. This will not require us to contact you directly. 
 
Women only: The effect of MRI scans on babies is unknown - for this reason, anyone who 
is pregnant or becomes pregnant during the study will be excluded. If you think you may 
be pregnant please inform the study doctor. 
 
What are the risks? 
There is no additional risk by taking these extra measurements during your angioplasty. If 
you are in the stent-later group there is a very small chance (<1 in 100) that your artery 
may block when you are on the ward. If this happens you would experience some chest 
pain and you would be treated by going back to the cath lab earlier than planned. 
The MRI scanner is very safe if you have not metal implants in your body.  
The dye used during the cardiac MRI scans is called gadolinium. It is generally harmless 
and will be washed out of your system by your kidneys. Side effects include mild headache 
and nausea. Rarely (less than 1 % of the time) low blood pressure and light-headedness 
occurs. Very rarely (less than one in a thousand), patients are allergic to the contrast agent. 
 
 
Senior doctors will be present during your angioplasty procedure and a senior 
doctor will be present during your cardiac MRI scans. The impact of any incidental 
finding will be followed up by referral to the appropriate specialist if not dealt with 
by cardiology staff. 
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The amount of blood and urine drawn does not place you at any risk. 
 
We would like to involve medical and/or physics students in our research team in order 
that they learn about and engage in research in imaging and heart disease.  
 
What are the potential benefits of taking part? 
You are unlikely to benefit directly from taking part in the study but the information that 
we get may help to improve treatment of patients in the future. This will provide additional 
information about your health, which could influence your future treatment. While the 
blood and urine results may be useful for clinical research purposes, we do not anticipate 
these results to be useful for the treatment of your condition. 
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you have grounds for a 
legal action but you may have to pay for it. Regardless of this, if you wish to complain, or 
have any concerns about any aspect of the way you have been approached or treated during 
the course of this study, the normal NHS complaints mechanisms will be available to you. 
 
Will my GP be informed? 
We will inform your GP that you have agreed to take part in this study. 
 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be kept 
strictly confidential. Any information about you that leaves the hospital will have your 
name and address removed so that you cannot be recognised from it. Your personal 
information will be kept on file and stored in a secure place at the BHF Glasgow 
Cardiovascular Research Centre and in the Department of Cardiology. All examinations 
(including urine and blood results and gene data) will be labelled with a code and not with 
any personal details so that all analyses will be carried out anonymously. All information 
which is collected about you  
during the course or the research will be kept strictly confidential. Any information about 
you which leaves the hospital or the Clinical Investigation Unit will have your name and 
address removed so that you cannot be recognised from it. 
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What will happen to the results of the research study? 
When the results become available they will be submitted to medical journals where they 
will be considered for publication. The final results will also be submitted to national and 
international medical conferences where they will be considered for publication. At the 
BHF Glasgow Cardiovascular Research Centre we will have events to inform the public 
about our ongoing research and about results from this and other studies. 
 
You will not be identified in any report or publication. 
If you would like a copy of the results, please ask your study doctor. 
 
Who is organising and funding the research? 
This study is organised by doctors from the Department of Cardiology, Golden Jubilee 
National Hospital, and scientists from the BHF Glasgow Cardiovascular Research Centre 
at Glasgow University. The study is funded by charities and researchers will not receive 
any payment for conducting this study. 
 
Who has reviewed the study? The West of Scotland Research Ethics Committee and the 
National Waiting Times Board has reviewed this study. 
 
Who can I contact for further information? 
 
Study doctors: Dr David Carrick 
   Department of Cardiology 
Golden Jubilee National Hospital  
Telephone: 0141-951-5875 or 0141 951 5180 
 
Supervisor:  Professor Colin Berry 
 
Thank you for taking the time to read this patient information sheet.
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Appendix 7 – amended patient consent form 
Version 1.2 April 2012                 CONSENT FORM  
 
Title of project: 
 
Detection and significance of heart injury in ST elevation MI  
 
Name of researcher: Professor Colin Berry      Please initial box 
 
 
1. I confirm that I have read and understand the information sheet for the above study and 
have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any      
time without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by responsible 
individuals from the research team or from regulatory authorities where it is relevant to  
my taking part in research. I give permission for these individuals to have access to my 
records. 
 
4. I agree to take part in the 'delayed stent' sub-study. 
 
5. I agree to follow-up information being collected on my future well-being and 
treatment from NHS and Government health records. 
 
6. I agree to take part in the above study.       
 
 
 
                                                                                                                                          
Name of patient         Date                 Signature 
 
 
                 
Name of Person taking consent        Date               Signature 
(if different from researcher)                                                                        
 
 
 Researcher                 Date                Signature 
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Appendix 8 – Tirofiban infusion protocol up to 16 hours 
 
 Patient with body weight < 84 Kg – Standard infusion will last 16 hours. If the 
patient has not been taken back to the lab after 16 hours set up dilute tirofiban 
infusion.  
 
 Patient with body weight 85-92 Kg – Standard infusion will run out between 12 and 
16 hours. If a new infusion is required use a second vial for high dose tirofiban but 
seek advice from medics if patient has not been to the lab by 16 hours. May decide 
to reduce tirofiban dose to 0.01 microgrammes/Kg/minute.  
 
 Patient with body weight >92Kg - Original infusion will run out before 12 hours. 
Use a second vial for high dose tirofiban but seek advice from medics if patient has 
not been to the lab by 16 hours. May decide to reduce dose to lower dose tirofiban 
at 0.01 microgrammes/Kg/minute. 
 
 Remember to reduce infusion rate by 50% if CrCl is <30ml/minute  
 
 
Ms Joanne Dunne, Cardiology Pharmacist, Golden Jubilee National Hospital 
Telephone 0141 951 5805 
 
3rd April 2012 
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